{
  "dataset": {
    "name": "pharmacy_copilot_pharmacist_eval_v1",
    "description": "Gold pharmacist scenarios for LLM evaluation (enriched for deterministic scoring).",
    "version": "1.2.0"
  },
  "metadata": {
    "question_count": 13,
    "evaluation_time": 40.80694603919983
  },
  "aggregated_metrics": {
    "retrieval": {
      "recall_at_k": {
        "1": 0.0,
        "3": 0.0,
        "5": 0.0,
        "10": 0.0,
        "20": 0.0
      },
      "precision_at_k": {
        "1": 0.0,
        "3": 0.0,
        "5": 0.0,
        "10": 0.0,
        "20": 0.0
      },
      "mean_reciprocal_rank": 0.0,
      "average_precision": 0.0,
      "ndcg_at_k": {
        "1": 0.0,
        "3": 0.0,
        "5": 0.0,
        "10": 0.0,
        "20": 0.0
      },
      "essential_recall_at_k": {
        "1": 0.0,
        "3": 0.0,
        "5": 0.0,
        "10": 0.0,
        "20": 0.0
      },
      "first_relevant_rank": 0.0,
      "total_relevant": 19,
      "total_essential": 12
    },
    "qa": {
      "bleu_score": 0.018185280560679702,
      "rouge_1_f1": 0.20027393244863195,
      "rouge_2_f1": 0.07352180678151385,
      "rouge_l_f1": 0.16461501654129723,
      "semantic_similarity": 0.5702543556690216,
      "key_points_covered": 0.20787545787545786,
      "key_points_found": [],
      "key_points_missing": [],
      "answer_length": 93,
      "has_answer": true,
      "factual_accuracy": null,
      "helpfulness": null
    }
  },
  "failure_cases": [
    {
      "question_id": "q001",
      "question": "5-year-old (18 kg) with acute otitis media. What is the amoxicillin dose and volume using 400 mg/5 mL suspension?",
      "failure_types": [
        "retrieval_miss",
        "retrieval_irrelevant",
        "qa_incomplete"
      ],
      "retrieved_chunks": [
        {
          "chunk_id": "amoxicillin-and-clavulanate-drug-information::F134628::0",
          "score": 0.9696499257688352,
          "rank": 1
        },
        {
          "chunk_id": "amoxicillin-and-clavulanate-drug-information::F134628::1",
          "score": 0.9628399937112313,
          "rank": 2
        },
        {
          "chunk_id": "amoxicillin-and-clavulanate-drug-information::F134628::4",
          "score": 0.9443774772774779,
          "rank": 3
        },
        {
          "chunk_id": "amoxicillin-and-clavulanate-drug-information::F134628::5",
          "score": 0.9153727910154332,
          "rank": 4
        },
        {
          "chunk_id": "amoxicillin-and-clavulanate-drug-information::F134628::3",
          "score": 0.9068805286374405,
          "rank": 5
        }
      ],
      "relevant_chunks_found": [],
      "essential_chunks_missed": [
        "lexi-amoxicillin-2018#dosage"
      ],
      "generated_answer": "For a 5-year-old weighing 18 kg with acute otitis media, the recommended dose of amoxicillin is 90 mg/kg/day, given twice daily. This equates to approximately 1620 mg per day. Using the 400 mg/5 mL suspension, the per-dose volume would be approximately 10 mL (rounded), with a maximum daily dose of 4 g. This dosing regimen is supported by [chunk_F134628::3]. No renal adjustment is necessary if the patient has normal renal function. However, it's important to note that this dosing is considered high-dose and is recommended for severe illness, those who have received amoxicillin in the past 30 days, treatment failure at 48 to 72 hours on first-line therapy, and when coverage for beta-lactamase positive H. influenzae and M. catarrhalis is needed. Always consult current clinical guidance for the most up-to-date information.",
      "expected_answer": "Amoxicillin 90 mg/kg/day divided q12h → 810 mg per dose (≈10.1 mL of 400 mg/5 mL), round to 10 mL per dose; max 4 g/day.",
      "key_points_missing": [
        "Uses high-dose 80–90 mg/kg/day regimen",
        "BID (q12h) frequency",
        "Volume ≈10.1 mL from 400 mg/5 mL (80 mg/mL); rounding to 10 mL OK",
        "Max daily 4 g acknowledged",
        "Cites pediatric dosage section"
      ],
      "retrieval_metrics": {
        "recall_at_k": {
          "1": 0.0,
          "3": 0.0,
          "5": 0.0,
          "10": 0.0,
          "20": 0.0
        },
        "precision_at_k": {
          "1": 0.0,
          "3": 0.0,
          "5": 0.0,
          "10": 0.0,
          "20": 0.0
        },
        "mean_reciprocal_rank": 0.0,
        "average_precision": 0.0,
        "ndcg_at_k": {
          "1": 0.0,
          "3": 0.0,
          "5": 0.0,
          "10": 0.0,
          "20": 0.0
        },
        "essential_recall_at_k": {
          "1": 0.0,
          "3": 0.0,
          "5": 0.0,
          "10": 0.0,
          "20": 0.0
        },
        "first_relevant_rank": 0.0,
        "total_relevant": 2,
        "total_essential": 1
      },
      "qa_metrics": {
        "bleu_score": 0.012209607336180515,
        "rouge_1_f1": 0.25287356321839083,
        "rouge_2_f1": 0.12790697674418605,
        "rouge_l_f1": 0.1954022988505747,
        "semantic_similarity": 0.7282848954200745,
        "key_points_covered": 0.2857142857142857,
        "key_points_found": [
          "Per-dose ≈810 mg for 18 kg",
          "No renal adjustment if normal function"
        ],
        "key_points_missing": [
          "Uses high-dose 80–90 mg/kg/day regimen",
          "BID (q12h) frequency",
          "Volume ≈10.1 mL from 400 mg/5 mL (80 mg/mL); rounding to 10 mL OK",
          "Max daily 4 g acknowledged",
          "Cites pediatric dosage section"
        ],
        "answer_length": 131,
        "has_answer": true,
        "factual_accuracy": null,
        "helpfulness": null
      },
      "root_cause": "both_systems",
      "severity": "high",
      "notes": null
    },
    {
      "question_id": "q002",
      "question": "12 kg child with fever: acetaminophen dose and volume using 160 mg/5 mL?",
      "failure_types": [
        "retrieval_miss",
        "retrieval_irrelevant",
        "qa_incomplete"
      ],
      "retrieved_chunks": [
        {
          "chunk_id": "acetaminophen-paracetamol-dextromethorphan-and-doxylamine-drug-information::F7677055::0",
          "score": 0.9387610943034719,
          "rank": 1
        },
        {
          "chunk_id": "acetaminophen-paracetamol-and-codeine-drug-information::F129503::0",
          "score": 0.9341212565159531,
          "rank": 2
        },
        {
          "chunk_id": "acetaminophen-paracetamol-dextromethorphan-and-phenylephrine-drug-information::F5093687::0",
          "score": 0.9065004236224677,
          "rank": 3
        },
        {
          "chunk_id": "acetaminophen-guaifenesin-and-phenylephrine-drug-information::F46679330::0",
          "score": 0.8996171395329055,
          "rank": 4
        },
        {
          "chunk_id": "acetaminophen-paracetamol-dextromethorphan-and-phenylephrine-drug-information::F5093686::0",
          "score": 0.8956243962421511,
          "rank": 5
        }
      ],
      "relevant_chunks_found": [],
      "essential_chunks_missed": [
        "lexi-acetaminophen-2018#peds-dosing"
      ],
      "generated_answer": "For a 12 kg child, the recommended dose of acetaminophen is 15 mg/kg, which equates to 180 mg per dose. Using a liquid formulation with a concentration of 32 mg/mL, the volume would be approximately 5.625 mL per dose. The maximum daily dose should not exceed 75 mg/kg/day or 4 grams, whichever is less.\n\nPlease refer to the pediatric dosing section for more detailed information [chunk_acetaminophen-paracetamol-dextromethorphan-and-phenylephrine-drug-information::F5093686::0]. It's important to note that when calculating the maximum daily dose, consider all sources of acetaminophen and all routes of administration. Do not exceed the maximum recommended daily dose.",
      "expected_answer": "Acetaminophen 15 mg/kg/dose q6h (range 10–15 mg/kg q4–6h) → 180 mg per dose ≈5.6 mL of 160 mg/5 mL; max 75 mg/kg/day (900 mg), and ≤4 g absolute.",
      "key_points_missing": [
        "Per-dose 15 mg/kg used",
        "q4–6h acceptable; target q6h in calc",
        "Volume ≈5.625 mL from 32 mg/mL",
        "Daily max 75 mg/kg/day and ≤4 g"
      ],
      "retrieval_metrics": {
        "recall_at_k": {
          "1": 0.0,
          "3": 0.0,
          "5": 0.0,
          "10": 0.0,
          "20": 0.0
        },
        "precision_at_k": {
          "1": 0.0,
          "3": 0.0,
          "5": 0.0,
          "10": 0.0,
          "20": 0.0
        },
        "mean_reciprocal_rank": 0.0,
        "average_precision": 0.0,
        "ndcg_at_k": {
          "1": 0.0,
          "3": 0.0,
          "5": 0.0,
          "10": 0.0,
          "20": 0.0
        },
        "essential_recall_at_k": {
          "1": 0.0,
          "3": 0.0,
          "5": 0.0,
          "10": 0.0,
          "20": 0.0
        },
        "first_relevant_rank": 0.0,
        "total_relevant": 2,
        "total_essential": 1
      },
      "qa_metrics": {
        "bleu_score": 0.029177728117107688,
        "rouge_1_f1": 0.2876712328767123,
        "rouge_2_f1": 0.11111111111111112,
        "rouge_l_f1": 0.24657534246575344,
        "semantic_similarity": 0.7394165396690369,
        "key_points_covered": 0.3333333333333333,
        "key_points_found": [
          "180 mg per dose for 12 kg",
          "Pediatric dosing section cited"
        ],
        "key_points_missing": [
          "Per-dose 15 mg/kg used",
          "q4–6h acceptable; target q6h in calc",
          "Volume ≈5.625 mL from 32 mg/mL",
          "Daily max 75 mg/kg/day and ≤4 g"
        ],
        "answer_length": 95,
        "has_answer": true,
        "factual_accuracy": null,
        "helpfulness": null
      },
      "root_cause": "both_systems",
      "severity": "high",
      "notes": null
    },
    {
      "question_id": "q003",
      "question": "12 kg child with fever: ibuprofen dose and volume using 100 mg/5 mL?",
      "failure_types": [
        "retrieval_miss",
        "retrieval_irrelevant",
        "qa_incomplete"
      ],
      "retrieved_chunks": [
        {
          "chunk_id": "ibuprofen-drug-information::F181483::0",
          "score": 0.9212129200352679,
          "rank": 1
        },
        {
          "chunk_id": "ibuprofen-drug-information::F181483::1",
          "score": 0.9075397476544838,
          "rank": 2
        },
        {
          "chunk_id": "aspirin-drug-information::F137119::4",
          "score": 0.9020363895576701,
          "rank": 3
        },
        {
          "chunk_id": "ibuprofen-drug-information::F181430::0",
          "score": 0.8459380646492902,
          "rank": 4
        },
        {
          "chunk_id": "diphenhydramine-systemic-drug-information::F8082169::1",
          "score": 0.7642147249945784,
          "rank": 5
        }
      ],
      "relevant_chunks_found": [],
      "essential_chunks_missed": [
        "lexi-ibuprofen-2018#peds-dosing"
      ],
      "generated_answer": "<s> [OUT] For a 12 kg child with fever, the recommended oral ibuprofen dose is 10 mg/kg every 6 to 8 hours, which equates to 120 mg per dose. Using a 100 mg/5 mL suspension, this would require 6 mL (100 mg/5 mL × 6 mL = 120 mg). The maximum daily dose is 40 mg/kg/day (480 mg). Ibuprofen is contraindicated in infants younger than 6 months and should be used with caution in patients with renal impairment or dehydration [Chunk ibuprofen-drug-information::F181483::0, Chunk ibuprofen-drug-information::F181483::1]. [/OUT]",
      "expected_answer": "Ibuprofen 10 mg/kg/dose q6–8h → 120 mg per dose (6 mL of 100 mg/5 mL); max 40 mg/kg/day (480 mg). Avoid if <6 months or dehydrated/renal issues.",
      "key_points_missing": [
        "q6–8h frequency",
        "6 mL at 20 mg/mL",
        "Contraindication: <6 months; caution renal/dehydration"
      ],
      "retrieval_metrics": {
        "recall_at_k": {
          "1": 0.0,
          "3": 0.0,
          "5": 0.0,
          "10": 0.0,
          "20": 0.0
        },
        "precision_at_k": {
          "1": 0.0,
          "3": 0.0,
          "5": 0.0,
          "10": 0.0,
          "20": 0.0
        },
        "mean_reciprocal_rank": 0.0,
        "average_precision": 0.0,
        "ndcg_at_k": {
          "1": 0.0,
          "3": 0.0,
          "5": 0.0,
          "10": 0.0,
          "20": 0.0
        },
        "essential_recall_at_k": {
          "1": 0.0,
          "3": 0.0,
          "5": 0.0,
          "10": 0.0,
          "20": 0.0
        },
        "first_relevant_rank": 0.0,
        "total_relevant": 2,
        "total_essential": 1
      },
      "qa_metrics": {
        "bleu_score": 0.0957707317125527,
        "rouge_1_f1": 0.40310077519379844,
        "rouge_2_f1": 0.25196850393700787,
        "rouge_l_f1": 0.37209302325581395,
        "semantic_similarity": 0.7674603462219238,
        "key_points_covered": 0.5,
        "key_points_found": [
          "10 mg/kg per dose",
          "120 mg per dose for 12 kg",
          "Max 40 mg/kg/day (480 mg)"
        ],
        "key_points_missing": [
          "q6–8h frequency",
          "6 mL at 20 mg/mL",
          "Contraindication: <6 months; caution renal/dehydration"
        ],
        "answer_length": 85,
        "has_answer": true,
        "factual_accuracy": null,
        "helpfulness": null
      },
      "root_cause": "both_systems",
      "severity": "high",
      "notes": null
    },
    {
      "question_id": "q004",
      "question": "Elderly patient with nonvalvular AF: 82 years, 58 kg, SCr 1.6 mg/dL. What apixaban dose?",
      "failure_types": [
        "retrieval_miss",
        "retrieval_irrelevant",
        "qa_no_answer",
        "e2e_low_quality"
      ],
      "retrieved_chunks": [
        {
          "chunk_id": "apixaban-drug-information::F14478989::5",
          "score": 0.9581692199234102,
          "rank": 1
        },
        {
          "chunk_id": "apixaban-drug-information::F14479017::0",
          "score": 0.947467184370913,
          "rank": 2
        },
        {
          "chunk_id": "apixaban-drug-information::F14479016::4",
          "score": 0.907039286312251,
          "rank": 3
        },
        {
          "chunk_id": "apixaban-drug-information::F14479013::1",
          "score": 0.8198538938553019,
          "rank": 4
        },
        {
          "chunk_id": "apixaban-drug-information::F14478989::3",
          "score": 0.7271677458975699,
          "rank": 5
        }
      ],
      "relevant_chunks_found": [],
      "essential_chunks_missed": [
        "lexi-apixaban-2018#dosing-nvaf"
      ],
      "generated_answer": "",
      "expected_answer": "Apixaban 2.5 mg BID (meets 2 of 3: age ≥80, weight ≤60 kg, SCr ≥1.5). Avoid with strong CYP3A4/P-gp inhibitors.",
      "key_points_missing": [
        "Dose reduction criteria (2 of 3)",
        "Final dose 2.5 mg BID",
        "Interaction caveat: strong CYP3A4/P-gp",
        "Hepatic impairment caution"
      ],
      "retrieval_metrics": {
        "recall_at_k": {
          "1": 0.0,
          "3": 0.0,
          "5": 0.0,
          "10": 0.0,
          "20": 0.0
        },
        "precision_at_k": {
          "1": 0.0,
          "3": 0.0,
          "5": 0.0,
          "10": 0.0,
          "20": 0.0
        },
        "mean_reciprocal_rank": 0.0,
        "average_precision": 0.0,
        "ndcg_at_k": {
          "1": 0.0,
          "3": 0.0,
          "5": 0.0,
          "10": 0.0,
          "20": 0.0
        },
        "essential_recall_at_k": {
          "1": 0.0,
          "3": 0.0,
          "5": 0.0,
          "10": 0.0,
          "20": 0.0
        },
        "first_relevant_rank": 0.0,
        "total_relevant": 2,
        "total_essential": 1
      },
      "qa_metrics": {
        "bleu_score": 0.0,
        "rouge_1_f1": 0.0,
        "rouge_2_f1": 0.0,
        "rouge_l_f1": 0.0,
        "semantic_similarity": 0.0,
        "key_points_covered": 0.0,
        "key_points_found": [],
        "key_points_missing": [
          "Dose reduction criteria (2 of 3)",
          "Final dose 2.5 mg BID",
          "Interaction caveat: strong CYP3A4/P-gp",
          "Hepatic impairment caution"
        ],
        "answer_length": 0,
        "has_answer": false,
        "factual_accuracy": null,
        "helpfulness": null
      },
      "root_cause": "both_systems",
      "severity": "critical",
      "notes": null
    },
    {
      "question_id": "q005",
      "question": "85 kg adult with acute DVT: What is the enoxaparin treatment dose (normal renal function)?",
      "failure_types": [
        "retrieval_miss",
        "retrieval_irrelevant",
        "qa_incomplete"
      ],
      "retrieved_chunks": [
        {
          "chunk_id": "enoxaparin-drug-information::F165080::0",
          "score": 0.974611806765285,
          "rank": 1
        },
        {
          "chunk_id": "enoxaparin-drug-information::F165080::4",
          "score": 0.9311993677533739,
          "rank": 2
        },
        {
          "chunk_id": "enoxaparin-drug-information::F165080::7",
          "score": 0.8299820035826407,
          "rank": 3
        },
        {
          "chunk_id": "enoxaparin-drug-information::F165082::1",
          "score": 0.7917338034459854,
          "rank": 4
        },
        {
          "chunk_id": "enoxaparin-drug-information::F165039::4",
          "score": 0.7558109038250175,
          "rank": 5
        }
      ],
      "relevant_chunks_found": [],
      "essential_chunks_missed": [
        "lexi-enoxaparin-2018#dosing"
      ],
      "generated_answer": "For an 85 kg adult with normal renal function (CrCl >30 mL/minute), the recommended enoxaparin treatment dose for acute DVT is 1 mg/kg every 12 hours, as per [chunk_165080::7]. This equates to a per-dose of 85 mg. However, it's important to note that in patients with venous thromboembolism (VTE) and without cancer, oral anticoagulants are preferred over LMWH (unless LMWH is used as initial parenteral anticoagulation prior to dabigatran, edoxaban, or while initiating warfarin) [chunk_165080::6]. As always, patient-specific factors and institutional protocols should be considered when determining the appropriate dose.",
      "expected_answer": "Enoxaparin 1 mg/kg SC q12h → 85 mg per dose (or 1.5 mg/kg once daily as alternative). If CrCl <30 mL/min: 1 mg/kg once daily.",
      "key_points_missing": [
        "1 mg/kg q12h primary regimen",
        "Alternative 1.5 mg/kg q24h",
        "Renal adjustment for CrCl <30"
      ],
      "retrieval_metrics": {
        "recall_at_k": {
          "1": 0.0,
          "3": 0.0,
          "5": 0.0,
          "10": 0.0,
          "20": 0.0
        },
        "precision_at_k": {
          "1": 0.0,
          "3": 0.0,
          "5": 0.0,
          "10": 0.0,
          "20": 0.0
        },
        "mean_reciprocal_rank": 0.0,
        "average_precision": 0.0,
        "ndcg_at_k": {
          "1": 0.0,
          "3": 0.0,
          "5": 0.0,
          "10": 0.0,
          "20": 0.0
        },
        "essential_recall_at_k": {
          "1": 0.0,
          "3": 0.0,
          "5": 0.0,
          "10": 0.0,
          "20": 0.0
        },
        "first_relevant_rank": 0.0,
        "total_relevant": 2,
        "total_essential": 1
      },
      "qa_metrics": {
        "bleu_score": 0.00543548164681866,
        "rouge_1_f1": 0.21875,
        "rouge_2_f1": 0.09523809523809523,
        "rouge_l_f1": 0.125,
        "semantic_similarity": 0.716378927230835,
        "key_points_covered": 0.25,
        "key_points_found": [
          "Per-dose 85 mg for 85 kg"
        ],
        "key_points_missing": [
          "1 mg/kg q12h primary regimen",
          "Alternative 1.5 mg/kg q24h",
          "Renal adjustment for CrCl <30"
        ],
        "answer_length": 90,
        "has_answer": true,
        "factual_accuracy": null,
        "helpfulness": null
      },
      "root_cause": "both_systems",
      "severity": "high",
      "notes": null
    },
    {
      "question_id": "q006",
      "question": "Type 2 diabetes patient with eGFR 28 mL/min/1.73 m². Can we use metformin?",
      "failure_types": [
        "retrieval_miss",
        "retrieval_irrelevant",
        "qa_incorrect",
        "qa_incomplete",
        "e2e_low_quality"
      ],
      "retrieved_chunks": [
        {
          "chunk_id": "canagliflozin-and-metformin-drug-information::F25746088::0",
          "score": 0.993142704078216,
          "rank": 1
        },
        {
          "chunk_id": "glipizide-and-metformin-drug-information::F50990977::0",
          "score": 0.9865639064736162,
          "rank": 2
        },
        {
          "chunk_id": "repaglinide-and-metformin-drug-information::F6213570::0",
          "score": 0.9756602542538222,
          "rank": 3
        },
        {
          "chunk_id": "glipizide-and-metformin-drug-information::F176387::5",
          "score": 0.9493433727628566,
          "rank": 4
        },
        {
          "chunk_id": "alogliptin-and-metformin-drug-information::F20453593::5",
          "score": 0.9404446661740784,
          "rank": 5
        }
      ],
      "relevant_chunks_found": [],
      "essential_chunks_missed": [
        "lexi-metformin-2018#renal"
      ],
      "generated_answer": "Based on the provided context, the use of metformin is contraindicated in patients with an eGFR less than 30 mL/min/1.73 m². For eGFR between 30 and 45 mL/min/1.73 m², it is not recommended to initiate metformin therapy. If metformin therapy is continued, a dosage reduction and monitoring of renal function every 3 months are recommended ([chunk_F176387], [chunk_F50990977], [chunk_F6213570]). The context does not provide information about the use of metformin in patients with an eGFR between 45 and 60 mL/min/1.73 m². For further guidance, please consult current clinical practice guidelines.",
      "expected_answer": "No—contraindicated at eGFR <30. If 30–45, generally avoid initiation; if continuing, reduce dose and monitor. Avoid in hepatic impairment.",
      "key_points_missing": [
        "30–45: avoid initiation; if continuing, reduce & monitor",
        "Hepatic impairment: avoid (lactic acidosis risk)"
      ],
      "retrieval_metrics": {
        "recall_at_k": {
          "1": 0.0,
          "3": 0.0,
          "5": 0.0,
          "10": 0.0,
          "20": 0.0
        },
        "precision_at_k": {
          "1": 0.0,
          "3": 0.0,
          "5": 0.0,
          "10": 0.0,
          "20": 0.0
        },
        "mean_reciprocal_rank": 0.0,
        "average_precision": 0.0,
        "ndcg_at_k": {
          "1": 0.0,
          "3": 0.0,
          "5": 0.0,
          "10": 0.0,
          "20": 0.0
        },
        "essential_recall_at_k": {
          "1": 0.0,
          "3": 0.0,
          "5": 0.0,
          "10": 0.0,
          "20": 0.0
        },
        "first_relevant_rank": 0.0,
        "total_relevant": 2,
        "total_essential": 1
      },
      "qa_metrics": {
        "bleu_score": 0.005280491229441622,
        "rouge_1_f1": 0.18032786885245902,
        "rouge_2_f1": 0.016666666666666666,
        "rouge_l_f1": 0.18032786885245902,
        "semantic_similarity": 0.5283296704292297,
        "key_points_covered": 0.3333333333333333,
        "key_points_found": [
          "Contraindicated if eGFR <30"
        ],
        "key_points_missing": [
          "30–45: avoid initiation; if continuing, reduce & monitor",
          "Hepatic impairment: avoid (lactic acidosis risk)"
        ],
        "answer_length": 89,
        "has_answer": true,
        "factual_accuracy": null,
        "helpfulness": null
      },
      "root_cause": "both_systems",
      "severity": "high",
      "notes": null
    },
    {
      "question_id": "q007",
      "question": "Uncomplicated cystitis: Should we use nitrofurantoin if eGFR is 25?",
      "failure_types": [
        "retrieval_miss",
        "retrieval_irrelevant",
        "qa_incomplete"
      ],
      "retrieved_chunks": [
        {
          "chunk_id": "nitrofurantoin-drug-information::F201984::0",
          "score": 1.0,
          "rank": 1
        },
        {
          "chunk_id": "nitrofurantoin-drug-information::F202012::0",
          "score": 0.8503409054126378,
          "rank": 2
        },
        {
          "chunk_id": "nitrofurantoin-drug-information::F201969::1",
          "score": 0.731684987719981,
          "rank": 3
        },
        {
          "chunk_id": "fosfomycin-drug-information::F174299::0",
          "score": 0.6573487594859675,
          "rank": 4
        },
        {
          "chunk_id": "canagliflozin-and-metformin-drug-information::F25746088::0",
          "score": 0.6006911661070586,
          "rank": 5
        }
      ],
      "relevant_chunks_found": [],
      "essential_chunks_missed": [
        "lexi-nitrofurantoin-2018#renal"
      ],
      "generated_answer": "Based on the provided context, nitrofurantoin should not be used for uncomplicated cystitis if the eGFR is 25, as the manufacturer contraindicates its use in CrCl <60 mL/minute [chunk_201969:1]. The Beers Criteria also recommends avoiding nitrofurantoin in geriatric patients with a CrCl, suggesting it may not be effective or safe in such cases. For uncomplicated cystitis, fosfomycin is an alternative option for women with susceptible strains of E. coli and Enterococcus faecalis [chunk_174299:0]. However, it's important to note that the context does not provide information on fosfomycin's safety and efficacy for patients with eGFR <30. Always consult current clinical guidance for the most up-to-date information.",
      "expected_answer": "Avoid nitrofurantoin when eGFR/CrCl <30 mL/min due to low urinary levels and toxicity risk.",
      "key_points_missing": [
        "Avoid if eGFR/CrCl <30",
        "Rationale: efficacy/toxicity",
        "List common contraindications where relevant"
      ],
      "retrieval_metrics": {
        "recall_at_k": {
          "1": 0.0,
          "3": 0.0,
          "5": 0.0,
          "10": 0.0,
          "20": 0.0
        },
        "precision_at_k": {
          "1": 0.0,
          "3": 0.0,
          "5": 0.0,
          "10": 0.0,
          "20": 0.0
        },
        "mean_reciprocal_rank": 0.0,
        "average_precision": 0.0,
        "ndcg_at_k": {
          "1": 0.0,
          "3": 0.0,
          "5": 0.0,
          "10": 0.0,
          "20": 0.0
        },
        "essential_recall_at_k": {
          "1": 0.0,
          "3": 0.0,
          "5": 0.0,
          "10": 0.0,
          "20": 0.0
        },
        "first_relevant_rank": 0.0,
        "total_relevant": 2,
        "total_essential": 1
      },
      "qa_metrics": {
        "bleu_score": 0.00407361445434004,
        "rouge_1_f1": 0.12307692307692307,
        "rouge_2_f1": 0.015625,
        "rouge_l_f1": 0.0923076923076923,
        "semantic_similarity": 0.7153726816177368,
        "key_points_covered": 0.0,
        "key_points_found": [],
        "key_points_missing": [
          "Avoid if eGFR/CrCl <30",
          "Rationale: efficacy/toxicity",
          "List common contraindications where relevant"
        ],
        "answer_length": 105,
        "has_answer": true,
        "factual_accuracy": null,
        "helpfulness": null
      },
      "root_cause": "both_systems",
      "severity": "high",
      "notes": null
    },
    {
      "question_id": "q008",
      "question": "Patient on warfarin needs TMP-SMX for UTI. Any interaction and what should we do?",
      "failure_types": [
        "retrieval_miss",
        "retrieval_irrelevant",
        "qa_incorrect",
        "qa_incomplete",
        "e2e_low_quality"
      ],
      "retrieved_chunks": [
        {
          "chunk_id": "trimethoprim-sulfamethoxazole-co-trimoxazole-drug-information::F154889::0",
          "score": 0.904299471438335,
          "rank": 1
        },
        {
          "chunk_id": "trimethoprim-sulfamethoxazole-co-trimoxazole-drug-information::F154863::0",
          "score": 0.8547943011724797,
          "rank": 2
        },
        {
          "chunk_id": "warfarin-drug-information::F234837::4",
          "score": 0.7873117016311454,
          "rank": 3
        },
        {
          "chunk_id": "capecitabine-drug-information::F5708655::0",
          "score": 0.6772235094198431,
          "rank": 4
        },
        {
          "chunk_id": "dalteparin-drug-information::F156483::6",
          "score": 0.6096730662878375,
          "rank": 5
        }
      ],
      "relevant_chunks_found": [],
      "essential_chunks_missed": [
        "lexi-warfarin-2018#ddi-tmp-smx"
      ],
      "generated_answer": "There is a major drug interaction between warfarin and trimethoprim-sulfamethoxazole (TMP-SMX). This interaction is due to CYP2C9 inhibition by TMP-SMX, which may increase warfarin's anticoagulant effect [capecitabine-drug-information::F5708655::0]. Therefore, it is recommended to either avoid using TMP-SMX in patients on warfarin or closely monitor the international normalized ratio (INR) and adjust the warfarin dose as necessary. [warfarin-drug-information::F234837::4]",
      "expected_answer": "Major interaction (CYP2C9 inhibition + gut flora). Avoid if possible; otherwise increase INR monitoring and reduce warfarin dose.",
      "key_points_missing": [
        "Mechanism: CYP2C9 inhibition + gut flora",
        "Severity: major",
        "Action: avoid or close INR monitoring with dose reduction"
      ],
      "retrieval_metrics": {
        "recall_at_k": {
          "1": 0.0,
          "3": 0.0,
          "5": 0.0,
          "10": 0.0,
          "20": 0.0
        },
        "precision_at_k": {
          "1": 0.0,
          "3": 0.0,
          "5": 0.0,
          "10": 0.0,
          "20": 0.0
        },
        "mean_reciprocal_rank": 0.0,
        "average_precision": 0.0,
        "ndcg_at_k": {
          "1": 0.0,
          "3": 0.0,
          "5": 0.0,
          "10": 0.0,
          "20": 0.0
        },
        "essential_recall_at_k": {
          "1": 0.0,
          "3": 0.0,
          "5": 0.0,
          "10": 0.0,
          "20": 0.0
        },
        "first_relevant_rank": 0.0,
        "total_relevant": 1,
        "total_essential": 1
      },
      "qa_metrics": {
        "bleu_score": 0.010524398322904265,
        "rouge_1_f1": 0.2558139534883721,
        "rouge_2_f1": 0.047619047619047616,
        "rouge_l_f1": 0.20930232558139533,
        "semantic_similarity": 0.582504153251648,
        "key_points_covered": 0.0,
        "key_points_found": [],
        "key_points_missing": [
          "Mechanism: CYP2C9 inhibition + gut flora",
          "Severity: major",
          "Action: avoid or close INR monitoring with dose reduction"
        ],
        "answer_length": 56,
        "has_answer": true,
        "factual_accuracy": null,
        "helpfulness": null
      },
      "root_cause": "both_systems",
      "severity": "high",
      "notes": null
    },
    {
      "question_id": "q009",
      "question": "Patient on atorvastatin needs clarithromycin. What’s the risk and action?",
      "failure_types": [
        "retrieval_miss",
        "retrieval_irrelevant",
        "qa_incorrect",
        "qa_incomplete",
        "e2e_low_quality"
      ],
      "retrieved_chunks": [
        {
          "chunk_id": "atorvastatin-drug-information::F137634::3",
          "score": 1.0,
          "rank": 1
        },
        {
          "chunk_id": "amlodipine-and-atorvastatin-drug-information::F134112::6",
          "score": 0.9613447568812422,
          "rank": 2
        },
        {
          "chunk_id": "omeprazole-clarithromycin-and-amoxicillin-copackaged-drug-information::F14471021::5",
          "score": 0.923656739017185,
          "rank": 3
        },
        {
          "chunk_id": "lansoprazole-amoxicillin-and-clarithromycin-copackaged-drug-information::F186882::5",
          "score": 0.923656739017185,
          "rank": 4
        },
        {
          "chunk_id": "clarithromycin-drug-information::F152340::4",
          "score": 0.8991064127181403,
          "rank": 5
        }
      ],
      "relevant_chunks_found": [],
      "essential_chunks_missed": [
        "lexi-atorvastatin-2018#ddi-macrolides"
      ],
      "generated_answer": "<s> [OUT] Clarithromycin is a strong CYP3A4 inhibitor that increases atorvastatin serum concentration, raising the risk of atorvastatin toxicity (e.g., myopathy, rhabdomyolysis). If the combination is unavoidable, limit atorvastatin to a maximum dose of 20 mg/day and monitor closely for signs of toxicity [Chunk atorvastatin-drug-information::F137634::3, Chunk amlodipine-and-atorvastatin-drug-information::F134112::6, Chunk omeprazole-clarithromycin-and-amoxicillin-copackaged-drug-information::F14471021::5, Chunk lansoprazole-amoxicillin-and-clarithromycin-copackaged-drug-information::F186882::5, Chunk clarithromycin-drug-information::F152340::4].",
      "expected_answer": "Major interaction (strong CYP3A4 inhibitor). Avoid coadministration; if unavoidable, hold atorvastatin or limit to the lowest dose and monitor for myopathy.",
      "key_points_missing": [
        "Mechanism: strong CYP3A4 inhibition",
        "Severity: major",
        "Action: avoid; if unavoidable hold or use lowest dose with monitoring"
      ],
      "retrieval_metrics": {
        "recall_at_k": {
          "1": 0.0,
          "3": 0.0,
          "5": 0.0,
          "10": 0.0,
          "20": 0.0
        },
        "precision_at_k": {
          "1": 0.0,
          "3": 0.0,
          "5": 0.0,
          "10": 0.0,
          "20": 0.0
        },
        "mean_reciprocal_rank": 0.0,
        "average_precision": 0.0,
        "ndcg_at_k": {
          "1": 0.0,
          "3": 0.0,
          "5": 0.0,
          "10": 0.0,
          "20": 0.0
        },
        "essential_recall_at_k": {
          "1": 0.0,
          "3": 0.0,
          "5": 0.0,
          "10": 0.0,
          "20": 0.0
        },
        "first_relevant_rank": 0.0,
        "total_relevant": 1,
        "total_essential": 1
      },
      "qa_metrics": {
        "bleu_score": 0.019617413945080493,
        "rouge_1_f1": 0.2641509433962264,
        "rouge_2_f1": 0.05769230769230768,
        "rouge_l_f1": 0.2075471698113208,
        "semantic_similarity": 0.5698187947273254,
        "key_points_covered": 0.0,
        "key_points_found": [],
        "key_points_missing": [
          "Mechanism: strong CYP3A4 inhibition",
          "Severity: major",
          "Action: avoid; if unavoidable hold or use lowest dose with monitoring"
        ],
        "answer_length": 53,
        "has_answer": true,
        "factual_accuracy": null,
        "helpfulness": null
      },
      "root_cause": "both_systems",
      "severity": "high",
      "notes": null
    },
    {
      "question_id": "q010",
      "question": "Starting linezolid in a patient on sertraline. Is this safe?",
      "failure_types": [
        "retrieval_miss",
        "retrieval_irrelevant",
        "qa_incomplete"
      ],
      "retrieved_chunks": [
        {
          "chunk_id": "linezolid-drug-information::F188931::2",
          "score": 0.6,
          "rank": 1
        },
        {
          "chunk_id": "ergoloid-mesylates-drug-information::F166177::3",
          "score": 0.5963595430433523,
          "rank": 2
        },
        {
          "chunk_id": "dihydroergotamine-drug-information::F160435::4",
          "score": 0.5963595430433523,
          "rank": 3
        },
        {
          "chunk_id": "ergotamine-drug-information::F166284::4",
          "score": 0.5963595430433523,
          "rank": 4
        },
        {
          "chunk_id": "linezolid-drug-information::F188931::1",
          "score": 0.5903083809084277,
          "rank": 5
        }
      ],
      "relevant_chunks_found": [],
      "essential_chunks_missed": [
        "lexi-linezolid-2018#ddi-ssri"
      ],
      "generated_answer": "Based on the provided context, the use of linezolid in a patient on sertraline (an SSRI) may pose a significant risk due to the potential for serotonin syndrome. This is because linezolid has MAOI activity, which can increase serotonin levels [chunk_188931::1]. The risk is major, and it is recommended to avoid the combination. If the use of linezolid is unavoidable, close monitoring for signs and symptoms of serotonin syndrome is necessary [chunk_188931::1]. It is also important to note that discontinuing sertraline 2 weeks prior to linezolid administration is recommended to mitigate the risk [chunk_166177::3, chunk_160435::4, chunk_166284::4].",
      "expected_answer": "Major interaction: risk of serotonin syndrome (linezolid has MAOI activity). Avoid; if benefits outweigh risks, withhold SSRI or monitor very closely.",
      "key_points_missing": [
        "Mechanism: MAOI activity → ↑serotonin",
        "Severity: major",
        "Action: avoid; or stop SSRI/close monitoring if unavoidable"
      ],
      "retrieval_metrics": {
        "recall_at_k": {
          "1": 0.0,
          "3": 0.0,
          "5": 0.0,
          "10": 0.0,
          "20": 0.0
        },
        "precision_at_k": {
          "1": 0.0,
          "3": 0.0,
          "5": 0.0,
          "10": 0.0,
          "20": 0.0
        },
        "mean_reciprocal_rank": 0.0,
        "average_precision": 0.0,
        "ndcg_at_k": {
          "1": 0.0,
          "3": 0.0,
          "5": 0.0,
          "10": 0.0,
          "20": 0.0
        },
        "essential_recall_at_k": {
          "1": 0.0,
          "3": 0.0,
          "5": 0.0,
          "10": 0.0,
          "20": 0.0
        },
        "first_relevant_rank": 0.0,
        "total_relevant": 1,
        "total_essential": 1
      },
      "qa_metrics": {
        "bleu_score": 0.03282402093642064,
        "rouge_1_f1": 0.23622047244094488,
        "rouge_2_f1": 0.08,
        "rouge_l_f1": 0.15748031496062992,
        "semantic_similarity": 0.7798409461975098,
        "key_points_covered": 0.0,
        "key_points_found": [],
        "key_points_missing": [
          "Mechanism: MAOI activity → ↑serotonin",
          "Severity: major",
          "Action: avoid; or stop SSRI/close monitoring if unavoidable"
        ],
        "answer_length": 96,
        "has_answer": true,
        "factual_accuracy": null,
        "helpfulness": null
      },
      "root_cause": "both_systems",
      "severity": "high",
      "notes": null
    },
    {
      "question_id": "q011",
      "question": "Patient on digoxin will start amiodarone. What’s the interaction management?",
      "failure_types": [
        "retrieval_miss",
        "retrieval_irrelevant",
        "qa_incorrect",
        "qa_incomplete"
      ],
      "retrieved_chunks": [
        {
          "chunk_id": "digoxin-drug-information::F160110::4",
          "score": 0.9713385544864623,
          "rank": 1
        },
        {
          "chunk_id": "digoxin-drug-information::F160110::0",
          "score": 0.9653535237565192,
          "rank": 2
        },
        {
          "chunk_id": "digoxin-drug-information::F160110::8",
          "score": 0.9518168384472304,
          "rank": 3
        },
        {
          "chunk_id": "dronedarone-drug-information::F7907323::10",
          "score": 0.7607655344131665,
          "rank": 4
        },
        {
          "chunk_id": "niacin-and-simvastatin-drug-information::F5925425::0",
          "score": 0.7477619106718761,
          "rank": 5
        }
      ],
      "relevant_chunks_found": [],
      "essential_chunks_missed": [
        "lexi-digoxin-2018#ddi-amio"
      ],
      "generated_answer": "In the provided context, it is stated that Amiodarone may increase the serum concentration of Digoxin [chunk_digoxin-drug-information::F160110::8]. This interaction is classified as major (Risk D: Consider therapy modification). The mechanism is likely due to P-gp inhibition. If a patient is on both Digoxin and Amiodarone, it is recommended to reduce the Digoxin dose by 30-50% and closely monitor Digoxin levels and ECG. [chunk_digoxin-drug-information::F160110::8] and [chunk_dronedarone-drug-information::F7907323::10] provide more details on this interaction. However, it's important to note that the context does not specify the exact dosage adjustments for the Amiodarone-Digoxin interaction, so further consultation with a healthcare professional is advised.",
      "expected_answer": "Major interaction (P-gp inhibition). Reduce digoxin dose by ~30–50% and monitor levels/ECG.",
      "key_points_missing": [
        "Mechanism: P-gp inhibition → ↑digoxin",
        "Severity: major"
      ],
      "retrieval_metrics": {
        "recall_at_k": {
          "1": 0.0,
          "3": 0.0,
          "5": 0.0,
          "10": 0.0,
          "20": 0.0
        },
        "precision_at_k": {
          "1": 0.0,
          "3": 0.0,
          "5": 0.0,
          "10": 0.0,
          "20": 0.0
        },
        "mean_reciprocal_rank": 0.0,
        "average_precision": 0.0,
        "ndcg_at_k": {
          "1": 0.0,
          "3": 0.0,
          "5": 0.0,
          "10": 0.0,
          "20": 0.0
        },
        "essential_recall_at_k": {
          "1": 0.0,
          "3": 0.0,
          "5": 0.0,
          "10": 0.0,
          "20": 0.0
        },
        "first_relevant_rank": 0.0,
        "total_relevant": 1,
        "total_essential": 1
      },
      "qa_metrics": {
        "bleu_score": 0.0126815034293817,
        "rouge_1_f1": 0.22556390977443605,
        "rouge_2_f1": 0.10687022900763359,
        "rouge_l_f1": 0.2105263157894737,
        "semantic_similarity": 0.6580440402030945,
        "key_points_covered": 0.3333333333333333,
        "key_points_found": [
          "Action: reduce dose ~30–50% + monitor levels and ECG"
        ],
        "key_points_missing": [
          "Mechanism: P-gp inhibition → ↑digoxin",
          "Severity: major"
        ],
        "answer_length": 99,
        "has_answer": true,
        "factual_accuracy": null,
        "helpfulness": null
      },
      "root_cause": "both_systems",
      "severity": "high",
      "notes": null
    },
    {
      "question_id": "q012",
      "question": "COVID-19 patient asks for Paxlovid dosing and interaction checks.",
      "failure_types": [
        "retrieval_miss",
        "retrieval_irrelevant",
        "qa_incorrect",
        "qa_incomplete",
        "e2e_low_quality"
      ],
      "retrieved_chunks": [
        {
          "chunk_id": "paroxetine-drug-information::F206599::0",
          "score": 0.6,
          "rank": 1
        },
        {
          "chunk_id": "paroxetine-drug-information::F206600::0",
          "score": 0.5872745209628127,
          "rank": 2
        },
        {
          "chunk_id": "cycloserine-drug-information::F155528::1",
          "score": 0.5864790296660842,
          "rank": 3
        },
        {
          "chunk_id": "oxycodone-drug-information::F10162706::0",
          "score": 0.5821163001757451,
          "rank": 4
        },
        {
          "chunk_id": "paroxetine-drug-information::F7874764::0",
          "score": 0.577602770806748,
          "rank": 5
        }
      ],
      "relevant_chunks_found": [],
      "essential_chunks_missed": [],
      "generated_answer": "I'm unable to provide a specific dosing or interaction check for Paxlovid as it is not mentioned in the provided context. However, I can share the dosing information for Paxil (paroxetine) based on the given context.\n\nFor COVID-19 patients, I recommend consulting current clinical guidance for Paxlovid, as it is not mentioned in the provided context.\n\nFor Paxil, the dosing varies depending on the condition and age group:\n- For adults with Major Depressive Disorder (MDD), Generalized Anxiety Disorder (GAD), and Obsessive-Compulsive Disorder (OCD), the initial dose is 20 mg once daily, with potential increases by 10 mg/day increments at 1-week intervals, up to a maximum of 50 mg/day for adults and 40 mg/day for geriatric patients [chunk_F206599, chunk_F206600].\n\nRegarding drug-drug interactions, potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult the drug interactions database for more detailed information [chunk_F155528].\n\nPlease refer to the FDA-approved medication guide for the specific Paxil product you are considering [chunk_F7874764]. For Paxlovid, I strongly advise consulting current clinical guidance to ensure safe and effective use.",
      "expected_answer": "ABSTAIN. Not in ≤2018 corpus; recency-sensitive therapy. Advise consulting current guidance/pharmacist.",
      "key_points_missing": [
        "Explicit abstention",
        "Sets recency_risk = true",
        "Advises pharmacist/current guidance"
      ],
      "retrieval_metrics": {
        "recall_at_k": {
          "1": 0.0,
          "3": 0.0,
          "5": 0.0,
          "10": 0.0,
          "20": 0.0
        },
        "precision_at_k": {
          "1": 0.0,
          "3": 0.0,
          "5": 0.0,
          "10": 0.0,
          "20": 0.0
        },
        "mean_reciprocal_rank": 0.0,
        "average_precision": 0.0,
        "ndcg_at_k": {
          "1": 0.0,
          "3": 0.0,
          "5": 0.0,
          "10": 0.0,
          "20": 0.0
        },
        "essential_recall_at_k": {
          "1": 0.0,
          "3": 0.0,
          "5": 0.0,
          "10": 0.0,
          "20": 0.0
        },
        "first_relevant_rank": 0.0,
        "total_relevant": 0,
        "total_essential": 0
      },
      "qa_metrics": {
        "bleu_score": 0.0058936917486878985,
        "rouge_1_f1": 0.06796116504854369,
        "rouge_2_f1": 0.0196078431372549,
        "rouge_l_f1": 0.06796116504854369,
        "semantic_similarity": 0.3818419277667999,
        "key_points_covered": 0.0,
        "key_points_found": [],
        "key_points_missing": [
          "Explicit abstention",
          "Sets recency_risk = true",
          "Advises pharmacist/current guidance"
        ],
        "answer_length": 180,
        "has_answer": true,
        "factual_accuracy": null,
        "helpfulness": null
      },
      "root_cause": "both_systems",
      "severity": "high",
      "notes": null
    },
    {
      "question_id": "q013",
      "question": "What is the current first-line pharmacologic therapy per latest hypertension guidelines?",
      "failure_types": [
        "retrieval_miss",
        "retrieval_irrelevant",
        "qa_incorrect",
        "qa_incomplete"
      ],
      "retrieved_chunks": [
        {
          "chunk_id": "epoprostenol-drug-information::F165840::0",
          "score": 0.9271672921779921,
          "rank": 1
        },
        {
          "chunk_id": "atenolol-drug-information::F137401::0",
          "score": 0.7487943067071376,
          "rank": 2
        },
        {
          "chunk_id": "metoprolol-drug-information::F195770::2",
          "score": 0.6539475332649507,
          "rank": 3
        },
        {
          "chunk_id": "quinapril-drug-information::F216329::0",
          "score": 0.6355413237936726,
          "rank": 4
        },
        {
          "chunk_id": "bisoprolol-drug-information::F141616::0",
          "score": 0.6,
          "rank": 5
        }
      ],
      "relevant_chunks_found": [],
      "essential_chunks_missed": [
        "lexi-hypertension-2014#jnc8"
      ],
      "generated_answer": "Based on the provided context, the latest hypertension guidelines from 2014 (JNC8) suggest that pharmacologic treatment to lower blood pressure should be initiated for various patient groups, including those aged 60 and older with a systolic blood pressure (SBP) of 150 mm Hg or higher, and those under 60 with an SBP of 140 mm Hg or higher. However, it is important to note that the JNC8 guidelines are outdated, and current guidelines may provide more up-to-date recommendations. For pulmonary arterial hypertension (PAH), the latest guidelines from the Fifth World Symposium on Pulmonary Hypertension (WSPH) and the American College of Chest Physicians (ACCP) recommend continuous IV epoprostenol as first-line therapy in PAH patients with WHO-FC IV symptoms (WSPH [Gailè 2013], ACCP [Taichman 2014]). Therefore, it is crucial to consult the most recent hypertension guidelines for current treatment recommendations. [recency_risk = true]",
      "expected_answer": "ABSTAIN if asked for ‘current’ guidance (2018 corpus includes JNC8/2014). Flag recency risk.",
      "key_points_missing": [
        "Explicit abstention for ‘current’ guideline ask"
      ],
      "retrieval_metrics": {
        "recall_at_k": {
          "1": 0.0,
          "3": 0.0,
          "5": 0.0,
          "10": 0.0,
          "20": 0.0
        },
        "precision_at_k": {
          "1": 0.0,
          "3": 0.0,
          "5": 0.0,
          "10": 0.0,
          "20": 0.0
        },
        "mean_reciprocal_rank": 0.0,
        "average_precision": 0.0,
        "ndcg_at_k": {
          "1": 0.0,
          "3": 0.0,
          "5": 0.0,
          "10": 0.0,
          "20": 0.0
        },
        "essential_recall_at_k": {
          "1": 0.0,
          "3": 0.0,
          "5": 0.0,
          "10": 0.0,
          "20": 0.0
        },
        "first_relevant_rank": 0.0,
        "total_relevant": 1,
        "total_essential": 1
      },
      "qa_metrics": {
        "bleu_score": 0.0029199644099198964,
        "rouge_1_f1": 0.0880503144654088,
        "rouge_2_f1": 0.025477707006369428,
        "rouge_l_f1": 0.07547169811320753,
        "semantic_similarity": 0.24601370096206665,
        "key_points_covered": 0.6666666666666666,
        "key_points_found": [
          "Recognize JNC8 (2014) is outdated for ‘current’",
          "Sets recency_risk = true"
        ],
        "key_points_missing": [
          "Explicit abstention for ‘current’ guideline ask"
        ],
        "answer_length": 141,
        "has_answer": true,
        "factual_accuracy": null,
        "helpfulness": null
      },
      "root_cause": "both_systems",
      "severity": "high",
      "notes": null
    }
  ],
  "questions": [
    {
      "question_id": "q001",
      "question": {
        "id": "q001",
        "question": "5-year-old (18 kg) with acute otitis media. What is the amoxicillin dose and volume using 400 mg/5 mL suspension?",
        "question_type": "dosage",
        "difficulty": "medium",
        "expected_answer": "Amoxicillin 90 mg/kg/day divided q12h → 810 mg per dose (≈10.1 mL of 400 mg/5 mL), round to 10 mL per dose; max 4 g/day.",
        "answer_key_points": [
          "Uses high-dose 80–90 mg/kg/day regimen",
          "BID (q12h) frequency",
          "Per-dose ≈810 mg for 18 kg",
          "Volume ≈10.1 mL from 400 mg/5 mL (80 mg/mL); rounding to 10 mL OK",
          "Max daily 4 g acknowledged",
          "No renal adjustment if normal function",
          "Cites pediatric dosage section"
        ],
        "relevant_chunks": [
          {
            "chunk_id": "lexi-amoxicillin-2018#dosage",
            "relevance_score": 1.0,
            "is_essential": true,
            "note": null
          },
          {
            "chunk_id": "lexi-amoxicillin-2018#peds",
            "relevance_score": 1.0,
            "is_essential": false,
            "note": null
          }
        ],
        "drug_names": [
          "amoxicillin"
        ],
        "tags": [
          "dosage"
        ],
        "source_note": null,
        "reasoning": null,
        "gold": {
          "dose_per_dose_mg": 810,
          "doses_per_day": 2,
          "total_daily_mg": 1620,
          "calc_rule": "90 mg/kg/day divided q12h",
          "max_daily_mg": 4000,
          "volume_per_dose_mL": 10.125,
          "rounding": {
            "to": "10 mL per dose",
            "basis": "80 mg/mL (400 mg/5 mL)"
          },
          "renal_adjustment": "none if normal renal function",
          "hepatic_adjustment": "none specified",
          "contraindications": [],
          "interactions": [],
          "recency_risk": false,
          "citations": [
            "lexi-amoxicillin-2018#dosage",
            "lexi-amoxicillin-2018#peds"
          ]
        }
      },
      "generated_answer": "For a 5-year-old weighing 18 kg with acute otitis media, the recommended dose of amoxicillin is 90 mg/kg/day, given twice daily. This equates to approximately 1620 mg per day. Using the 400 mg/5 mL suspension, the per-dose volume would be approximately 10 mL (rounded), with a maximum daily dose of 4 g. This dosing regimen is supported by [chunk_F134628::3]. No renal adjustment is necessary if the patient has normal renal function. However, it's important to note that this dosing is considered high-dose and is recommended for severe illness, those who have received amoxicillin in the past 30 days, treatment failure at 48 to 72 hours on first-line therapy, and when coverage for beta-lactamase positive H. influenzae and M. catarrhalis is needed. Always consult current clinical guidance for the most up-to-date information.",
      "expected_answer": "Amoxicillin 90 mg/kg/day divided q12h → 810 mg per dose (≈10.1 mL of 400 mg/5 mL), round to 10 mL per dose; max 4 g/day.",
      "retrieval_metrics": {
        "recall_at_k": {
          "1": 0.0,
          "3": 0.0,
          "5": 0.0,
          "10": 0.0,
          "20": 0.0
        },
        "precision_at_k": {
          "1": 0.0,
          "3": 0.0,
          "5": 0.0,
          "10": 0.0,
          "20": 0.0
        },
        "mean_reciprocal_rank": 0.0,
        "average_precision": 0.0,
        "ndcg_at_k": {
          "1": 0.0,
          "3": 0.0,
          "5": 0.0,
          "10": 0.0,
          "20": 0.0
        },
        "essential_recall_at_k": {
          "1": 0.0,
          "3": 0.0,
          "5": 0.0,
          "10": 0.0,
          "20": 0.0
        },
        "first_relevant_rank": 0.0,
        "total_relevant": 2,
        "total_essential": 1
      },
      "qa_metrics": {
        "bleu_score": 0.012209607336180515,
        "rouge_1_f1": 0.25287356321839083,
        "rouge_2_f1": 0.12790697674418605,
        "rouge_l_f1": 0.1954022988505747,
        "semantic_similarity": 0.7282848954200745,
        "key_points_covered": 0.2857142857142857,
        "key_points_found": [
          "Per-dose ≈810 mg for 18 kg",
          "No renal adjustment if normal function"
        ],
        "key_points_missing": [
          "Uses high-dose 80–90 mg/kg/day regimen",
          "BID (q12h) frequency",
          "Volume ≈10.1 mL from 400 mg/5 mL (80 mg/mL); rounding to 10 mL OK",
          "Max daily 4 g acknowledged",
          "Cites pediatric dosage section"
        ],
        "answer_length": 131,
        "has_answer": true,
        "factual_accuracy": null,
        "helpfulness": null
      },
      "retrieval_results": [
        {
          "chunk_id": "amoxicillin-and-clavulanate-drug-information::F134628::0",
          "score": 0.9696499257688352,
          "rank": 1
        },
        {
          "chunk_id": "amoxicillin-and-clavulanate-drug-information::F134628::1",
          "score": 0.9628399937112313,
          "rank": 2
        },
        {
          "chunk_id": "amoxicillin-and-clavulanate-drug-information::F134628::4",
          "score": 0.9443774772774779,
          "rank": 3
        },
        {
          "chunk_id": "amoxicillin-and-clavulanate-drug-information::F134628::5",
          "score": 0.9153727910154332,
          "rank": 4
        },
        {
          "chunk_id": "amoxicillin-and-clavulanate-drug-information::F134628::3",
          "score": 0.9068805286374405,
          "rank": 5
        }
      ],
      "context_chunks": [
        {
          "rank": 1,
          "score": 0.9696499257688352,
          "dense_score": 0.9578234970369355,
          "bm25_score": 0.987389568866685,
          "chunk_id": "amoxicillin-and-clavulanate-drug-information::F134628::0",
          "doc_id": "amoxicillin-and-clavulanate-drug-information",
          "section_title": "Dosing: Pediatric",
          "section_code": "dop",
          "drug_title": "Amoxicillin and clavulanate: Drug information",
          "source_url": "https://maadi-clinical.byethost8.com/d/topic.htm?path=amoxicillin-and-clavulanate-drug-information",
          "snippet": "Dosing: Pediatric  (For additional information see \"Amoxicillin and clavulanate: Pediatric drug information\")  Note: Dose is based on the amoxicillin component. Dose and frequency are product specific; not all products are interchangeable.…",
          "text": "Dosing: Pediatric\n\n(For additional information see \"Amoxicillin and clavulanate: Pediatric drug information\")\n\nNote: Dose is based on the amoxicillin component. Dose and frequency are product specific; not all products are interchangeable. Using a product with the incorrect amoxicillin:clavulanate ratio could result in subtherapeutic clavulanic acid concentrations or severe diarrhea.\n\nUsual dosage range:\n\nInfants <3 months: Oral: Amoxicillin 30 mg/kg/day divided every 12 hours using the 125 mg per 5 mL suspension only\n\nInfants ≥3 months, Children, and Adolescents <40 kg: Oral: Immediate release:\n\nMild to moderate infections: Amoxicillin 25 mg/kg/day in divided doses twice daily (using the 200 mg per 5 mL or 400 mg per 5 mL suspension or 200 mg or 400 mg chewable tablets) or amoxicillin 20 mg/kg/day in divided doses 3 times daily (using the 125 mg per 5 mL or 250 mg per 5 mL suspension) (maximum single dose: 500 mg amoxicillin)"
        },
        {
          "rank": 2,
          "score": 0.9628399937112313,
          "dense_score": 0.9467607727290666,
          "bm25_score": 0.9869588251844785,
          "chunk_id": "amoxicillin-and-clavulanate-drug-information::F134628::1",
          "doc_id": "amoxicillin-and-clavulanate-drug-information",
          "section_title": "Dosing: Pediatric",
          "section_code": "dop",
          "drug_title": "Amoxicillin and clavulanate: Drug information",
          "source_url": "https://maadi-clinical.byethost8.com/d/topic.htm?path=amoxicillin-and-clavulanate-drug-information",
          "snippet": "Severe infections: Amoxicillin 45 mg/kg/day in divided doses twice daily (using the 200 mg per 5 mL or 400 mg per 5 mL suspension or 200 mg or 400 mg chewable tablets) (maximum single dose: Amoxicillin 875 mg) or amoxicillin 40 mg/kg/day in…",
          "text": "Severe infections: Amoxicillin 45 mg/kg/day in divided doses twice daily (using the 200 mg per 5 mL or 400 mg per 5 mL suspension or 200 mg or 400 mg chewable tablets) (maximum single dose: Amoxicillin 875 mg) or amoxicillin 40 mg/kg/day in divided doses 3 times daily (using the 125 mg per 5 mL or 250 mg per 5 mL suspension) (maximum single dose: Amoxicillin 500 mg)\n\nChildren and Adolescents ≥40 kg: Oral:\n\nMild to moderate infections: Immediate release: Amoxicillin 500 mg every 12 hours (using the 500 mg tablet; if difficulty swallowing the 125 mg per 5 mL or 250 mg per 5 mL suspension may be used) or 250 mg amoxicillin every 8 hours (using the 250 mg tablet)\n\nSevere infections:\n\nImmediate release: Amoxicillin 875 mg every 12 hours (using the 875 mg tablet; if difficulty swallowing, the 200 mg per 5 mL or 400 mg per 5 mL suspension may be used) or amoxicillin 500 mg every 8 hours (using the 500 mg tablet; if difficulty swallowing, the 125 mg per 5 mL or 250 mg per 5 mL suspension may be used).\n\nExtended release: Amoxicillin 2,000 mg every 12 hours\n\nIndication-specific dosing:"
        },
        {
          "rank": 3,
          "score": 0.9443774772774779,
          "dense_score": 0.9072957954624632,
          "bm25_score": 1.0,
          "chunk_id": "amoxicillin-and-clavulanate-drug-information::F134628::4",
          "doc_id": "amoxicillin-and-clavulanate-drug-information",
          "section_title": "Dosing: Pediatric",
          "section_code": "dop",
          "drug_title": "Amoxicillin and clavulanate: Drug information",
          "source_url": "https://maadi-clinical.byethost8.com/d/topic.htm?path=amoxicillin-and-clavulanate-drug-information",
          "snippet": "Patients weighing <40 kg: Immediate release: Amoxicillin 45 mg/kg/day in divided doses twice daily (using the 200 mg per 5 mL or 400 mg per 5 mL suspension or the 200 mg or 400 mg chewable tablets) (maximum single dose: Amoxicillin 875 mg)…",
          "text": "Patients weighing <40 kg: Immediate release: Amoxicillin 45 mg/kg/day in divided doses twice daily (using the 200 mg per 5 mL or 400 mg per 5 mL suspension or the 200 mg or 400 mg chewable tablets) (maximum single dose: Amoxicillin 875 mg) or amoxicillin 40 mg/kg/day in divided doses 3 times daily (using the 125 mg per 5 mL or 250 mg per 5 mL suspension) (maximum single dose: Amoxicillin 500 mg)\n\nPatients weighing ≥40 kg:\n\nImmediate release: Amoxicillin 875 mg every 12 hours using the 875 mg tablet or if difficulty swallowing, the 200 mg/5 mL or the 400 mg/5 mL oral suspension may be used or 500 mg amoxicillin every 8 hours using the 500 mg tablet or if difficulty swallowing, the 125 mg/5 mL or 250 mg/5 mL oral suspension may be used\n\nExtended release: 2,000 mg amoxicillin every 12 hours\n\nAlternate dosing (off-label dosing): Beta-lactamase positive H. influenzae strains (IDSA/PIDS [Bradley 2011]): Immediate release:\n\nStandard dose: Amoxicillin 45 mg/kg/day in divided doses 3 times daily (using the 125 mg per 5 mL or 250 mg per 5 mL suspension) (maximum single dose: Amoxicillin 500 mg)"
        },
        {
          "rank": 4,
          "score": 0.9153727910154332,
          "dense_score": 0.9316550793792524,
          "bm25_score": 0.8909493584697046,
          "chunk_id": "amoxicillin-and-clavulanate-drug-information::F134628::5",
          "doc_id": "amoxicillin-and-clavulanate-drug-information",
          "section_title": "Dosing: Pediatric",
          "section_code": "dop",
          "drug_title": "Amoxicillin and clavulanate: Drug information",
          "source_url": "https://maadi-clinical.byethost8.com/d/topic.htm?path=amoxicillin-and-clavulanate-drug-information",
          "snippet": "High dose: Amoxicillin 90 mg/kg/day in divided doses 2 times daily (using the 600 mg per 5 mL suspension). Note: A wider dosing range of 80 to 100 mg/kg/day divided every 8 hours has also been used (Bradley 2002).  Sinusitis, acute bacteria…",
          "text": "High dose: Amoxicillin 90 mg/kg/day in divided doses 2 times daily (using the 600 mg per 5 mL suspension). Note: A wider dosing range of 80 to 100 mg/kg/day divided every 8 hours has also been used (Bradley 2002).\n\nSinusitis, acute bacterial: Oral:\n\nIDSA recommendations:\n\nInfants ≥3 months, Children, and Adolescents <40 kg: Immediate release:\n\nStandard dose: Amoxicillin 45 mg/kg/day divided every 12 hours for 10 to 14 days (using the 200 mg per 5 mL or 400 mg per 5 mL suspension or 200 mg or 400 mg chewable tablets only) (IDSA [Chow 2012])\n\nHigh dose (off-label dose): Amoxicillin 90 mg/kg/day divided every 12 hours for 10 to 14 days (using the 600 mg per 5 mL suspension only). Note: Use recommended in the following: If initial therapy fails (as second-line therapy), in areas with high endemic rates of penicillin-nonsusceptible S. pneumoniae, those with severe infections, daycare attendance, age <2 years, recent hospitalization, antibiotic use within the past month, or who are immunocompromised (IDSA [Chow 2012]).\n\nChildren and Adolescents ≥40 kg: Refer to adult dosing.\n\nAAP recommendations: Children and Adolescents: Immediate release:"
        },
        {
          "rank": 5,
          "score": 0.9068805286374405,
          "dense_score": 1.0,
          "bm25_score": 0.7672013215936013,
          "chunk_id": "amoxicillin-and-clavulanate-drug-information::F134628::3",
          "doc_id": "amoxicillin-and-clavulanate-drug-information",
          "section_title": "Dosing: Pediatric",
          "section_code": "dop",
          "drug_title": "Amoxicillin and clavulanate: Drug information",
          "source_url": "https://maadi-clinical.byethost8.com/d/topic.htm?path=amoxicillin-and-clavulanate-drug-information",
          "snippet": "Otitis media, acute: Infants ≥6 months and Children: Oral: Immediate release: Amoxicillin 90 mg/kg/day divided every 12 hours (using the 600 mg per 5 mL suspension only). Note: Use for severe illness, those who have received amoxicillin in…",
          "text": "Otitis media, acute: Infants ≥6 months and Children: Oral: Immediate release: Amoxicillin 90 mg/kg/day divided every 12 hours (using the 600 mg per 5 mL suspension only). Note: Use for severe illness, those who have received amoxicillin in the past 30 days, who have treatment failure at 48 to 72 hours on first-line therapy, and when coverage for beta-lactamase positive H. influenzae and M. catarrhalis is needed. Variable duration of therapy; the manufacturer’s labeling suggests 10-day course in all patients; however, new data suggest a shorter-course in some cases: If <2 years of age or severe symptoms (any age): 10-day course; if 2 to 5 years of age with mild to moderate symptoms: 7-day course; if ≥6 years of age with mild to moderate symptoms: 5- to 7-day course (AAP [Lieberthal 2013]). Note: Per the manufacturer, the 600 mg/5 mL formulation should only be used for patients weighing <40 kg.\n\nPneumonia, community-acquired (CAP) and respiratory tract infections, lower: Infants ≥3 months, Children, and Adolescents: Oral:\n\nManufacturer's labeling:"
        }
      ],
      "failure_analysis": {
        "question_id": "q001",
        "question": "5-year-old (18 kg) with acute otitis media. What is the amoxicillin dose and volume using 400 mg/5 mL suspension?",
        "failure_types": [
          "retrieval_miss",
          "retrieval_irrelevant",
          "qa_incomplete"
        ],
        "retrieved_chunks": [
          {
            "chunk_id": "amoxicillin-and-clavulanate-drug-information::F134628::0",
            "score": 0.9696499257688352,
            "rank": 1
          },
          {
            "chunk_id": "amoxicillin-and-clavulanate-drug-information::F134628::1",
            "score": 0.9628399937112313,
            "rank": 2
          },
          {
            "chunk_id": "amoxicillin-and-clavulanate-drug-information::F134628::4",
            "score": 0.9443774772774779,
            "rank": 3
          },
          {
            "chunk_id": "amoxicillin-and-clavulanate-drug-information::F134628::5",
            "score": 0.9153727910154332,
            "rank": 4
          },
          {
            "chunk_id": "amoxicillin-and-clavulanate-drug-information::F134628::3",
            "score": 0.9068805286374405,
            "rank": 5
          }
        ],
        "relevant_chunks_found": [],
        "essential_chunks_missed": [
          "lexi-amoxicillin-2018#dosage"
        ],
        "generated_answer": "For a 5-year-old weighing 18 kg with acute otitis media, the recommended dose of amoxicillin is 90 mg/kg/day, given twice daily. This equates to approximately 1620 mg per day. Using the 400 mg/5 mL suspension, the per-dose volume would be approximately 10 mL (rounded), with a maximum daily dose of 4 g. This dosing regimen is supported by [chunk_F134628::3]. No renal adjustment is necessary if the patient has normal renal function. However, it's important to note that this dosing is considered high-dose and is recommended for severe illness, those who have received amoxicillin in the past 30 days, treatment failure at 48 to 72 hours on first-line therapy, and when coverage for beta-lactamase positive H. influenzae and M. catarrhalis is needed. Always consult current clinical guidance for the most up-to-date information.",
        "expected_answer": "Amoxicillin 90 mg/kg/day divided q12h → 810 mg per dose (≈10.1 mL of 400 mg/5 mL), round to 10 mL per dose; max 4 g/day.",
        "key_points_missing": [
          "Uses high-dose 80–90 mg/kg/day regimen",
          "BID (q12h) frequency",
          "Volume ≈10.1 mL from 400 mg/5 mL (80 mg/mL); rounding to 10 mL OK",
          "Max daily 4 g acknowledged",
          "Cites pediatric dosage section"
        ],
        "retrieval_metrics": {
          "recall_at_k": {
            "1": 0.0,
            "3": 0.0,
            "5": 0.0,
            "10": 0.0,
            "20": 0.0
          },
          "precision_at_k": {
            "1": 0.0,
            "3": 0.0,
            "5": 0.0,
            "10": 0.0,
            "20": 0.0
          },
          "mean_reciprocal_rank": 0.0,
          "average_precision": 0.0,
          "ndcg_at_k": {
            "1": 0.0,
            "3": 0.0,
            "5": 0.0,
            "10": 0.0,
            "20": 0.0
          },
          "essential_recall_at_k": {
            "1": 0.0,
            "3": 0.0,
            "5": 0.0,
            "10": 0.0,
            "20": 0.0
          },
          "first_relevant_rank": 0.0,
          "total_relevant": 2,
          "total_essential": 1
        },
        "qa_metrics": {
          "bleu_score": 0.012209607336180515,
          "rouge_1_f1": 0.25287356321839083,
          "rouge_2_f1": 0.12790697674418605,
          "rouge_l_f1": 0.1954022988505747,
          "semantic_similarity": 0.7282848954200745,
          "key_points_covered": 0.2857142857142857,
          "key_points_found": [
            "Per-dose ≈810 mg for 18 kg",
            "No renal adjustment if normal function"
          ],
          "key_points_missing": [
            "Uses high-dose 80–90 mg/kg/day regimen",
            "BID (q12h) frequency",
            "Volume ≈10.1 mL from 400 mg/5 mL (80 mg/mL); rounding to 10 mL OK",
            "Max daily 4 g acknowledged",
            "Cites pediatric dosage section"
          ],
          "answer_length": 131,
          "has_answer": true,
          "factual_accuracy": null,
          "helpfulness": null
        },
        "root_cause": "both_systems",
        "severity": "high",
        "notes": null
      }
    },
    {
      "question_id": "q002",
      "question": {
        "id": "q002",
        "question": "12 kg child with fever: acetaminophen dose and volume using 160 mg/5 mL?",
        "question_type": "dosage",
        "difficulty": "medium",
        "expected_answer": "Acetaminophen 15 mg/kg/dose q6h (range 10–15 mg/kg q4–6h) → 180 mg per dose ≈5.6 mL of 160 mg/5 mL; max 75 mg/kg/day (900 mg), and ≤4 g absolute.",
        "answer_key_points": [
          "Per-dose 15 mg/kg used",
          "q4–6h acceptable; target q6h in calc",
          "180 mg per dose for 12 kg",
          "Volume ≈5.625 mL from 32 mg/mL",
          "Daily max 75 mg/kg/day and ≤4 g",
          "Pediatric dosing section cited"
        ],
        "relevant_chunks": [
          {
            "chunk_id": "lexi-acetaminophen-2018#peds-dosing",
            "relevance_score": 1.0,
            "is_essential": true,
            "note": null
          },
          {
            "chunk_id": "lexi-acetaminophen-2018#max",
            "relevance_score": 1.0,
            "is_essential": false,
            "note": null
          }
        ],
        "drug_names": [
          "acetaminophen"
        ],
        "tags": [
          "dosage"
        ],
        "source_note": null,
        "reasoning": null,
        "gold": {
          "dose_per_dose_mg": 180,
          "doses_per_day": 4,
          "total_daily_mg": 720,
          "calc_rule": "15 mg/kg/dose q6h (10–15 mg/kg q4–6h acceptable)",
          "max_daily_mg": 900,
          "volume_per_dose_mL": 5.625,
          "rounding": {
            "to": "5.6 mL",
            "basis": "32 mg/mL (160 mg/5 mL)"
          },
          "renal_adjustment": "none for standard antipyresis",
          "hepatic_adjustment": "use caution in hepatic impairment",
          "contraindications": [],
          "interactions": [],
          "recency_risk": false,
          "citations": [
            "lexi-acetaminophen-2018#peds-dosing",
            "lexi-acetaminophen-2018#max"
          ]
        }
      },
      "generated_answer": "For a 12 kg child, the recommended dose of acetaminophen is 15 mg/kg, which equates to 180 mg per dose. Using a liquid formulation with a concentration of 32 mg/mL, the volume would be approximately 5.625 mL per dose. The maximum daily dose should not exceed 75 mg/kg/day or 4 grams, whichever is less.\n\nPlease refer to the pediatric dosing section for more detailed information [chunk_acetaminophen-paracetamol-dextromethorphan-and-phenylephrine-drug-information::F5093686::0]. It's important to note that when calculating the maximum daily dose, consider all sources of acetaminophen and all routes of administration. Do not exceed the maximum recommended daily dose.",
      "expected_answer": "Acetaminophen 15 mg/kg/dose q6h (range 10–15 mg/kg q4–6h) → 180 mg per dose ≈5.6 mL of 160 mg/5 mL; max 75 mg/kg/day (900 mg), and ≤4 g absolute.",
      "retrieval_metrics": {
        "recall_at_k": {
          "1": 0.0,
          "3": 0.0,
          "5": 0.0,
          "10": 0.0,
          "20": 0.0
        },
        "precision_at_k": {
          "1": 0.0,
          "3": 0.0,
          "5": 0.0,
          "10": 0.0,
          "20": 0.0
        },
        "mean_reciprocal_rank": 0.0,
        "average_precision": 0.0,
        "ndcg_at_k": {
          "1": 0.0,
          "3": 0.0,
          "5": 0.0,
          "10": 0.0,
          "20": 0.0
        },
        "essential_recall_at_k": {
          "1": 0.0,
          "3": 0.0,
          "5": 0.0,
          "10": 0.0,
          "20": 0.0
        },
        "first_relevant_rank": 0.0,
        "total_relevant": 2,
        "total_essential": 1
      },
      "qa_metrics": {
        "bleu_score": 0.029177728117107688,
        "rouge_1_f1": 0.2876712328767123,
        "rouge_2_f1": 0.11111111111111112,
        "rouge_l_f1": 0.24657534246575344,
        "semantic_similarity": 0.7394165396690369,
        "key_points_covered": 0.3333333333333333,
        "key_points_found": [
          "180 mg per dose for 12 kg",
          "Pediatric dosing section cited"
        ],
        "key_points_missing": [
          "Per-dose 15 mg/kg used",
          "q4–6h acceptable; target q6h in calc",
          "Volume ≈5.625 mL from 32 mg/mL",
          "Daily max 75 mg/kg/day and ≤4 g"
        ],
        "answer_length": 95,
        "has_answer": true,
        "factual_accuracy": null,
        "helpfulness": null
      },
      "retrieval_results": [
        {
          "chunk_id": "acetaminophen-paracetamol-dextromethorphan-and-doxylamine-drug-information::F7677055::0",
          "score": 0.9387610943034719,
          "rank": 1
        },
        {
          "chunk_id": "acetaminophen-paracetamol-and-codeine-drug-information::F129503::0",
          "score": 0.9341212565159531,
          "rank": 2
        },
        {
          "chunk_id": "acetaminophen-paracetamol-dextromethorphan-and-phenylephrine-drug-information::F5093687::0",
          "score": 0.9065004236224677,
          "rank": 3
        },
        {
          "chunk_id": "acetaminophen-guaifenesin-and-phenylephrine-drug-information::F46679330::0",
          "score": 0.8996171395329055,
          "rank": 4
        },
        {
          "chunk_id": "acetaminophen-paracetamol-dextromethorphan-and-phenylephrine-drug-information::F5093686::0",
          "score": 0.8956243962421511,
          "rank": 5
        }
      ],
      "context_chunks": [
        {
          "rank": 1,
          "score": 0.9387610943034719,
          "dense_score": 0.9399239208246516,
          "bm25_score": 0.9370168545217022,
          "chunk_id": "acetaminophen-paracetamol-dextromethorphan-and-doxylamine-drug-information::F7677055::0",
          "doc_id": "acetaminophen-paracetamol-dextromethorphan-and-doxylamine-drug-information",
          "section_title": "Dosing: Adult",
          "section_code": "doa",
          "drug_title": "Acetaminophen (paracetamol), dextromethorphan, and doxylamine: Drug information",
          "source_url": "https://maadi-clinical.byethost8.com/d/topic.htm?path=acetaminophen-paracetamol-dextromethorphan-and-doxylamine-drug-information",
          "snippet": "Dosing: Adult  Note: When calculating the maximum daily dose, consider all sources of acetaminophen (prescription and OTC) and all routes of administration. Do not exceed the maximum recommended daily dose.  Cold and flu symptoms: Oral:  Ca…",
          "text": "Dosing: Adult\n\nNote: When calculating the maximum daily dose, consider all sources of acetaminophen (prescription and OTC) and all routes of administration. Do not exceed the maximum recommended daily dose.\n\nCold and flu symptoms: Oral:\n\nCapsule: Acetaminophen 325 mg/dextromethorphan 10 mg/doxylamine 6.25 mg per capsule: Two capsules (acetaminophen 650 mg/dextromethorphan 20 mg/doxylamine 12.5 mg) every 4 hours (maximum: 8 capsules [acetaminophen 2,600 mg/dextromethorphan 80 mg/doxylamine 50 mg] per 24 hours).\n\nLiquid: Acetaminophen 650 mg/dextromethorphan 30 mg/doxylamine 12.5 mg per 30 mL: 30 mL every 6 hours (maximum: 120 mL [acetaminophen 2,600 mg/dextromethorphan 120 mg/doxylamine 50 mg] per 24 hours"
        },
        {
          "rank": 2,
          "score": 0.9341212565159531,
          "dense_score": 0.9287687399671777,
          "bm25_score": 0.9421500313391162,
          "chunk_id": "acetaminophen-paracetamol-and-codeine-drug-information::F129503::0",
          "doc_id": "acetaminophen-paracetamol-and-codeine-drug-information",
          "section_title": "Dosing: Pediatric",
          "section_code": "dop",
          "drug_title": "Acetaminophen (paracetamol) and codeine: Drug information",
          "source_url": "https://maadi-clinical.byethost8.com/d/topic.htm?path=acetaminophen-paracetamol-and-codeine-drug-information",
          "snippet": "Dosing: Pediatric  (For additional information see \"Acetaminophen (paracetamol) and codeine: Pediatric drug information\")  Note: The FDA has recommended that codeine not be used in pediatric patients <12 years of age and all pediatric patie…",
          "text": "Dosing: Pediatric\n\n(For additional information see \"Acetaminophen (paracetamol) and codeine: Pediatric drug information\")\n\nNote: The FDA has recommended that codeine not be used in pediatric patients <12 years of age and all pediatric patients undergoing tonsillectomy and/or adenoidectomy (FDA 2015; FDA 2017).\n\nPain management: Oral: Solution or suspension:\n\nAcetaminophen 120 mg/codeine 12 mg per 5 mL: Adolescents: Refer to adult dosing\n\nAcetaminophen 160 mg/codeine 8 mg per 5 mL [Canadian product]: Children ≥12 years and Adolescents: Refer to adult dosing."
        },
        {
          "rank": 3,
          "score": 0.9065004236224677,
          "dense_score": 0.9531259300368946,
          "bm25_score": 0.8365621640008275,
          "chunk_id": "acetaminophen-paracetamol-dextromethorphan-and-phenylephrine-drug-information::F5093687::0",
          "doc_id": "acetaminophen-paracetamol-dextromethorphan-and-phenylephrine-drug-information",
          "section_title": "Dosing: Adult",
          "section_code": "doa",
          "drug_title": "Acetaminophen (paracetamol), dextromethorphan, and phenylephrine: Drug information",
          "source_url": "https://maadi-clinical.byethost8.com/d/topic.htm?path=acetaminophen-paracetamol-dextromethorphan-and-phenylephrine-drug-information",
          "snippet": "Dosing: Adult  Note: When calculating the maximum daily dose, consider all sources of acetaminophen (prescription and OTC) and all routes of administration. Do not exceed the maximum recommended daily dose.  Cold and flu symptoms: Oral:  Ac…",
          "text": "Dosing: Adult\n\nNote: When calculating the maximum daily dose, consider all sources of acetaminophen (prescription and OTC) and all routes of administration. Do not exceed the maximum recommended daily dose.\n\nCold and flu symptoms: Oral:\n\nAcetaminophen 325 mg/dextromethorphan 10 mg/phenylephrine 5 mg per capsule/tablet: Two capsules/tablets every 4 hours. Refer to product-specific labeling for maximum daily dosage; varies by product (maximum dosage range: 8 to 12 capsules/tablets [acetaminophen 2,600 to 3,900 mg/dextromethorphan 80 to 120 mg/phenylephrine 40 to 60 mg] per 24 hours)\n\nAcetaminophen 325 mg/dextromethorphan 10 mg/phenylephrine 5 mg per 15 mL (liquid/syrup): 30 mL every 4 hours. Refer to product-specific labeling for maximum daily dosage; varies by product (maximum: 120 to 180 mL [acetaminophen 2,600 to 3,900 mg/dextromethorphan 80 to 120 mg/phenylephrine 40 to 60 mg] per 24 hours)\n\nAcetaminophen 500 mg/dextromethorphan 20 mg/phenylephrine 10 mg per packet (as powder for solution): One packet every 4 hours (maximum: 6 packets [acetaminophen 3,000 mg/dextromethorphan 120 mg/phenylephrine 60 mg] per 24 hours)."
        },
        {
          "rank": 4,
          "score": 0.8996171395329055,
          "dense_score": 0.9414560112491369,
          "bm25_score": 0.8368588319585581,
          "chunk_id": "acetaminophen-guaifenesin-and-phenylephrine-drug-information::F46679330::0",
          "doc_id": "acetaminophen-guaifenesin-and-phenylephrine-drug-information",
          "section_title": "Dosing: Adult",
          "section_code": "doa",
          "drug_title": "Acetaminophen, guaifenesin, and phenylephrine: Drug information",
          "source_url": "https://maadi-clinical.byethost8.com/d/topic.htm?path=acetaminophen-guaifenesin-and-phenylephrine-drug-information",
          "snippet": "Dosing: Adult  Note: When calculating the maximum daily dose, consider all sources of acetaminophen (prescription and OTC) and all routes of administration. Do not exceed the maximum recommended daily dose.  Allergies/common cold/hay fever:…",
          "text": "Dosing: Adult\n\nNote: When calculating the maximum daily dose, consider all sources of acetaminophen (prescription and OTC) and all routes of administration. Do not exceed the maximum recommended daily dose.\n\nAllergies/common cold/hay fever: Oral: Acetaminophen 325 mg/guaifenesin 200 mg/phenylephrine 5 mg: Two tablets every 4 hours (maximum: 10 tablets [acetaminophen 3,250 mg/guaifenesin 2,000 mg/phenylephrine 50 mg]/24 hours)."
        },
        {
          "rank": 5,
          "score": 0.8956243962421511,
          "dense_score": 0.9736539885159728,
          "bm25_score": 0.7785800078314185,
          "chunk_id": "acetaminophen-paracetamol-dextromethorphan-and-phenylephrine-drug-information::F5093686::0",
          "doc_id": "acetaminophen-paracetamol-dextromethorphan-and-phenylephrine-drug-information",
          "section_title": "Dosing: Pediatric",
          "section_code": "dop",
          "drug_title": "Acetaminophen (paracetamol), dextromethorphan, and phenylephrine: Drug information",
          "source_url": "https://maadi-clinical.byethost8.com/d/topic.htm?path=acetaminophen-paracetamol-dextromethorphan-and-phenylephrine-drug-information",
          "snippet": "Dosing: Pediatric  Cold and flu symptoms: Oral:  Children 6 to 11 years: Vicks DayQuil Cold & Flu Multi-Symptom Liquid: Acetaminophen 325 mg/dextromethorphan 10 mg/phenylephrine 5 mg per 15 mL: 15 mL every 4 hours (maximum: 60 mL [acetamino…",
          "text": "Dosing: Pediatric\n\nCold and flu symptoms: Oral:\n\nChildren 6 to 11 years: Vicks DayQuil Cold & Flu Multi-Symptom Liquid: Acetaminophen 325 mg/dextromethorphan 10 mg/phenylephrine 5 mg per 15 mL: 15 mL every 4 hours (maximum: 60 mL [acetaminophen 1,300 mg/dextromethorphan 40 mg/phenylephrine 20 mg] per 24 hours)\n\nChildren ≥12 years and Adolescents: Refer to adult dosing."
        }
      ],
      "failure_analysis": {
        "question_id": "q002",
        "question": "12 kg child with fever: acetaminophen dose and volume using 160 mg/5 mL?",
        "failure_types": [
          "retrieval_miss",
          "retrieval_irrelevant",
          "qa_incomplete"
        ],
        "retrieved_chunks": [
          {
            "chunk_id": "acetaminophen-paracetamol-dextromethorphan-and-doxylamine-drug-information::F7677055::0",
            "score": 0.9387610943034719,
            "rank": 1
          },
          {
            "chunk_id": "acetaminophen-paracetamol-and-codeine-drug-information::F129503::0",
            "score": 0.9341212565159531,
            "rank": 2
          },
          {
            "chunk_id": "acetaminophen-paracetamol-dextromethorphan-and-phenylephrine-drug-information::F5093687::0",
            "score": 0.9065004236224677,
            "rank": 3
          },
          {
            "chunk_id": "acetaminophen-guaifenesin-and-phenylephrine-drug-information::F46679330::0",
            "score": 0.8996171395329055,
            "rank": 4
          },
          {
            "chunk_id": "acetaminophen-paracetamol-dextromethorphan-and-phenylephrine-drug-information::F5093686::0",
            "score": 0.8956243962421511,
            "rank": 5
          }
        ],
        "relevant_chunks_found": [],
        "essential_chunks_missed": [
          "lexi-acetaminophen-2018#peds-dosing"
        ],
        "generated_answer": "For a 12 kg child, the recommended dose of acetaminophen is 15 mg/kg, which equates to 180 mg per dose. Using a liquid formulation with a concentration of 32 mg/mL, the volume would be approximately 5.625 mL per dose. The maximum daily dose should not exceed 75 mg/kg/day or 4 grams, whichever is less.\n\nPlease refer to the pediatric dosing section for more detailed information [chunk_acetaminophen-paracetamol-dextromethorphan-and-phenylephrine-drug-information::F5093686::0]. It's important to note that when calculating the maximum daily dose, consider all sources of acetaminophen and all routes of administration. Do not exceed the maximum recommended daily dose.",
        "expected_answer": "Acetaminophen 15 mg/kg/dose q6h (range 10–15 mg/kg q4–6h) → 180 mg per dose ≈5.6 mL of 160 mg/5 mL; max 75 mg/kg/day (900 mg), and ≤4 g absolute.",
        "key_points_missing": [
          "Per-dose 15 mg/kg used",
          "q4–6h acceptable; target q6h in calc",
          "Volume ≈5.625 mL from 32 mg/mL",
          "Daily max 75 mg/kg/day and ≤4 g"
        ],
        "retrieval_metrics": {
          "recall_at_k": {
            "1": 0.0,
            "3": 0.0,
            "5": 0.0,
            "10": 0.0,
            "20": 0.0
          },
          "precision_at_k": {
            "1": 0.0,
            "3": 0.0,
            "5": 0.0,
            "10": 0.0,
            "20": 0.0
          },
          "mean_reciprocal_rank": 0.0,
          "average_precision": 0.0,
          "ndcg_at_k": {
            "1": 0.0,
            "3": 0.0,
            "5": 0.0,
            "10": 0.0,
            "20": 0.0
          },
          "essential_recall_at_k": {
            "1": 0.0,
            "3": 0.0,
            "5": 0.0,
            "10": 0.0,
            "20": 0.0
          },
          "first_relevant_rank": 0.0,
          "total_relevant": 2,
          "total_essential": 1
        },
        "qa_metrics": {
          "bleu_score": 0.029177728117107688,
          "rouge_1_f1": 0.2876712328767123,
          "rouge_2_f1": 0.11111111111111112,
          "rouge_l_f1": 0.24657534246575344,
          "semantic_similarity": 0.7394165396690369,
          "key_points_covered": 0.3333333333333333,
          "key_points_found": [
            "180 mg per dose for 12 kg",
            "Pediatric dosing section cited"
          ],
          "key_points_missing": [
            "Per-dose 15 mg/kg used",
            "q4–6h acceptable; target q6h in calc",
            "Volume ≈5.625 mL from 32 mg/mL",
            "Daily max 75 mg/kg/day and ≤4 g"
          ],
          "answer_length": 95,
          "has_answer": true,
          "factual_accuracy": null,
          "helpfulness": null
        },
        "root_cause": "both_systems",
        "severity": "high",
        "notes": null
      }
    },
    {
      "question_id": "q003",
      "question": {
        "id": "q003",
        "question": "12 kg child with fever: ibuprofen dose and volume using 100 mg/5 mL?",
        "question_type": "dosage",
        "difficulty": "medium",
        "expected_answer": "Ibuprofen 10 mg/kg/dose q6–8h → 120 mg per dose (6 mL of 100 mg/5 mL); max 40 mg/kg/day (480 mg). Avoid if <6 months or dehydrated/renal issues.",
        "answer_key_points": [
          "10 mg/kg per dose",
          "q6–8h frequency",
          "120 mg per dose for 12 kg",
          "6 mL at 20 mg/mL",
          "Max 40 mg/kg/day (480 mg)",
          "Contraindication: <6 months; caution renal/dehydration"
        ],
        "relevant_chunks": [
          {
            "chunk_id": "lexi-ibuprofen-2018#peds-dosing",
            "relevance_score": 1.0,
            "is_essential": true,
            "note": null
          },
          {
            "chunk_id": "lexi-ibuprofen-2018#max",
            "relevance_score": 1.0,
            "is_essential": false,
            "note": null
          }
        ],
        "drug_names": [
          "ibuprofen"
        ],
        "tags": [
          "dosage"
        ],
        "source_note": null,
        "reasoning": null,
        "gold": {
          "dose_per_dose_mg": 120,
          "doses_per_day": 4,
          "total_daily_mg": 480,
          "calc_rule": "10 mg/kg/dose q6–8h; max 40 mg/kg/day",
          "max_daily_mg": 480,
          "volume_per_dose_mL": 6.0,
          "rounding": {
            "to": "6 mL",
            "basis": "20 mg/mL (100 mg/5 mL)"
          },
          "renal_adjustment": "avoid in significant renal impairment/dehydration",
          "hepatic_adjustment": "use caution",
          "contraindications": [
            "<6 months age",
            "active GI bleed"
          ],
          "interactions": [],
          "recency_risk": false,
          "citations": [
            "lexi-ibuprofen-2018#peds-dosing",
            "lexi-ibuprofen-2018#max"
          ]
        }
      },
      "generated_answer": "<s> [OUT] For a 12 kg child with fever, the recommended oral ibuprofen dose is 10 mg/kg every 6 to 8 hours, which equates to 120 mg per dose. Using a 100 mg/5 mL suspension, this would require 6 mL (100 mg/5 mL × 6 mL = 120 mg). The maximum daily dose is 40 mg/kg/day (480 mg). Ibuprofen is contraindicated in infants younger than 6 months and should be used with caution in patients with renal impairment or dehydration [Chunk ibuprofen-drug-information::F181483::0, Chunk ibuprofen-drug-information::F181483::1]. [/OUT]",
      "expected_answer": "Ibuprofen 10 mg/kg/dose q6–8h → 120 mg per dose (6 mL of 100 mg/5 mL); max 40 mg/kg/day (480 mg). Avoid if <6 months or dehydrated/renal issues.",
      "retrieval_metrics": {
        "recall_at_k": {
          "1": 0.0,
          "3": 0.0,
          "5": 0.0,
          "10": 0.0,
          "20": 0.0
        },
        "precision_at_k": {
          "1": 0.0,
          "3": 0.0,
          "5": 0.0,
          "10": 0.0,
          "20": 0.0
        },
        "mean_reciprocal_rank": 0.0,
        "average_precision": 0.0,
        "ndcg_at_k": {
          "1": 0.0,
          "3": 0.0,
          "5": 0.0,
          "10": 0.0,
          "20": 0.0
        },
        "essential_recall_at_k": {
          "1": 0.0,
          "3": 0.0,
          "5": 0.0,
          "10": 0.0,
          "20": 0.0
        },
        "first_relevant_rank": 0.0,
        "total_relevant": 2,
        "total_essential": 1
      },
      "qa_metrics": {
        "bleu_score": 0.0957707317125527,
        "rouge_1_f1": 0.40310077519379844,
        "rouge_2_f1": 0.25196850393700787,
        "rouge_l_f1": 0.37209302325581395,
        "semantic_similarity": 0.7674603462219238,
        "key_points_covered": 0.5,
        "key_points_found": [
          "10 mg/kg per dose",
          "120 mg per dose for 12 kg",
          "Max 40 mg/kg/day (480 mg)"
        ],
        "key_points_missing": [
          "q6–8h frequency",
          "6 mL at 20 mg/mL",
          "Contraindication: <6 months; caution renal/dehydration"
        ],
        "answer_length": 85,
        "has_answer": true,
        "factual_accuracy": null,
        "helpfulness": null
      },
      "retrieval_results": [
        {
          "chunk_id": "ibuprofen-drug-information::F181483::0",
          "score": 0.9212129200352679,
          "rank": 1
        },
        {
          "chunk_id": "ibuprofen-drug-information::F181483::1",
          "score": 0.9075397476544838,
          "rank": 2
        },
        {
          "chunk_id": "aspirin-drug-information::F137119::4",
          "score": 0.9020363895576701,
          "rank": 3
        },
        {
          "chunk_id": "ibuprofen-drug-information::F181430::0",
          "score": 0.8459380646492902,
          "rank": 4
        },
        {
          "chunk_id": "diphenhydramine-systemic-drug-information::F8082169::1",
          "score": 0.7642147249945784,
          "rank": 5
        }
      ],
      "context_chunks": [
        {
          "rank": 1,
          "score": 0.9212129200352679,
          "dense_score": 0.9857173395179257,
          "bm25_score": 0.8244562908112812,
          "chunk_id": "ibuprofen-drug-information::F181483::0",
          "doc_id": "ibuprofen-drug-information",
          "section_title": "Dosing: Pediatric",
          "section_code": "dop",
          "drug_title": "Ibuprofen: Drug information",
          "source_url": "https://maadi-clinical.byethost8.com/d/topic.htm?path=ibuprofen-drug-information",
          "snippet": "Dosing: Pediatric  (For additional information see \"Ibuprofen: Pediatric drug information\")  Analgesia:  IV (Caldolor): Note: Patients should be well hydrated prior to administration.  Infants ≥6 months and Children <12 years: 10 mg/kg (max…",
          "text": "Dosing: Pediatric\n\n(For additional information see \"Ibuprofen: Pediatric drug information\")\n\nAnalgesia:\n\nIV (Caldolor): Note: Patients should be well hydrated prior to administration.\n\nInfants ≥6 months and Children <12 years: 10 mg/kg (maximum dose: 400 mg) every 4 to 6 hours as needed; maximum daily dose: 40 mg/kg/day or 2,400 mg/day, whichever is less.\n\nChildren and Adolescents 12 to 17 years: 400 mg every 4 to 6 hours as needed; maximum daily dose: 2,400 mg/day.\n\nOral: Infants and Children <50 kg: Limited data available in infants <6 months: 4 to 10 mg/kg/dose every 6 to 8 hours; maximum single dose: 400 mg; maximum daily dose: 40 mg/kg/day (American Pain Society 2016; Berde 1990; Berde 2002; Kliegman 2011)\n\nAntipyretic:\n\nIV (Caldolor): Note: Patients should be well hydrated prior to administration.\n\nInfants ≥6 months and Children <12 years: 10 mg/kg (maximum dose: 400 mg) every 4 to 6 hours as needed; maximum daily dose: 40 mg/kg/day or 2,400 mg/day, whichever is less.\n\nChildren and Adolescents 12 to 17 years: 400 mg every 4 to 6 hours as needed (maximum daily dose: 2,400 mg/day)"
        },
        {
          "rank": 2,
          "score": 0.9075397476544838,
          "dense_score": 0.9502859048509137,
          "bm25_score": 0.843420511859839,
          "chunk_id": "ibuprofen-drug-information::F181483::1",
          "doc_id": "ibuprofen-drug-information",
          "section_title": "Dosing: Pediatric",
          "section_code": "dop",
          "drug_title": "Ibuprofen: Drug information",
          "source_url": "https://maadi-clinical.byethost8.com/d/topic.htm?path=ibuprofen-drug-information",
          "snippet": "Oral: Infants ≥6 months, Children, and Adolescents: 5 to 10 mg/kg/dose every 6 to 8 hours; maximum single dose: 400 mg; maximum daily dose: 40 mg/kg/day up to 1,200 mg, unless directed by physician (under physician supervision, not to excee…",
          "text": "Oral: Infants ≥6 months, Children, and Adolescents: 5 to 10 mg/kg/dose every 6 to 8 hours; maximum single dose: 400 mg; maximum daily dose: 40 mg/kg/day up to 1,200 mg, unless directed by physician (under physician supervision, not to exceed maximum of 2,400 mg daily) (Litalien 2001; Sullivan 2011).\n\nJuvenile idiopathic arthritis (JIA) (off-label use): Oral: Children and Adolescents: 30 to 40 mg/kg/day in 3 to 4 divided doses; start at lower end of dosing range and titrate; patients with milder disease may be treated with 20 mg/kg/day; patients with more severe disease may require up to 50 mg/kg/day; maximum single dose: 800 mg; maximum daily dose: 2,400 mg (Giannini 1990; Kliegman 2011; Litalien 2001).\n\nPatent ductus arteriosus: IV (ibuprofen lysine [NeoProfen]): Infants weighing between 500 to 1,500 g and ≤32 weeks' GA: Initial dose: Ibuprofen 10 mg/kg, followed by two doses of 5 mg/kg at 24 and 48 hours. Dose should be based on birth weight.\n\nOTC labeling (analgesic, antipyretic): Oral: Note: Discontinue use and consult health care provider if no improvement within 24 hours after initiating therapy or if symptoms persist >3 days or worsen."
        },
        {
          "rank": 3,
          "score": 0.9020363895576701,
          "dense_score": 0.9308233848430707,
          "bm25_score": 0.8588558966295692,
          "chunk_id": "aspirin-drug-information::F137119::4",
          "doc_id": "aspirin-drug-information",
          "section_title": "Dosing: Pediatric",
          "section_code": "dop",
          "drug_title": "Aspirin: Drug information",
          "source_url": "https://maadi-clinical.byethost8.com/d/topic.htm?path=aspirin-drug-information",
          "snippet": "Moderate dose: 30 to 50 mg/kg/day divided every 6 hours for up to 14 days until fever resolves for at least 48 to 72 hours (AHA [McCrindle 2017]).  Subsequent therapy (low-dose; antiplatelet effects): 3 to 5 mg/kg/day once daily; reported d…",
          "text": "Moderate dose: 30 to 50 mg/kg/day divided every 6 hours for up to 14 days until fever resolves for at least 48 to 72 hours (AHA [McCrindle 2017]).\n\nSubsequent therapy (low-dose; antiplatelet effects): 3 to 5 mg/kg/day once daily; reported dosing range: 1 to 5 mg/kg/day; initiate after fever resolution (or after 14 days). In patients without coronary artery abnormalities, administer the lower dose for 6 to 8 weeks. In patients with coronary artery abnormalities, low-dose aspirin should be continued indefinitely (in addition to therapy with warfarin) (AAP [Red Book 2015]; ACCP [Monagle 2012]; AHA [Giglia 2013]; AHA [McCrindle 2017]).\n\nRheumatic fever (off-label use): Limited data available: Infants, Children, and Adolescents: Oral: Initial: 100 mg/kg/day divided into 4 to 5 doses; if response inadequate, may increase dose to 125 mg/kg/day; continue for 2 weeks; then decrease dose to 60 to 70 mg/kg/day in divided doses for an additional 3 to 6 weeks (WHO Guidelines 2004)."
        },
        {
          "rank": 4,
          "score": 0.8459380646492902,
          "dense_score": 0.9317700885098792,
          "bm25_score": 0.7171900288584068,
          "chunk_id": "ibuprofen-drug-information::F181430::0",
          "doc_id": "ibuprofen-drug-information",
          "section_title": "Dosage Forms",
          "section_code": "foc",
          "drug_title": "Ibuprofen: Drug information",
          "source_url": "https://maadi-clinical.byethost8.com/d/topic.htm?path=ibuprofen-drug-information",
          "snippet": "Dosage Forms  Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product  Capsule, Oral:  Advil: 200 mg  Advil Migraine: 200 mg  GoodSense Ibuprofen:…",
          "text": "Dosage Forms\n\nExcipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product\n\nCapsule, Oral:\n\nAdvil: 200 mg\n\nAdvil Migraine: 200 mg\n\nGoodSense Ibuprofen: 200 mg [gluten free; contains brilliant blue fcf (fd&c blue #1)]\n\nKS Ibuprofen: 200 mg [contains fd&c blue #2 (indigotine)]\n\nGeneric: 200 mg\n\nKit, Combination:\n\nIbuprofen Comfort Pac: 800 mg [contains methylparaben, trolamine (triethanolamine)]\n\nSolution, Intravenous:\n\nCaldolor: 400 mg/4 mL (4 mL [DSC]); 800 mg/8 mL (8 mL)\n\nSolution, Intravenous, as lysine [preservative free]:\n\nNeoProfen: 10 mg/mL (2 mL)\n\nGeneric: 10 mg/mL (2 mL)\n\nSuspension, Oral:\n\nChildrens Advil: 100 mg/5 mL (120 mL) [fruit flavor]\n\nChildrens Advil: 100 mg/5 mL (120 mL) [contains edetate disodium, fd&c red #40, polysorbate 80, propylene glycol, sodium benzoate]\n\nChildrens Advil: 100 mg/5 mL (120 mL) [alcohol free; grape flavor]\n\nChildrens Advil: 100 mg/5 mL (120 mL) [alcohol free; contains brilliant blue fcf (fd&c blue #1), edetate disodium, fd&c red #40, polysorbate 80, propylene glycol, sodium benzoate; grape flavor]"
        },
        {
          "rank": 5,
          "score": 0.7642147249945784,
          "dense_score": 0.9204996513523056,
          "bm25_score": 0.5297873354579877,
          "chunk_id": "diphenhydramine-systemic-drug-information::F8082169::1",
          "doc_id": "diphenhydramine-systemic-drug-information",
          "section_title": "Dosing: Pediatric",
          "section_code": "dop",
          "drug_title": "Diphenhydramine (systemic): Drug information",
          "source_url": "https://maadi-clinical.byethost8.com/d/topic.htm?path=diphenhydramine-systemic-drug-information",
          "snippet": "Children ≥12 years and Adolescents: Refer to adult dosing.  Motion sickness:  Prophylaxis: Oral:  Manufacturer's labeling: Infants, Children, and Adolescents: Note: Administer 30 minutes before motion  Weight-directed dosing: 5 mg/kg/day di…",
          "text": "Children ≥12 years and Adolescents: Refer to adult dosing.\n\nMotion sickness:\n\nProphylaxis: Oral:\n\nManufacturer's labeling: Infants, Children, and Adolescents: Note: Administer 30 minutes before motion\n\nWeight-directed dosing: 5 mg/kg/day divided into 3 to 4 doses; maximum: 300 mg daily\n\nFixed dosing: 12.5 to 25 mg 3 to 4 times daily\n\nAlternate dosing: Children 2 to 12 years: Limited data available: 0.5 to 1 mg/kg/dose every 6 hours; maximum single dose: 25 mg. First dose should be administered 1 hour before travel (CDC, 2014).\n\nTreatment: Infants, Children, and Adolescents:\n\nIV, IM: 5 mg/kg/day divided into 4 doses; maximum: 300 mg daily\n\nOral:\n\nWeight-directed dosing: 5 mg/kg/day divided into 3 to 4 doses; maximum: 300 mg daily\n\nFixed dosing: 12.5 to 25 mg 3 to 4 times daily\n\nRhinitis, sneezing due to common cold: Oral:\n\nChildren 6 to <12 years: 12.5 to 25 mg every 4 to 6 hours; maximum: 150 mg daily\n\nChildren ≥12 years and Adolescents: Refer to adult dosing."
        }
      ],
      "failure_analysis": {
        "question_id": "q003",
        "question": "12 kg child with fever: ibuprofen dose and volume using 100 mg/5 mL?",
        "failure_types": [
          "retrieval_miss",
          "retrieval_irrelevant",
          "qa_incomplete"
        ],
        "retrieved_chunks": [
          {
            "chunk_id": "ibuprofen-drug-information::F181483::0",
            "score": 0.9212129200352679,
            "rank": 1
          },
          {
            "chunk_id": "ibuprofen-drug-information::F181483::1",
            "score": 0.9075397476544838,
            "rank": 2
          },
          {
            "chunk_id": "aspirin-drug-information::F137119::4",
            "score": 0.9020363895576701,
            "rank": 3
          },
          {
            "chunk_id": "ibuprofen-drug-information::F181430::0",
            "score": 0.8459380646492902,
            "rank": 4
          },
          {
            "chunk_id": "diphenhydramine-systemic-drug-information::F8082169::1",
            "score": 0.7642147249945784,
            "rank": 5
          }
        ],
        "relevant_chunks_found": [],
        "essential_chunks_missed": [
          "lexi-ibuprofen-2018#peds-dosing"
        ],
        "generated_answer": "<s> [OUT] For a 12 kg child with fever, the recommended oral ibuprofen dose is 10 mg/kg every 6 to 8 hours, which equates to 120 mg per dose. Using a 100 mg/5 mL suspension, this would require 6 mL (100 mg/5 mL × 6 mL = 120 mg). The maximum daily dose is 40 mg/kg/day (480 mg). Ibuprofen is contraindicated in infants younger than 6 months and should be used with caution in patients with renal impairment or dehydration [Chunk ibuprofen-drug-information::F181483::0, Chunk ibuprofen-drug-information::F181483::1]. [/OUT]",
        "expected_answer": "Ibuprofen 10 mg/kg/dose q6–8h → 120 mg per dose (6 mL of 100 mg/5 mL); max 40 mg/kg/day (480 mg). Avoid if <6 months or dehydrated/renal issues.",
        "key_points_missing": [
          "q6–8h frequency",
          "6 mL at 20 mg/mL",
          "Contraindication: <6 months; caution renal/dehydration"
        ],
        "retrieval_metrics": {
          "recall_at_k": {
            "1": 0.0,
            "3": 0.0,
            "5": 0.0,
            "10": 0.0,
            "20": 0.0
          },
          "precision_at_k": {
            "1": 0.0,
            "3": 0.0,
            "5": 0.0,
            "10": 0.0,
            "20": 0.0
          },
          "mean_reciprocal_rank": 0.0,
          "average_precision": 0.0,
          "ndcg_at_k": {
            "1": 0.0,
            "3": 0.0,
            "5": 0.0,
            "10": 0.0,
            "20": 0.0
          },
          "essential_recall_at_k": {
            "1": 0.0,
            "3": 0.0,
            "5": 0.0,
            "10": 0.0,
            "20": 0.0
          },
          "first_relevant_rank": 0.0,
          "total_relevant": 2,
          "total_essential": 1
        },
        "qa_metrics": {
          "bleu_score": 0.0957707317125527,
          "rouge_1_f1": 0.40310077519379844,
          "rouge_2_f1": 0.25196850393700787,
          "rouge_l_f1": 0.37209302325581395,
          "semantic_similarity": 0.7674603462219238,
          "key_points_covered": 0.5,
          "key_points_found": [
            "10 mg/kg per dose",
            "120 mg per dose for 12 kg",
            "Max 40 mg/kg/day (480 mg)"
          ],
          "key_points_missing": [
            "q6–8h frequency",
            "6 mL at 20 mg/mL",
            "Contraindication: <6 months; caution renal/dehydration"
          ],
          "answer_length": 85,
          "has_answer": true,
          "factual_accuracy": null,
          "helpfulness": null
        },
        "root_cause": "both_systems",
        "severity": "high",
        "notes": null
      }
    },
    {
      "question_id": "q004",
      "question": {
        "id": "q004",
        "question": "Elderly patient with nonvalvular AF: 82 years, 58 kg, SCr 1.6 mg/dL. What apixaban dose?",
        "question_type": "dosage",
        "difficulty": "medium",
        "expected_answer": "Apixaban 2.5 mg BID (meets 2 of 3: age ≥80, weight ≤60 kg, SCr ≥1.5). Avoid with strong CYP3A4/P-gp inhibitors.",
        "answer_key_points": [
          "Dose reduction criteria (2 of 3)",
          "Final dose 2.5 mg BID",
          "Interaction caveat: strong CYP3A4/P-gp",
          "Hepatic impairment caution"
        ],
        "relevant_chunks": [
          {
            "chunk_id": "lexi-apixaban-2018#dosing-nvaf",
            "relevance_score": 1.0,
            "is_essential": true,
            "note": null
          },
          {
            "chunk_id": "lexi-apixaban-2018#ddi",
            "relevance_score": 1.0,
            "is_essential": false,
            "note": null
          }
        ],
        "drug_names": [
          "apixaban"
        ],
        "tags": [
          "dosage"
        ],
        "source_note": null,
        "reasoning": null,
        "gold": {
          "dose_per_dose_mg": 2.5,
          "doses_per_day": 2,
          "total_daily_mg": 5,
          "calc_rule": "If ≥2 of {age ≥80, weight ≤60 kg, SCr ≥1.5} → 2.5 mg BID",
          "max_daily_mg": 10,
          "renal_adjustment": "criteria-based reduction as above",
          "hepatic_adjustment": "avoid in severe hepatic impairment",
          "contraindications": [
            "active bleeding"
          ],
          "interactions": [
            {
              "drug": "strong CYP3A4/P-gp inhibitors",
              "severity": "major",
              "action": "avoid or reduce/monitor"
            }
          ],
          "recency_risk": false,
          "citations": [
            "lexi-apixaban-2018#dosing-nvaf",
            "lexi-apixaban-2018#ddi"
          ]
        }
      },
      "generated_answer": "",
      "expected_answer": "Apixaban 2.5 mg BID (meets 2 of 3: age ≥80, weight ≤60 kg, SCr ≥1.5). Avoid with strong CYP3A4/P-gp inhibitors.",
      "retrieval_metrics": {
        "recall_at_k": {
          "1": 0.0,
          "3": 0.0,
          "5": 0.0,
          "10": 0.0,
          "20": 0.0
        },
        "precision_at_k": {
          "1": 0.0,
          "3": 0.0,
          "5": 0.0,
          "10": 0.0,
          "20": 0.0
        },
        "mean_reciprocal_rank": 0.0,
        "average_precision": 0.0,
        "ndcg_at_k": {
          "1": 0.0,
          "3": 0.0,
          "5": 0.0,
          "10": 0.0,
          "20": 0.0
        },
        "essential_recall_at_k": {
          "1": 0.0,
          "3": 0.0,
          "5": 0.0,
          "10": 0.0,
          "20": 0.0
        },
        "first_relevant_rank": 0.0,
        "total_relevant": 2,
        "total_essential": 1
      },
      "qa_metrics": {
        "bleu_score": 0.0,
        "rouge_1_f1": 0.0,
        "rouge_2_f1": 0.0,
        "rouge_l_f1": 0.0,
        "semantic_similarity": 0.0,
        "key_points_covered": 0.0,
        "key_points_found": [],
        "key_points_missing": [
          "Dose reduction criteria (2 of 3)",
          "Final dose 2.5 mg BID",
          "Interaction caveat: strong CYP3A4/P-gp",
          "Hepatic impairment caution"
        ],
        "answer_length": 0,
        "has_answer": false,
        "factual_accuracy": null,
        "helpfulness": null
      },
      "retrieval_results": [
        {
          "chunk_id": "apixaban-drug-information::F14478989::5",
          "score": 0.9581692199234102,
          "rank": 1
        },
        {
          "chunk_id": "apixaban-drug-information::F14479017::0",
          "score": 0.947467184370913,
          "rank": 2
        },
        {
          "chunk_id": "apixaban-drug-information::F14479016::4",
          "score": 0.907039286312251,
          "rank": 3
        },
        {
          "chunk_id": "apixaban-drug-information::F14479013::1",
          "score": 0.8198538938553019,
          "rank": 4
        },
        {
          "chunk_id": "apixaban-drug-information::F14478989::3",
          "score": 0.7271677458975699,
          "rank": 5
        }
      ],
      "context_chunks": [
        {
          "rank": 1,
          "score": 0.9581692199234102,
          "dense_score": 1.0,
          "bm25_score": 0.8954230498085254,
          "chunk_id": "apixaban-drug-information::F14478989::5",
          "doc_id": "apixaban-drug-information",
          "section_title": "Warnings/Precautions",
          "section_code": "war",
          "drug_title": "Apixaban: Drug information",
          "source_url": "https://maadi-clinical.byethost8.com/d/topic.htm?path=apixaban-drug-information",
          "snippet": "• Elderly: Systemic exposure is increased ~32% in patients >65 years of age; however, dose reductions are not required. Dosage reduction is recommended for patients with nonvalvular atrial fibrillation who are ≥80 years of age and either we…",
          "text": "• Elderly: Systemic exposure is increased ~32% in patients >65 years of age; however, dose reductions are not required. Dosage reduction is recommended for patients with nonvalvular atrial fibrillation who are ≥80 years of age and either weigh ≤60 kg or with a serum creatinine ≥1.5 mg/dL.\n\nOther warnings/precautions:\n\n• Appropriate use: In hemodynamically unstable patients with acute PE or patients with PE requiring thrombolysis or pulmonary embolectomy, the use of apixaban is not recommended as an alternative to unfractionated heparin for initial treatment.\n\n• Body weight: Systemic exposure may be increased by 20% to 30% in patients <50 kg and decreased by 20% to 30% in patients >120 kg; dosage reduction is recommended for patients with nonvalvular atrial fibrillation weighing ≤60 kg and either ≥80 years of age or with a serum creatinine ≥1.5 mg/dL."
        },
        {
          "rank": 2,
          "score": 0.947467184370913,
          "dense_score": 0.9124453072848551,
          "bm25_score": 1.0,
          "chunk_id": "apixaban-drug-information::F14479017::0",
          "doc_id": "apixaban-drug-information",
          "section_title": "Dosing: Geriatric",
          "section_code": "doe",
          "drug_title": "Apixaban: Drug information",
          "source_url": "https://maadi-clinical.byethost8.com/d/topic.htm?path=apixaban-drug-information",
          "snippet": "Dosing: Geriatric  Refer to adult dosing. Nonvalvular atrial fibrillation (to prevent stroke and systemic embolism): If patient is ≥80 years of age and either weighs ≤60 kg or has a serum creatinine ≥1.5 mg/dL, then reduce dose to 2.5 mg tw…",
          "text": "Dosing: Geriatric\n\nRefer to adult dosing. Nonvalvular atrial fibrillation (to prevent stroke and systemic embolism): If patient is ≥80 years of age and either weighs ≤60 kg or has a serum creatinine ≥1.5 mg/dL, then reduce dose to 2.5 mg twice daily."
        },
        {
          "rank": 3,
          "score": 0.907039286312251,
          "dense_score": 0.8484308286721864,
          "bm25_score": 0.9949519727723477,
          "chunk_id": "apixaban-drug-information::F14479016::4",
          "doc_id": "apixaban-drug-information",
          "section_title": "Dosing: Adult",
          "section_code": "doa",
          "drug_title": "Apixaban: Drug information",
          "source_url": "https://maadi-clinical.byethost8.com/d/topic.htm?path=apixaban-drug-information",
          "snippet": "Conversion from apixaban to other non-warfarin anticoagulants (oral or parenteral): Discontinue apixaban and begin taking the new non-warfarin anticoagulant at the usual time of the next scheduled dose of apixaban.  Conversion from other no…",
          "text": "Conversion from apixaban to other non-warfarin anticoagulants (oral or parenteral): Discontinue apixaban and begin taking the new non-warfarin anticoagulant at the usual time of the next scheduled dose of apixaban.\n\nConversion from other non-warfarin anticoagulants (oral or parenteral) to apixaban: Discontinue the other non-warfarin anticoagulant and begin taking apixaban at the usual time of the next scheduled dose of the other non-warfarin anticoagulant.\n\nDosage adjustment of apixaban with concomitant medications: For patients receiving dual strong CYP3A4 and P-glycoprotein inhibitors (eg, ketoconazole, itraconazole, ritonavir) and apixaban doses >2.5 mg twice daily, reduce apixaban dose by 50%. Note: Avoid concomitant use with dual strong CYP3A4 and P-glycoprotein inhibitors if patient is already taking apixaban 2.5 mg twice daily or patient meets 2 of the following criteria: Age ≥80 years, body weight ≤60 kg, or serum creatinine ≥1.5 mg/dL."
        },
        {
          "rank": 4,
          "score": 0.8198538938553019,
          "dense_score": 0.8457041792143648,
          "bm25_score": 0.7810784658167078,
          "chunk_id": "apixaban-drug-information::F14479013::1",
          "doc_id": "apixaban-drug-information",
          "section_title": "Dosing: Renal Impairment",
          "section_code": "dor",
          "drug_title": "Apixaban: Drug information",
          "source_url": "https://maadi-clinical.byethost8.com/d/topic.htm?path=apixaban-drug-information",
          "snippet": "Serum creatinine ≥1.5 mg/dL and either ≥80 years of age or body weight ≤60 kg: 2.5 mg twice daily. Note: Patients with a serum creatinine >2.5 mg/dL or CrCl <25 mL/minute (as determined by Cockcroft-Gault equation) were excluded from clinic…",
          "text": "Serum creatinine ≥1.5 mg/dL and either ≥80 years of age or body weight ≤60 kg: 2.5 mg twice daily. Note: Patients with a serum creatinine >2.5 mg/dL or CrCl <25 mL/minute (as determined by Cockcroft-Gault equation) were excluded from clinical trials (Connolly 2011; Granger 2011).\n\nSevere or ESRD not requiring hemodialysis: Warfarin remains the anticoagulant of choice (AHA/ACC/HRS [January 2014]). However, in patients who cannot take warfarin, some experts consider apixaban to be a reasonable alternative (Manning 2018)."
        },
        {
          "rank": 5,
          "score": 0.7271677458975699,
          "dense_score": 0.8482231633897543,
          "bm25_score": 0.5455846196592934,
          "chunk_id": "apixaban-drug-information::F14478989::3",
          "doc_id": "apixaban-drug-information",
          "section_title": "Warnings/Precautions",
          "section_code": "war",
          "drug_title": "Apixaban: Drug information",
          "source_url": "https://maadi-clinical.byethost8.com/d/topic.htm?path=apixaban-drug-information",
          "snippet": "• Renal impairment: Systemic exposure increases with worsening renal function. Bleeding risk may be increased in severe renal impairment (CrCl <15 to 29 mL/minute); use with caution. Patients with significant renal impairment (eg, CrCl <30…",
          "text": "• Renal impairment: Systemic exposure increases with worsening renal function. Bleeding risk may be increased in severe renal impairment (CrCl <15 to 29 mL/minute); use with caution. Patients with significant renal impairment (eg, CrCl <30 mL/minute) were excluded from clinical trials. Dosage reduction is recommended for patients with nonvalvular atrial fibrillation and 2 of the 3 following risk factors: Serum creatinine ≥1.5 mg/dL, age ≥80 years, or weight ≤60 kg. Compared to warfarin, apixaban has been shown to be associated with less major bleeding among all ranges of estimated GFRs as determined by initial serum creatinine; however, patients with a serum creatinine >2.5 mg/dL or CrCl <25 mL/minute (as determined by Cockcroft-Gault equation) were excluded from the analysis (Hohnloser 2012). Use with caution in patients on hemodialysis; limited information is available. In patients who develop acute kidney injury during use, closely monitor or consider switching to an alternative anticoagulant due to an increased risk of bleeding in this population (AHA [Raval 2017])."
        }
      ],
      "failure_analysis": {
        "question_id": "q004",
        "question": "Elderly patient with nonvalvular AF: 82 years, 58 kg, SCr 1.6 mg/dL. What apixaban dose?",
        "failure_types": [
          "retrieval_miss",
          "retrieval_irrelevant",
          "qa_no_answer",
          "e2e_low_quality"
        ],
        "retrieved_chunks": [
          {
            "chunk_id": "apixaban-drug-information::F14478989::5",
            "score": 0.9581692199234102,
            "rank": 1
          },
          {
            "chunk_id": "apixaban-drug-information::F14479017::0",
            "score": 0.947467184370913,
            "rank": 2
          },
          {
            "chunk_id": "apixaban-drug-information::F14479016::4",
            "score": 0.907039286312251,
            "rank": 3
          },
          {
            "chunk_id": "apixaban-drug-information::F14479013::1",
            "score": 0.8198538938553019,
            "rank": 4
          },
          {
            "chunk_id": "apixaban-drug-information::F14478989::3",
            "score": 0.7271677458975699,
            "rank": 5
          }
        ],
        "relevant_chunks_found": [],
        "essential_chunks_missed": [
          "lexi-apixaban-2018#dosing-nvaf"
        ],
        "generated_answer": "",
        "expected_answer": "Apixaban 2.5 mg BID (meets 2 of 3: age ≥80, weight ≤60 kg, SCr ≥1.5). Avoid with strong CYP3A4/P-gp inhibitors.",
        "key_points_missing": [
          "Dose reduction criteria (2 of 3)",
          "Final dose 2.5 mg BID",
          "Interaction caveat: strong CYP3A4/P-gp",
          "Hepatic impairment caution"
        ],
        "retrieval_metrics": {
          "recall_at_k": {
            "1": 0.0,
            "3": 0.0,
            "5": 0.0,
            "10": 0.0,
            "20": 0.0
          },
          "precision_at_k": {
            "1": 0.0,
            "3": 0.0,
            "5": 0.0,
            "10": 0.0,
            "20": 0.0
          },
          "mean_reciprocal_rank": 0.0,
          "average_precision": 0.0,
          "ndcg_at_k": {
            "1": 0.0,
            "3": 0.0,
            "5": 0.0,
            "10": 0.0,
            "20": 0.0
          },
          "essential_recall_at_k": {
            "1": 0.0,
            "3": 0.0,
            "5": 0.0,
            "10": 0.0,
            "20": 0.0
          },
          "first_relevant_rank": 0.0,
          "total_relevant": 2,
          "total_essential": 1
        },
        "qa_metrics": {
          "bleu_score": 0.0,
          "rouge_1_f1": 0.0,
          "rouge_2_f1": 0.0,
          "rouge_l_f1": 0.0,
          "semantic_similarity": 0.0,
          "key_points_covered": 0.0,
          "key_points_found": [],
          "key_points_missing": [
            "Dose reduction criteria (2 of 3)",
            "Final dose 2.5 mg BID",
            "Interaction caveat: strong CYP3A4/P-gp",
            "Hepatic impairment caution"
          ],
          "answer_length": 0,
          "has_answer": false,
          "factual_accuracy": null,
          "helpfulness": null
        },
        "root_cause": "both_systems",
        "severity": "critical",
        "notes": null
      }
    },
    {
      "question_id": "q005",
      "question": {
        "id": "q005",
        "question": "85 kg adult with acute DVT: What is the enoxaparin treatment dose (normal renal function)?",
        "question_type": "dosage",
        "difficulty": "medium",
        "expected_answer": "Enoxaparin 1 mg/kg SC q12h → 85 mg per dose (or 1.5 mg/kg once daily as alternative). If CrCl <30 mL/min: 1 mg/kg once daily.",
        "answer_key_points": [
          "1 mg/kg q12h primary regimen",
          "Alternative 1.5 mg/kg q24h",
          "Per-dose 85 mg for 85 kg",
          "Renal adjustment for CrCl <30"
        ],
        "relevant_chunks": [
          {
            "chunk_id": "lexi-enoxaparin-2018#dosing",
            "relevance_score": 1.0,
            "is_essential": true,
            "note": null
          },
          {
            "chunk_id": "lexi-enoxaparin-2018#renal",
            "relevance_score": 1.0,
            "is_essential": false,
            "note": null
          }
        ],
        "drug_names": [
          "enoxaparin"
        ],
        "tags": [
          "dosage"
        ],
        "source_note": null,
        "reasoning": null,
        "gold": {
          "dose_per_dose_mg": 85,
          "doses_per_day": 2,
          "total_daily_mg": 170,
          "calc_rule": "1 mg/kg q12h (or 1.5 mg/kg q24h alternative)",
          "max_daily_mg": null,
          "renal_adjustment": "CrCl <30: 1 mg/kg once daily",
          "hepatic_adjustment": "use caution",
          "contraindications": [
            "active major bleeding",
            "history of HIT (use alternative)"
          ],
          "interactions": [],
          "recency_risk": false,
          "citations": [
            "lexi-enoxaparin-2018#dosing",
            "lexi-enoxaparin-2018#renal"
          ]
        }
      },
      "generated_answer": "For an 85 kg adult with normal renal function (CrCl >30 mL/minute), the recommended enoxaparin treatment dose for acute DVT is 1 mg/kg every 12 hours, as per [chunk_165080::7]. This equates to a per-dose of 85 mg. However, it's important to note that in patients with venous thromboembolism (VTE) and without cancer, oral anticoagulants are preferred over LMWH (unless LMWH is used as initial parenteral anticoagulation prior to dabigatran, edoxaban, or while initiating warfarin) [chunk_165080::6]. As always, patient-specific factors and institutional protocols should be considered when determining the appropriate dose.",
      "expected_answer": "Enoxaparin 1 mg/kg SC q12h → 85 mg per dose (or 1.5 mg/kg once daily as alternative). If CrCl <30 mL/min: 1 mg/kg once daily.",
      "retrieval_metrics": {
        "recall_at_k": {
          "1": 0.0,
          "3": 0.0,
          "5": 0.0,
          "10": 0.0,
          "20": 0.0
        },
        "precision_at_k": {
          "1": 0.0,
          "3": 0.0,
          "5": 0.0,
          "10": 0.0,
          "20": 0.0
        },
        "mean_reciprocal_rank": 0.0,
        "average_precision": 0.0,
        "ndcg_at_k": {
          "1": 0.0,
          "3": 0.0,
          "5": 0.0,
          "10": 0.0,
          "20": 0.0
        },
        "essential_recall_at_k": {
          "1": 0.0,
          "3": 0.0,
          "5": 0.0,
          "10": 0.0,
          "20": 0.0
        },
        "first_relevant_rank": 0.0,
        "total_relevant": 2,
        "total_essential": 1
      },
      "qa_metrics": {
        "bleu_score": 0.00543548164681866,
        "rouge_1_f1": 0.21875,
        "rouge_2_f1": 0.09523809523809523,
        "rouge_l_f1": 0.125,
        "semantic_similarity": 0.716378927230835,
        "key_points_covered": 0.25,
        "key_points_found": [
          "Per-dose 85 mg for 85 kg"
        ],
        "key_points_missing": [
          "1 mg/kg q12h primary regimen",
          "Alternative 1.5 mg/kg q24h",
          "Renal adjustment for CrCl <30"
        ],
        "answer_length": 90,
        "has_answer": true,
        "factual_accuracy": null,
        "helpfulness": null
      },
      "retrieval_results": [
        {
          "chunk_id": "enoxaparin-drug-information::F165080::0",
          "score": 0.974611806765285,
          "rank": 1
        },
        {
          "chunk_id": "enoxaparin-drug-information::F165080::4",
          "score": 0.9311993677533739,
          "rank": 2
        },
        {
          "chunk_id": "enoxaparin-drug-information::F165080::7",
          "score": 0.8299820035826407,
          "rank": 3
        },
        {
          "chunk_id": "enoxaparin-drug-information::F165082::1",
          "score": 0.7917338034459854,
          "rank": 4
        },
        {
          "chunk_id": "enoxaparin-drug-information::F165039::4",
          "score": 0.7558109038250175,
          "rank": 5
        }
      ],
      "context_chunks": [
        {
          "rank": 1,
          "score": 0.974611806765285,
          "dense_score": 1.0,
          "bm25_score": 0.9365295169132126,
          "chunk_id": "enoxaparin-drug-information::F165080::0",
          "doc_id": "enoxaparin-drug-information",
          "section_title": "Dosing: Adult",
          "section_code": "doa",
          "drug_title": "Enoxaparin: Drug information",
          "source_url": "https://maadi-clinical.byethost8.com/d/topic.htm?path=enoxaparin-drug-information",
          "snippet": "Dosing: Adult  Note: One mg of enoxaparin is equal to 100 units of anti-Xa activity (World Health Organization First International Low Molecular Weight Heparin Reference Standard). Weight-based doses (eg, 1 mg/kg) are commonly rounded to th…",
          "text": "Dosing: Adult\n\nNote: One mg of enoxaparin is equal to 100 units of anti-Xa activity (World Health Organization First International Low Molecular Weight Heparin Reference Standard). Weight-based doses (eg, 1 mg/kg) are commonly rounded to the nearest 10 mg; also see institution-specific rounding protocols if available. Most available prefilled syringes are graduated in 10 mg increments.\n\nDVT prophylaxis: SubQ:\n\nObesity:\n\nNote: In morbidly-obese patients (BMI ≥40 kg/m2), increasing the prophylactic dose by 30% may be appropriate for some indications (Nutescu 2009). For bariatric surgery, dose increases may be >30% based on clinical trial data.\n\nAbdominal surgery: 40 mg once daily, with initial dose given 2 hours prior to surgery; continue until risk of DVT has diminished (usually 7 to 10 days).\n\nHip replacement surgery:"
        },
        {
          "rank": 2,
          "score": 0.9311993677533739,
          "dense_score": 0.8853322795889564,
          "bm25_score": 1.0,
          "chunk_id": "enoxaparin-drug-information::F165080::4",
          "doc_id": "enoxaparin-drug-information",
          "section_title": "Dosing: Adult",
          "section_code": "doa",
          "drug_title": "Enoxaparin: Drug information",
          "source_url": "https://maadi-clinical.byethost8.com/d/topic.htm?path=enoxaparin-drug-information",
          "snippet": "Prevention of recurrent venous thromboembolism in pregnancy (off-label use): 40 mg once daily. Therapy should continue for 6 weeks postpartum in high-risk women (Bates 2012).  DVT treatment (acute) and pulmonary embolism (acute) (off-label)…",
          "text": "Prevention of recurrent venous thromboembolism in pregnancy (off-label use): 40 mg once daily. Therapy should continue for 6 weeks postpartum in high-risk women (Bates 2012).\n\nDVT treatment (acute) and pulmonary embolism (acute) (off-label): SubQ: Note: In patients with VTE and without cancer, oral anticoagulants are preferred over LMWH (unless LMWH is used as initial parenteral anticoagulation prior to dabigatran, edoxaban, or while initiating warfarin) (Kearon 2012; Kearon 2016). In patients transitioning to warfarin, start warfarin on the first or second treatment day and continue enoxaparin until INR is ≥2 for at least 24 hours (usually 5 to 7 days) (Guyatt 2012).\n\nInpatient treatment of DVT (with or without pulmonary embolism) and pulmonary embolism: 1 mg/kg/dose every 12 hours or 1.5 mg/kg once daily (Kearon 2012; Kearon 2016)\n\nOutpatient treatment (without pulmonary embolism): 1 mg/kg/dose every 12 hours\n\nObesity: Use actual body weight to calculate dose; a fixed upper dose limit is not recommended, however, increased monitoring and dosage adjustment based on anti-Xa levels may be warranted; use of twice daily dosing preferred (Nutescu 2009)."
        },
        {
          "rank": 3,
          "score": 0.8299820035826407,
          "dense_score": 0.8336894799493411,
          "bm25_score": 0.8244207890325902,
          "chunk_id": "enoxaparin-drug-information::F165080::7",
          "doc_id": "enoxaparin-drug-information",
          "section_title": "Dosing: Adult",
          "section_code": "doa",
          "drug_title": "Enoxaparin: Drug information",
          "source_url": "https://maadi-clinical.byethost8.com/d/topic.htm?path=enoxaparin-drug-information",
          "snippet": "Mechanical heart valve (aortic or mitral position) to bridge anticoagulation (off-label use): SubQ: 1 mg/kg every 12 hours (ACCP [Douketis, 2012]). Note: If used in pregnant patients, target anti-Xa level of 0.8 to 1.2 units/mL, 4 to 6 hour…",
          "text": "Mechanical heart valve (aortic or mitral position) to bridge anticoagulation (off-label use): SubQ: 1 mg/kg every 12 hours (ACCP [Douketis, 2012]). Note: If used in pregnant patients, target anti-Xa level of 0.8 to 1.2 units/mL, 4 to 6 hours postdose (AHA/ACC [Nishimura 2014]).\n\nUnstable angina or non-ST-elevation MI (NSTEMI) (also referred to as NSTE-ACS): SubQ: 1 mg/kg every 12 hours in conjunction with oral aspirin therapy; continue for the duration of hospitalization or until PCI is performed; in select patients, an initial 30 mg IV loading dose has been used (ACC/AHA [Amsterdam 2014]).\n\nObesity: Use actual body weight to calculate dose; a fixed upper dose limit is not recommended (Nutescu 2009)\n\nConversion:\n\nConversion from IV unfractionated heparin (UFH) infusion to SubQ enoxaparin (Nutescu 2007): Calculate specific dose for enoxaparin based on indication, discontinue UFH and begin enoxaparin within 1 hour.\n\nConversion from SubQ enoxaparin (therapeutically dosed) to IV UFH infusion (Nutescu 2007):"
        },
        {
          "rank": 4,
          "score": 0.7917338034459854,
          "dense_score": 0.830184464380884,
          "bm25_score": 0.7340578120436376,
          "chunk_id": "enoxaparin-drug-information::F165082::1",
          "doc_id": "enoxaparin-drug-information",
          "section_title": "Dosing: Renal Impairment",
          "section_code": "dor",
          "drug_title": "Enoxaparin: Drug information",
          "source_url": "https://maadi-clinical.byethost8.com/d/topic.htm?path=enoxaparin-drug-information",
          "snippet": "Dialysis: Enoxaparin has not been FDA approved for use in dialysis patients. Its elimination is primarily via the renal route. Serious bleeding complications have been reported with use in patients who are dialysis dependent or have severe…",
          "text": "Dialysis: Enoxaparin has not been FDA approved for use in dialysis patients. Its elimination is primarily via the renal route. Serious bleeding complications have been reported with use in patients who are dialysis dependent or have severe renal failure. LMWH administration at fixed doses without monitoring has greater unpredictable anticoagulant effects in patients with chronic kidney disease. If used, dosages should be reduced and anti-Xa levels frequently monitored, as accumulation may occur with repeated doses. Many clinicians would not use enoxaparin in this population especially without timely anti-Xa levels.\n\nHemodialysis: Not dialyzable (NCS/SCCM [Frontera 2016]). Supplemental dose is not necessary.\n\nPeritoneal dialysis: Significant drug removal is unlikely based on physiochemical characteristics."
        },
        {
          "rank": 5,
          "score": 0.7558109038250175,
          "dense_score": 0.8772161332460431,
          "bm25_score": 0.5737030596934791,
          "chunk_id": "enoxaparin-drug-information::F165039::4",
          "doc_id": "enoxaparin-drug-information",
          "section_title": "Warnings/Precautions",
          "section_code": "war",
          "drug_title": "Enoxaparin: Drug information",
          "source_url": "https://maadi-clinical.byethost8.com/d/topic.htm?path=enoxaparin-drug-information",
          "snippet": "• Renal impairment: Use with caution in patients with renal failure; dosage adjustment needed if CrCl <30 mL/minute.  Special populations:  • Elderly: Use with caution in the elderly; delayed elimination may occur. Dosage alteration/adjustm…",
          "text": "• Renal impairment: Use with caution in patients with renal failure; dosage adjustment needed if CrCl <30 mL/minute.\n\nSpecial populations:\n\n• Elderly: Use with caution in the elderly; delayed elimination may occur. Dosage alteration/adjustment may be required (eg, omission of IV bolus in acute STEMI in patients ≥75 years of age).\n\n• Low weight patients: Risk of bleeding may be increased in women <45 kg and in men <57 kg.\n\n• Obesity: Safety and efficacy of prophylactic dosing of enoxaparin has not been established in patients who are obese (>30 kg/m2) nor is there a consensus regarding dosage adjustments; monitor closely for signs/symptoms of thromboembolism. Anti-Xa levels are increased to appropriate levels when enoxaparin is dosed on actual body weight in obese patients weighing up to 144 kg (Sanderink 2002). Monitoring of anti-Xa levels 4 hours after the dose may be warranted. The American College of Chest Physicians Practice Guidelines suggest consulting with a pharmacist regarding dosing in bariatric surgery patients and other obese patients who may require higher doses of LMWH (ACCP [Gould 2012])."
        }
      ],
      "failure_analysis": {
        "question_id": "q005",
        "question": "85 kg adult with acute DVT: What is the enoxaparin treatment dose (normal renal function)?",
        "failure_types": [
          "retrieval_miss",
          "retrieval_irrelevant",
          "qa_incomplete"
        ],
        "retrieved_chunks": [
          {
            "chunk_id": "enoxaparin-drug-information::F165080::0",
            "score": 0.974611806765285,
            "rank": 1
          },
          {
            "chunk_id": "enoxaparin-drug-information::F165080::4",
            "score": 0.9311993677533739,
            "rank": 2
          },
          {
            "chunk_id": "enoxaparin-drug-information::F165080::7",
            "score": 0.8299820035826407,
            "rank": 3
          },
          {
            "chunk_id": "enoxaparin-drug-information::F165082::1",
            "score": 0.7917338034459854,
            "rank": 4
          },
          {
            "chunk_id": "enoxaparin-drug-information::F165039::4",
            "score": 0.7558109038250175,
            "rank": 5
          }
        ],
        "relevant_chunks_found": [],
        "essential_chunks_missed": [
          "lexi-enoxaparin-2018#dosing"
        ],
        "generated_answer": "For an 85 kg adult with normal renal function (CrCl >30 mL/minute), the recommended enoxaparin treatment dose for acute DVT is 1 mg/kg every 12 hours, as per [chunk_165080::7]. This equates to a per-dose of 85 mg. However, it's important to note that in patients with venous thromboembolism (VTE) and without cancer, oral anticoagulants are preferred over LMWH (unless LMWH is used as initial parenteral anticoagulation prior to dabigatran, edoxaban, or while initiating warfarin) [chunk_165080::6]. As always, patient-specific factors and institutional protocols should be considered when determining the appropriate dose.",
        "expected_answer": "Enoxaparin 1 mg/kg SC q12h → 85 mg per dose (or 1.5 mg/kg once daily as alternative). If CrCl <30 mL/min: 1 mg/kg once daily.",
        "key_points_missing": [
          "1 mg/kg q12h primary regimen",
          "Alternative 1.5 mg/kg q24h",
          "Renal adjustment for CrCl <30"
        ],
        "retrieval_metrics": {
          "recall_at_k": {
            "1": 0.0,
            "3": 0.0,
            "5": 0.0,
            "10": 0.0,
            "20": 0.0
          },
          "precision_at_k": {
            "1": 0.0,
            "3": 0.0,
            "5": 0.0,
            "10": 0.0,
            "20": 0.0
          },
          "mean_reciprocal_rank": 0.0,
          "average_precision": 0.0,
          "ndcg_at_k": {
            "1": 0.0,
            "3": 0.0,
            "5": 0.0,
            "10": 0.0,
            "20": 0.0
          },
          "essential_recall_at_k": {
            "1": 0.0,
            "3": 0.0,
            "5": 0.0,
            "10": 0.0,
            "20": 0.0
          },
          "first_relevant_rank": 0.0,
          "total_relevant": 2,
          "total_essential": 1
        },
        "qa_metrics": {
          "bleu_score": 0.00543548164681866,
          "rouge_1_f1": 0.21875,
          "rouge_2_f1": 0.09523809523809523,
          "rouge_l_f1": 0.125,
          "semantic_similarity": 0.716378927230835,
          "key_points_covered": 0.25,
          "key_points_found": [
            "Per-dose 85 mg for 85 kg"
          ],
          "key_points_missing": [
            "1 mg/kg q12h primary regimen",
            "Alternative 1.5 mg/kg q24h",
            "Renal adjustment for CrCl <30"
          ],
          "answer_length": 90,
          "has_answer": true,
          "factual_accuracy": null,
          "helpfulness": null
        },
        "root_cause": "both_systems",
        "severity": "high",
        "notes": null
      }
    },
    {
      "question_id": "q006",
      "question": {
        "id": "q006",
        "question": "Type 2 diabetes patient with eGFR 28 mL/min/1.73 m². Can we use metformin?",
        "question_type": "dosage",
        "difficulty": "medium",
        "expected_answer": "No—contraindicated at eGFR <30. If 30–45, generally avoid initiation; if continuing, reduce dose and monitor. Avoid in hepatic impairment.",
        "answer_key_points": [
          "Contraindicated if eGFR <30",
          "30–45: avoid initiation; if continuing, reduce & monitor",
          "Hepatic impairment: avoid (lactic acidosis risk)"
        ],
        "relevant_chunks": [
          {
            "chunk_id": "lexi-metformin-2018#renal",
            "relevance_score": 1.0,
            "is_essential": true,
            "note": null
          },
          {
            "chunk_id": "lexi-metformin-2018#contra",
            "relevance_score": 1.0,
            "is_essential": false,
            "note": null
          }
        ],
        "drug_names": [
          "metformin"
        ],
        "tags": [
          "dosage"
        ],
        "source_note": null,
        "reasoning": null,
        "gold": {
          "decision": "contraindicated",
          "calc_rule": "eGFR <30 → do not initiate/continue",
          "renal_adjustment": "eGFR 30–45: avoid initiation; reduce if continuing; monitor",
          "hepatic_adjustment": "avoid in hepatic impairment",
          "contraindications": [
            "eGFR <30",
            "acute/chronic metabolic acidosis"
          ],
          "interactions": [
            {
              "drug": "iodinated contrast",
              "severity": "major",
              "action": "hold around procedure per eGFR"
            }
          ],
          "recency_risk": false,
          "citations": [
            "lexi-metformin-2018#renal",
            "lexi-metformin-2018#contra"
          ]
        }
      },
      "generated_answer": "Based on the provided context, the use of metformin is contraindicated in patients with an eGFR less than 30 mL/min/1.73 m². For eGFR between 30 and 45 mL/min/1.73 m², it is not recommended to initiate metformin therapy. If metformin therapy is continued, a dosage reduction and monitoring of renal function every 3 months are recommended ([chunk_F176387], [chunk_F50990977], [chunk_F6213570]). The context does not provide information about the use of metformin in patients with an eGFR between 45 and 60 mL/min/1.73 m². For further guidance, please consult current clinical practice guidelines.",
      "expected_answer": "No—contraindicated at eGFR <30. If 30–45, generally avoid initiation; if continuing, reduce dose and monitor. Avoid in hepatic impairment.",
      "retrieval_metrics": {
        "recall_at_k": {
          "1": 0.0,
          "3": 0.0,
          "5": 0.0,
          "10": 0.0,
          "20": 0.0
        },
        "precision_at_k": {
          "1": 0.0,
          "3": 0.0,
          "5": 0.0,
          "10": 0.0,
          "20": 0.0
        },
        "mean_reciprocal_rank": 0.0,
        "average_precision": 0.0,
        "ndcg_at_k": {
          "1": 0.0,
          "3": 0.0,
          "5": 0.0,
          "10": 0.0,
          "20": 0.0
        },
        "essential_recall_at_k": {
          "1": 0.0,
          "3": 0.0,
          "5": 0.0,
          "10": 0.0,
          "20": 0.0
        },
        "first_relevant_rank": 0.0,
        "total_relevant": 2,
        "total_essential": 1
      },
      "qa_metrics": {
        "bleu_score": 0.005280491229441622,
        "rouge_1_f1": 0.18032786885245902,
        "rouge_2_f1": 0.016666666666666666,
        "rouge_l_f1": 0.18032786885245902,
        "semantic_similarity": 0.5283296704292297,
        "key_points_covered": 0.3333333333333333,
        "key_points_found": [
          "Contraindicated if eGFR <30"
        ],
        "key_points_missing": [
          "30–45: avoid initiation; if continuing, reduce & monitor",
          "Hepatic impairment: avoid (lactic acidosis risk)"
        ],
        "answer_length": 89,
        "has_answer": true,
        "factual_accuracy": null,
        "helpfulness": null
      },
      "retrieval_results": [
        {
          "chunk_id": "canagliflozin-and-metformin-drug-information::F25746088::0",
          "score": 0.993142704078216,
          "rank": 1
        },
        {
          "chunk_id": "glipizide-and-metformin-drug-information::F50990977::0",
          "score": 0.9865639064736162,
          "rank": 2
        },
        {
          "chunk_id": "repaglinide-and-metformin-drug-information::F6213570::0",
          "score": 0.9756602542538222,
          "rank": 3
        },
        {
          "chunk_id": "glipizide-and-metformin-drug-information::F176387::5",
          "score": 0.9493433727628566,
          "rank": 4
        },
        {
          "chunk_id": "alogliptin-and-metformin-drug-information::F20453593::5",
          "score": 0.9404446661740784,
          "rank": 5
        }
      ],
      "context_chunks": [
        {
          "rank": 1,
          "score": 0.993142704078216,
          "dense_score": 0.9885711734636934,
          "bm25_score": 1.0,
          "chunk_id": "canagliflozin-and-metformin-drug-information::F25746088::0",
          "doc_id": "canagliflozin-and-metformin-drug-information",
          "section_title": "Dosing: Renal Impairment",
          "section_code": "dor",
          "drug_title": "Canagliflozin and metformin: Drug information",
          "source_url": "https://maadi-clinical.byethost8.com/d/topic.htm?path=canagliflozin-and-metformin-drug-information",
          "snippet": "Dosing: Renal Impairment  eGFR ≥60 mL/minute/1.73 m2: No dosage adjustment necessary.  eGFR 45 to <60 mL/minute/1.73 m2: Limit the dose of canagliflozin/metformin to canagliflozin 100 mg/day. If patient is receiving concurrent UGT enzyme in…",
          "text": "Dosing: Renal Impairment\n\neGFR ≥60 mL/minute/1.73 m2: No dosage adjustment necessary.\n\neGFR 45 to <60 mL/minute/1.73 m2: Limit the dose of canagliflozin/metformin to canagliflozin 100 mg/day. If patient is receiving concurrent UGT enzyme inducers (eg, rifampin, phenytoin, phenobarbital, ritonavir) and has eGFR 45 to <60 mL/minute/1.73 m2, consider the use of another antidiabetic agent.\n\neGFR <45 mL/minute/1.73 m2: Use is contraindicated.\n\nEnd stage renal disease (ESRD) or hemodialysis: Use is contraindicated."
        },
        {
          "rank": 2,
          "score": 0.9865639064736162,
          "dense_score": 1.0,
          "bm25_score": 0.9664097661840405,
          "chunk_id": "glipizide-and-metformin-drug-information::F50990977::0",
          "doc_id": "glipizide-and-metformin-drug-information",
          "section_title": "Dosing: Renal Impairment (Adult)",
          "section_code": "dora",
          "drug_title": "Glipizide and metformin: Drug information",
          "source_url": "https://maadi-clinical.byethost8.com/d/topic.htm?path=glipizide-and-metformin-drug-information",
          "snippet": "Dosing: Renal Impairment (Adult)  eGFR ≥45 mL/minute/1.73 m2: There are no dosage adjustments provided in the manufacturer's labeling.  eGFR 30 to <45 mL/minute/1.73 m2:  Preexisting impairment: Use of glipizide/metformin is not recommended…",
          "text": "Dosing: Renal Impairment (Adult)\n\neGFR ≥45 mL/minute/1.73 m2: There are no dosage adjustments provided in the manufacturer's labeling.\n\neGFR 30 to <45 mL/minute/1.73 m2:\n\nPreexisting impairment: Use of glipizide/metformin is not recommended for initiation of therapy. Refer also to individual agents.\n\nIf eGFR falls between 30 to <45 mL/minute/1.73 m2 during therapy: Consider benefits/risks of continuing therapy. If continuing metformin therapy, a dosage reduction of 50% (maximum: metformin 1,000 mg/day) and monitoring of renal function every 3 months is recommended (ADA [Lipska 2011]; Inzucchi 2014).\n\neGFR <30 mL/minute/1.73 m2: Use is contraindicated."
        },
        {
          "rank": 3,
          "score": 0.9756602542538222,
          "dense_score": 0.9833922384180203,
          "bm25_score": 0.9640622780075251,
          "chunk_id": "repaglinide-and-metformin-drug-information::F6213570::0",
          "doc_id": "repaglinide-and-metformin-drug-information",
          "section_title": "Dosing: Renal Impairment",
          "section_code": "dor",
          "drug_title": "Repaglinide and metformin: Drug information",
          "source_url": "https://maadi-clinical.byethost8.com/d/topic.htm?path=repaglinide-and-metformin-drug-information",
          "snippet": "Dosing: Renal Impairment  eGFR >45 mL/minute/1.73 m2: No dosage adjustment necessary  eGFR 30 to 45 mL/minute/1.73 m2:  Preexisting impairment: Use of repaglinide/metformin is not recommended for initiation of therapy. Refer also to individ…",
          "text": "Dosing: Renal Impairment\n\neGFR >45 mL/minute/1.73 m2: No dosage adjustment necessary\n\neGFR 30 to 45 mL/minute/1.73 m2:\n\nPreexisting impairment: Use of repaglinide/metformin is not recommended for initiation of therapy. Refer also to individual agents.\n\nIf eGFR falls between 30 to <45 mL/minute/1.73 m2 during therapy: Consider benefits/risks of continuing therapy. If continuing metformin therapy, a dosage reduction of 50% (maximum: Metformin 1,000 mg/day) and monitoring of renal function every 3 months is recommended (ADA [Lipska 2011]; Inzucchi 2014).\n\neGFR <30 mL/minute/1.73m2: Use is contraindicated"
        },
        {
          "rank": 4,
          "score": 0.9493433727628566,
          "dense_score": 0.9670141446609671,
          "bm25_score": 0.9228372149156908,
          "chunk_id": "glipizide-and-metformin-drug-information::F176387::5",
          "doc_id": "glipizide-and-metformin-drug-information",
          "section_title": "Warnings/Precautions",
          "section_code": "war",
          "drug_title": "Glipizide and metformin: Drug information",
          "source_url": "https://maadi-clinical.byethost8.com/d/topic.htm?path=glipizide-and-metformin-drug-information",
          "snippet": "• Renal impairment: The metabolism and excretion of glipizide may be slowed in patients with renal impairment. Metformin is substantially excreted by the kidney; assess renal function prior to initiation of therapy and periodically thereaft…",
          "text": "• Renal impairment: The metabolism and excretion of glipizide may be slowed in patients with renal impairment. Metformin is substantially excreted by the kidney; assess renal function prior to initiation of therapy and periodically thereafter using eGFR. The risk of metformin accumulation and lactic acidosis increases with degree of renal impairment. Initiation of therapy is not recommended if eGFR is between 30 to 45 mL/minute/1.73 m2 and is contraindicated in patients with eGFR <30 mL/minute/1.73 m2. Assess benefits/risks of continuing metformin therapy in patients whose eGFR falls below 45 mL/minute/1.73 m2 during therapy; if used, metformin dosage reduction is recommended (ADA [Lipska 2011]; Inzucchi 2014). Use of concomitant medications that may affect renal function (ie, affect tubular secretion) may also affect metformin disposition. Metformin should be withheld in patients with dehydration and/or prerenal azotemia.\n\n• Stress-related states: It may be necessary to discontinue metformin and administer insulin if the patient is exposed to stress (fever, trauma, infection, surgery).\n\nSpecial populations:"
        },
        {
          "rank": 5,
          "score": 0.9404446661740784,
          "dense_score": 0.9546927717467238,
          "bm25_score": 0.9190725078151101,
          "chunk_id": "alogliptin-and-metformin-drug-information::F20453593::5",
          "doc_id": "alogliptin-and-metformin-drug-information",
          "section_title": "Warnings/Precautions",
          "section_code": "war",
          "drug_title": "Alogliptin and metformin: Drug information",
          "source_url": "https://maadi-clinical.byethost8.com/d/topic.htm?path=alogliptin-and-metformin-drug-information",
          "snippet": "• Hepatic impairment: The manufacturer recommends to generally avoid use in patients with hepatic impairment due to potential for lactic acidosis. However, continued use of metformin in patients with diabetes with liver dysfunction, includi…",
          "text": "• Hepatic impairment: The manufacturer recommends to generally avoid use in patients with hepatic impairment due to potential for lactic acidosis. However, continued use of metformin in patients with diabetes with liver dysfunction, including cirrhosis, may be associated with a survival benefit in carefully selected patients (Brackett 2010; Crowley 2017; Zhang 2014).\n\n• Renal impairment: Metformin is substantially excreted by the kidney; assess renal function prior to initiation of therapy and periodically thereafter using eGFR. The risk of metformin accumulation and lactic acidosis increases with degree of renal impairment. Use of alogliptin/metformin combination product is not recommended in patients with eGFR 30 to 60 mL/minute/1.73 m2 and is contraindicated in patients with eGFR <30 mL/minute/1.73 m2. Use of concomitant medications that may affect renal function (ie, affect tubular secretion) may also affect metformin disposition. Metformin should be withheld in patients with dehydration and/or prerenal azotemia.\n\n• Stress-related states: It may be necessary to discontinue metformin and administer insulin if the patient is exposed to stress (fever, trauma, infection, surgery)."
        }
      ],
      "failure_analysis": {
        "question_id": "q006",
        "question": "Type 2 diabetes patient with eGFR 28 mL/min/1.73 m². Can we use metformin?",
        "failure_types": [
          "retrieval_miss",
          "retrieval_irrelevant",
          "qa_incorrect",
          "qa_incomplete",
          "e2e_low_quality"
        ],
        "retrieved_chunks": [
          {
            "chunk_id": "canagliflozin-and-metformin-drug-information::F25746088::0",
            "score": 0.993142704078216,
            "rank": 1
          },
          {
            "chunk_id": "glipizide-and-metformin-drug-information::F50990977::0",
            "score": 0.9865639064736162,
            "rank": 2
          },
          {
            "chunk_id": "repaglinide-and-metformin-drug-information::F6213570::0",
            "score": 0.9756602542538222,
            "rank": 3
          },
          {
            "chunk_id": "glipizide-and-metformin-drug-information::F176387::5",
            "score": 0.9493433727628566,
            "rank": 4
          },
          {
            "chunk_id": "alogliptin-and-metformin-drug-information::F20453593::5",
            "score": 0.9404446661740784,
            "rank": 5
          }
        ],
        "relevant_chunks_found": [],
        "essential_chunks_missed": [
          "lexi-metformin-2018#renal"
        ],
        "generated_answer": "Based on the provided context, the use of metformin is contraindicated in patients with an eGFR less than 30 mL/min/1.73 m². For eGFR between 30 and 45 mL/min/1.73 m², it is not recommended to initiate metformin therapy. If metformin therapy is continued, a dosage reduction and monitoring of renal function every 3 months are recommended ([chunk_F176387], [chunk_F50990977], [chunk_F6213570]). The context does not provide information about the use of metformin in patients with an eGFR between 45 and 60 mL/min/1.73 m². For further guidance, please consult current clinical practice guidelines.",
        "expected_answer": "No—contraindicated at eGFR <30. If 30–45, generally avoid initiation; if continuing, reduce dose and monitor. Avoid in hepatic impairment.",
        "key_points_missing": [
          "30–45: avoid initiation; if continuing, reduce & monitor",
          "Hepatic impairment: avoid (lactic acidosis risk)"
        ],
        "retrieval_metrics": {
          "recall_at_k": {
            "1": 0.0,
            "3": 0.0,
            "5": 0.0,
            "10": 0.0,
            "20": 0.0
          },
          "precision_at_k": {
            "1": 0.0,
            "3": 0.0,
            "5": 0.0,
            "10": 0.0,
            "20": 0.0
          },
          "mean_reciprocal_rank": 0.0,
          "average_precision": 0.0,
          "ndcg_at_k": {
            "1": 0.0,
            "3": 0.0,
            "5": 0.0,
            "10": 0.0,
            "20": 0.0
          },
          "essential_recall_at_k": {
            "1": 0.0,
            "3": 0.0,
            "5": 0.0,
            "10": 0.0,
            "20": 0.0
          },
          "first_relevant_rank": 0.0,
          "total_relevant": 2,
          "total_essential": 1
        },
        "qa_metrics": {
          "bleu_score": 0.005280491229441622,
          "rouge_1_f1": 0.18032786885245902,
          "rouge_2_f1": 0.016666666666666666,
          "rouge_l_f1": 0.18032786885245902,
          "semantic_similarity": 0.5283296704292297,
          "key_points_covered": 0.3333333333333333,
          "key_points_found": [
            "Contraindicated if eGFR <30"
          ],
          "key_points_missing": [
            "30–45: avoid initiation; if continuing, reduce & monitor",
            "Hepatic impairment: avoid (lactic acidosis risk)"
          ],
          "answer_length": 89,
          "has_answer": true,
          "factual_accuracy": null,
          "helpfulness": null
        },
        "root_cause": "both_systems",
        "severity": "high",
        "notes": null
      }
    },
    {
      "question_id": "q007",
      "question": {
        "id": "q007",
        "question": "Uncomplicated cystitis: Should we use nitrofurantoin if eGFR is 25?",
        "question_type": "dosage",
        "difficulty": "medium",
        "expected_answer": "Avoid nitrofurantoin when eGFR/CrCl <30 mL/min due to low urinary levels and toxicity risk.",
        "answer_key_points": [
          "Avoid if eGFR/CrCl <30",
          "Rationale: efficacy/toxicity",
          "List common contraindications where relevant"
        ],
        "relevant_chunks": [
          {
            "chunk_id": "lexi-nitrofurantoin-2018#renal",
            "relevance_score": 1.0,
            "is_essential": true,
            "note": null
          },
          {
            "chunk_id": "lexi-nitrofurantoin-2018#contra",
            "relevance_score": 1.0,
            "is_essential": false,
            "note": null
          }
        ],
        "drug_names": [
          "nitrofurantoin"
        ],
        "tags": [
          "dosage"
        ],
        "source_note": null,
        "reasoning": null,
        "gold": {
          "decision": "avoid",
          "calc_rule": "Avoid if eGFR/CrCl <30",
          "renal_adjustment": "not recommended below threshold",
          "hepatic_adjustment": "use caution",
          "contraindications": [
            "CrCl <30",
            "late-term pregnancy (at term)"
          ],
          "interactions": [],
          "recency_risk": false,
          "citations": [
            "lexi-nitrofurantoin-2018#renal",
            "lexi-nitrofurantoin-2018#contra"
          ]
        }
      },
      "generated_answer": "Based on the provided context, nitrofurantoin should not be used for uncomplicated cystitis if the eGFR is 25, as the manufacturer contraindicates its use in CrCl <60 mL/minute [chunk_201969:1]. The Beers Criteria also recommends avoiding nitrofurantoin in geriatric patients with a CrCl, suggesting it may not be effective or safe in such cases. For uncomplicated cystitis, fosfomycin is an alternative option for women with susceptible strains of E. coli and Enterococcus faecalis [chunk_174299:0]. However, it's important to note that the context does not provide information on fosfomycin's safety and efficacy for patients with eGFR <30. Always consult current clinical guidance for the most up-to-date information.",
      "expected_answer": "Avoid nitrofurantoin when eGFR/CrCl <30 mL/min due to low urinary levels and toxicity risk.",
      "retrieval_metrics": {
        "recall_at_k": {
          "1": 0.0,
          "3": 0.0,
          "5": 0.0,
          "10": 0.0,
          "20": 0.0
        },
        "precision_at_k": {
          "1": 0.0,
          "3": 0.0,
          "5": 0.0,
          "10": 0.0,
          "20": 0.0
        },
        "mean_reciprocal_rank": 0.0,
        "average_precision": 0.0,
        "ndcg_at_k": {
          "1": 0.0,
          "3": 0.0,
          "5": 0.0,
          "10": 0.0,
          "20": 0.0
        },
        "essential_recall_at_k": {
          "1": 0.0,
          "3": 0.0,
          "5": 0.0,
          "10": 0.0,
          "20": 0.0
        },
        "first_relevant_rank": 0.0,
        "total_relevant": 2,
        "total_essential": 1
      },
      "qa_metrics": {
        "bleu_score": 0.00407361445434004,
        "rouge_1_f1": 0.12307692307692307,
        "rouge_2_f1": 0.015625,
        "rouge_l_f1": 0.0923076923076923,
        "semantic_similarity": 0.7153726816177368,
        "key_points_covered": 0.0,
        "key_points_found": [],
        "key_points_missing": [
          "Avoid if eGFR/CrCl <30",
          "Rationale: efficacy/toxicity",
          "List common contraindications where relevant"
        ],
        "answer_length": 105,
        "has_answer": true,
        "factual_accuracy": null,
        "helpfulness": null
      },
      "retrieval_results": [
        {
          "chunk_id": "nitrofurantoin-drug-information::F201984::0",
          "score": 1.0,
          "rank": 1
        },
        {
          "chunk_id": "nitrofurantoin-drug-information::F202012::0",
          "score": 0.8503409054126378,
          "rank": 2
        },
        {
          "chunk_id": "nitrofurantoin-drug-information::F201969::1",
          "score": 0.731684987719981,
          "rank": 3
        },
        {
          "chunk_id": "fosfomycin-drug-information::F174299::0",
          "score": 0.6573487594859675,
          "rank": 4
        },
        {
          "chunk_id": "canagliflozin-and-metformin-drug-information::F25746088::0",
          "score": 0.6006911661070586,
          "rank": 5
        }
      ],
      "context_chunks": [
        {
          "rank": 1,
          "score": 1.0,
          "dense_score": 1.0,
          "bm25_score": 1.0,
          "chunk_id": "nitrofurantoin-drug-information::F201984::0",
          "doc_id": "nitrofurantoin-drug-information",
          "section_title": "Use",
          "section_code": "use",
          "drug_title": "Nitrofurantoin: Drug information",
          "source_url": "https://maadi-clinical.byethost8.com/d/topic.htm?path=nitrofurantoin-drug-information",
          "snippet": "Use  Cystitis, acute uncomplicated:  Nitrofurantoin monohydrate/macrocrystals (Macrobid): Treatment of acute uncomplicated cystitis caused by susceptible strains of Escherichia coli or Staphylococcus saprophyticus in patients ≥12 years of a…",
          "text": "Use\n\nCystitis, acute uncomplicated:\n\nNitrofurantoin monohydrate/macrocrystals (Macrobid): Treatment of acute uncomplicated cystitis caused by susceptible strains of Escherichia coli or Staphylococcus saprophyticus in patients ≥12 years of age\n\nNitrofurantoin macrocrystals (Furadantin, Macrodantin): Treatment of acute uncomplicated cystitis when caused by susceptible strains of E. coli, enterococci, Staphylococcus aureus, and certain susceptible strains of Klebsiella and Enterobacter species. May also be used for chronic suppression of recurrent UTIs.\n\nLimitations of use: Not indicated for treatment of pyelonephritis or perinephric abscess"
        },
        {
          "rank": 2,
          "score": 0.8503409054126378,
          "dense_score": 0.8569454121020709,
          "bm25_score": 0.8404341453784882,
          "chunk_id": "nitrofurantoin-drug-information::F202012::0",
          "doc_id": "nitrofurantoin-drug-information",
          "section_title": "Dosing: Adult",
          "section_code": "doa",
          "drug_title": "Nitrofurantoin: Drug information",
          "source_url": "https://maadi-clinical.byethost8.com/d/topic.htm?path=nitrofurantoin-drug-information",
          "snippet": "Dosing: Adult  Cystitis, acute uncomplicated, treatment:  Nitrofurantoin monohydrate/macrocrystals (Macrobid): Oral: 100 mg twice daily for 5 days (Gupta 2011; Gupta 2007).  Nitrofurantoin macrocrystals (Furadantin, Macrodantin): Oral: 50 t…",
          "text": "Dosing: Adult\n\nCystitis, acute uncomplicated, treatment:\n\nNitrofurantoin monohydrate/macrocrystals (Macrobid): Oral: 100 mg twice daily for 5 days (Gupta 2011; Gupta 2007).\n\nNitrofurantoin macrocrystals (Furadantin, Macrodantin): Oral: 50 to 100 mg every 6 hours; administer for 7 days or at least 3 days after obtaining sterile urine.\n\nUTI, prophylaxis: Nitrofurantoin macrocrystals (Furadantin, Macrodantin): Oral: 50 to 100 mg once daily at bedtime."
        },
        {
          "rank": 3,
          "score": 0.731684987719981,
          "dense_score": 0.8677265030177431,
          "bm25_score": 0.5276227147733379,
          "chunk_id": "nitrofurantoin-drug-information::F201969::1",
          "doc_id": "nitrofurantoin-drug-information",
          "section_title": "Warnings/Precautions",
          "section_code": "war",
          "drug_title": "Nitrofurantoin: Drug information",
          "source_url": "https://maadi-clinical.byethost8.com/d/topic.htm?path=nitrofurantoin-drug-information",
          "snippet": "• Superinfection: Prolonged use may result in fungal or bacterial superinfection, including C. difficile-associated diarrhea (CDAD) and pseudomembranous colitis; CDAD has been observed >2 months postantibiotic treatment.  Disease-related co…",
          "text": "• Superinfection: Prolonged use may result in fungal or bacterial superinfection, including C. difficile-associated diarrhea (CDAD) and pseudomembranous colitis; CDAD has been observed >2 months postantibiotic treatment.\n\nDisease-related concerns:\n\n• Hemolytic anemia: Use caution in patients with G6PD deficiency; may be at increased risk for hemolytic anemia. Discontinue therapy if occurs.\n\n• Renal impairment: Urinary nitrofurantoin concentrations are variable in patients with impaired renal function. The manufacturer contraindicates use in CrCl <60 mL/minute; however, limited data suggest nitrofurantoin is safe and effective for short-term treatment of uncomplicated UTI in patients with CrCl 30 to 60 mL/minute (Oplinger 2013; Santos 2016; Singh 2015). The Beers Criteria recommends avoiding use in geriatric patients ≥65 years with a CrCl <30 mL/minute (Beers Criteria [AGS 2015]).\n\nConcurrent drug therapy issues:\n\n• Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information."
        },
        {
          "rank": 4,
          "score": 0.6573487594859675,
          "dense_score": 0.8422210637884838,
          "bm25_score": 0.38004030303219305,
          "chunk_id": "fosfomycin-drug-information::F174299::0",
          "doc_id": "fosfomycin-drug-information",
          "section_title": "Use",
          "section_code": "use",
          "drug_title": "Fosfomycin: Drug information",
          "source_url": "https://maadi-clinical.byethost8.com/d/topic.htm?path=fosfomycin-drug-information",
          "snippet": "Use  Uncomplicated urinary tract infections: Treatment of uncomplicated urinary tract infections (acute cystitis) in women due to susceptible strains of Escherichia coli and Enterococcus faecalis.  Limitations of use: Not indicated for the…",
          "text": "Use\n\nUncomplicated urinary tract infections: Treatment of uncomplicated urinary tract infections (acute cystitis) in women due to susceptible strains of Escherichia coli and Enterococcus faecalis.\n\nLimitations of use: Not indicated for the treatment of pyelonephritis or perinephric abscess. If persistence or reappearance of bacteriuria occurs after treatment with fosfomycin, other therapeutic agents should be selected."
        },
        {
          "rank": 5,
          "score": 0.6006911661070586,
          "dense_score": 0.8672945702377606,
          "bm25_score": 0.2007860599110059,
          "chunk_id": "canagliflozin-and-metformin-drug-information::F25746088::0",
          "doc_id": "canagliflozin-and-metformin-drug-information",
          "section_title": "Dosing: Renal Impairment",
          "section_code": "dor",
          "drug_title": "Canagliflozin and metformin: Drug information",
          "source_url": "https://maadi-clinical.byethost8.com/d/topic.htm?path=canagliflozin-and-metformin-drug-information",
          "snippet": "Dosing: Renal Impairment  eGFR ≥60 mL/minute/1.73 m2: No dosage adjustment necessary.  eGFR 45 to <60 mL/minute/1.73 m2: Limit the dose of canagliflozin/metformin to canagliflozin 100 mg/day. If patient is receiving concurrent UGT enzyme in…",
          "text": "Dosing: Renal Impairment\n\neGFR ≥60 mL/minute/1.73 m2: No dosage adjustment necessary.\n\neGFR 45 to <60 mL/minute/1.73 m2: Limit the dose of canagliflozin/metformin to canagliflozin 100 mg/day. If patient is receiving concurrent UGT enzyme inducers (eg, rifampin, phenytoin, phenobarbital, ritonavir) and has eGFR 45 to <60 mL/minute/1.73 m2, consider the use of another antidiabetic agent.\n\neGFR <45 mL/minute/1.73 m2: Use is contraindicated.\n\nEnd stage renal disease (ESRD) or hemodialysis: Use is contraindicated."
        }
      ],
      "failure_analysis": {
        "question_id": "q007",
        "question": "Uncomplicated cystitis: Should we use nitrofurantoin if eGFR is 25?",
        "failure_types": [
          "retrieval_miss",
          "retrieval_irrelevant",
          "qa_incomplete"
        ],
        "retrieved_chunks": [
          {
            "chunk_id": "nitrofurantoin-drug-information::F201984::0",
            "score": 1.0,
            "rank": 1
          },
          {
            "chunk_id": "nitrofurantoin-drug-information::F202012::0",
            "score": 0.8503409054126378,
            "rank": 2
          },
          {
            "chunk_id": "nitrofurantoin-drug-information::F201969::1",
            "score": 0.731684987719981,
            "rank": 3
          },
          {
            "chunk_id": "fosfomycin-drug-information::F174299::0",
            "score": 0.6573487594859675,
            "rank": 4
          },
          {
            "chunk_id": "canagliflozin-and-metformin-drug-information::F25746088::0",
            "score": 0.6006911661070586,
            "rank": 5
          }
        ],
        "relevant_chunks_found": [],
        "essential_chunks_missed": [
          "lexi-nitrofurantoin-2018#renal"
        ],
        "generated_answer": "Based on the provided context, nitrofurantoin should not be used for uncomplicated cystitis if the eGFR is 25, as the manufacturer contraindicates its use in CrCl <60 mL/minute [chunk_201969:1]. The Beers Criteria also recommends avoiding nitrofurantoin in geriatric patients with a CrCl, suggesting it may not be effective or safe in such cases. For uncomplicated cystitis, fosfomycin is an alternative option for women with susceptible strains of E. coli and Enterococcus faecalis [chunk_174299:0]. However, it's important to note that the context does not provide information on fosfomycin's safety and efficacy for patients with eGFR <30. Always consult current clinical guidance for the most up-to-date information.",
        "expected_answer": "Avoid nitrofurantoin when eGFR/CrCl <30 mL/min due to low urinary levels and toxicity risk.",
        "key_points_missing": [
          "Avoid if eGFR/CrCl <30",
          "Rationale: efficacy/toxicity",
          "List common contraindications where relevant"
        ],
        "retrieval_metrics": {
          "recall_at_k": {
            "1": 0.0,
            "3": 0.0,
            "5": 0.0,
            "10": 0.0,
            "20": 0.0
          },
          "precision_at_k": {
            "1": 0.0,
            "3": 0.0,
            "5": 0.0,
            "10": 0.0,
            "20": 0.0
          },
          "mean_reciprocal_rank": 0.0,
          "average_precision": 0.0,
          "ndcg_at_k": {
            "1": 0.0,
            "3": 0.0,
            "5": 0.0,
            "10": 0.0,
            "20": 0.0
          },
          "essential_recall_at_k": {
            "1": 0.0,
            "3": 0.0,
            "5": 0.0,
            "10": 0.0,
            "20": 0.0
          },
          "first_relevant_rank": 0.0,
          "total_relevant": 2,
          "total_essential": 1
        },
        "qa_metrics": {
          "bleu_score": 0.00407361445434004,
          "rouge_1_f1": 0.12307692307692307,
          "rouge_2_f1": 0.015625,
          "rouge_l_f1": 0.0923076923076923,
          "semantic_similarity": 0.7153726816177368,
          "key_points_covered": 0.0,
          "key_points_found": [],
          "key_points_missing": [
            "Avoid if eGFR/CrCl <30",
            "Rationale: efficacy/toxicity",
            "List common contraindications where relevant"
          ],
          "answer_length": 105,
          "has_answer": true,
          "factual_accuracy": null,
          "helpfulness": null
        },
        "root_cause": "both_systems",
        "severity": "high",
        "notes": null
      }
    },
    {
      "question_id": "q008",
      "question": {
        "id": "q008",
        "question": "Patient on warfarin needs TMP-SMX for UTI. Any interaction and what should we do?",
        "question_type": "interaction",
        "difficulty": "medium",
        "expected_answer": "Major interaction (CYP2C9 inhibition + gut flora). Avoid if possible; otherwise increase INR monitoring and reduce warfarin dose.",
        "answer_key_points": [
          "Mechanism: CYP2C9 inhibition + gut flora",
          "Severity: major",
          "Action: avoid or close INR monitoring with dose reduction"
        ],
        "relevant_chunks": [
          {
            "chunk_id": "lexi-warfarin-2018#ddi-tmp-smx",
            "relevance_score": 1.0,
            "is_essential": true,
            "note": null
          }
        ],
        "drug_names": [
          "warfarin"
        ],
        "tags": [
          "interaction"
        ],
        "source_note": null,
        "reasoning": null,
        "gold": {
          "interactions": [
            {
              "drug": "trimethoprim/sulfamethoxazole",
              "mechanism": "CYP2C9 inhibition + gut flora change",
              "severity": "major",
              "action": "avoid if possible; otherwise increase INR monitoring and reduce warfarin dose"
            }
          ],
          "contraindications": [],
          "recency_risk": false,
          "citations": [
            "lexi-warfarin-2018#ddi-tmp-smx"
          ]
        }
      },
      "generated_answer": "There is a major drug interaction between warfarin and trimethoprim-sulfamethoxazole (TMP-SMX). This interaction is due to CYP2C9 inhibition by TMP-SMX, which may increase warfarin's anticoagulant effect [capecitabine-drug-information::F5708655::0]. Therefore, it is recommended to either avoid using TMP-SMX in patients on warfarin or closely monitor the international normalized ratio (INR) and adjust the warfarin dose as necessary. [warfarin-drug-information::F234837::4]",
      "expected_answer": "Major interaction (CYP2C9 inhibition + gut flora). Avoid if possible; otherwise increase INR monitoring and reduce warfarin dose.",
      "retrieval_metrics": {
        "recall_at_k": {
          "1": 0.0,
          "3": 0.0,
          "5": 0.0,
          "10": 0.0,
          "20": 0.0
        },
        "precision_at_k": {
          "1": 0.0,
          "3": 0.0,
          "5": 0.0,
          "10": 0.0,
          "20": 0.0
        },
        "mean_reciprocal_rank": 0.0,
        "average_precision": 0.0,
        "ndcg_at_k": {
          "1": 0.0,
          "3": 0.0,
          "5": 0.0,
          "10": 0.0,
          "20": 0.0
        },
        "essential_recall_at_k": {
          "1": 0.0,
          "3": 0.0,
          "5": 0.0,
          "10": 0.0,
          "20": 0.0
        },
        "first_relevant_rank": 0.0,
        "total_relevant": 1,
        "total_essential": 1
      },
      "qa_metrics": {
        "bleu_score": 0.010524398322904265,
        "rouge_1_f1": 0.2558139534883721,
        "rouge_2_f1": 0.047619047619047616,
        "rouge_l_f1": 0.20930232558139533,
        "semantic_similarity": 0.582504153251648,
        "key_points_covered": 0.0,
        "key_points_found": [],
        "key_points_missing": [
          "Mechanism: CYP2C9 inhibition + gut flora",
          "Severity: major",
          "Action: avoid or close INR monitoring with dose reduction"
        ],
        "answer_length": 56,
        "has_answer": true,
        "factual_accuracy": null,
        "helpfulness": null
      },
      "retrieval_results": [
        {
          "chunk_id": "trimethoprim-sulfamethoxazole-co-trimoxazole-drug-information::F154889::0",
          "score": 0.904299471438335,
          "rank": 1
        },
        {
          "chunk_id": "trimethoprim-sulfamethoxazole-co-trimoxazole-drug-information::F154863::0",
          "score": 0.8547943011724797,
          "rank": 2
        },
        {
          "chunk_id": "warfarin-drug-information::F234837::4",
          "score": 0.7873117016311454,
          "rank": 3
        },
        {
          "chunk_id": "capecitabine-drug-information::F5708655::0",
          "score": 0.6772235094198431,
          "rank": 4
        },
        {
          "chunk_id": "dalteparin-drug-information::F156483::6",
          "score": 0.6096730662878375,
          "rank": 5
        }
      ],
      "context_chunks": [
        {
          "rank": 1,
          "score": 0.904299471438335,
          "dense_score": 0.9242648060538616,
          "bm25_score": 0.8743514695150452,
          "chunk_id": "trimethoprim-sulfamethoxazole-co-trimoxazole-drug-information::F154889::0",
          "doc_id": "trimethoprim-sulfamethoxazole-co-trimoxazole-drug-information",
          "section_title": "Dosing: Adult",
          "section_code": "doa",
          "drug_title": "Trimethoprim-sulfamethoxazole (co-trimoxazole): Drug information",
          "source_url": "https://maadi-clinical.byethost8.com/d/topic.htm?path=trimethoprim-sulfamethoxazole-co-trimoxazole-drug-information",
          "snippet": "Dosing: Adult  Note: Weight-based dosing recommendations are based on the trimethoprim (TMP) component. Each double-strength tablet contains TMP 160 mg and sulfamethoxazole (SMX) 800 mg. Each single-strength tablet contains TMP 80 mg and SM…",
          "text": "Dosing: Adult\n\nNote: Weight-based dosing recommendations are based on the trimethoprim (TMP) component. Each double-strength tablet contains TMP 160 mg and sulfamethoxazole (SMX) 800 mg. Each single-strength tablet contains TMP 80 mg and SMX 400 mg. The undiluted IV solution contains TMP 16 mg per mL and SMX 80 mg per mL. IV solutions must be diluted in D5W prior to use. Diluted IV solutions have limited stability and can precipitate unpredictably; refer to a detailed IV compatibility reference.\n\nGeneral dosing guidelines:\n\nOral: 1 to 2 double-strength tablets every 12 to 24 hours. Note: Serum creatinine and potassium concentrations should be monitored in outpatients receiving high-dose therapy (>5 mg/kg TMP component/day) (Gentry 2013)\n\nIV: 8 to 20 mg (TMP component)/kg/day divided every 6 to 12 hours"
        },
        {
          "rank": 2,
          "score": 0.8547943011724797,
          "dense_score": 0.9101867397681123,
          "bm25_score": 0.7717056432790307,
          "chunk_id": "trimethoprim-sulfamethoxazole-co-trimoxazole-drug-information::F154863::0",
          "doc_id": "trimethoprim-sulfamethoxazole-co-trimoxazole-drug-information",
          "section_title": "Pharmacodynamics/Kinetics",
          "section_code": "phk",
          "drug_title": "Trimethoprim-sulfamethoxazole (co-trimoxazole): Drug information",
          "source_url": "https://maadi-clinical.byethost8.com/d/topic.htm?path=trimethoprim-sulfamethoxazole-co-trimoxazole-drug-information",
          "snippet": "Pharmacodynamics/Kinetics  Absorption: Oral: Rapid; almost completely (90% to 100%)  Distribution: Both SMX and TMP distribute to middle ear fluid, sputum, vaginal fluid; TMP also distributes into bronchial secretions  Vd: TMP:  Newborns: ~…",
          "text": "Pharmacodynamics/Kinetics\n\nAbsorption: Oral: Rapid; almost completely (90% to 100%)\n\nDistribution: Both SMX and TMP distribute to middle ear fluid, sputum, vaginal fluid; TMP also distributes into bronchial secretions\n\nVd: TMP:\n\nNewborns: ~2.7 L/kg (range: 1.3 to 4.1 hours) (Springer 1982)\n\nInfants: 1.5 L/kg (Hoppu 1989)\n\nChildren 1 to 10 years: 0.86 to 1 L/kg (Hoppu 1987)\n\nAdults: ~1.3 L/kg (Hoppu 1987)\n\nProtein binding: SMX: ~70%, TMP: ~44%\n\nMetabolism: Hepatic, both to multiple metabolites; SMX to hydroxy (via CYP2C9) and acetyl derivatives, and also conjugated with glucuronide; TMP to oxide and hydroxy derivatives; the free forms of both SMX and TMP are therapeutically active\n\nHalf-life elimination:\n\nTMP: Prolonged in renal failure\n\nNewborns: ~19 hours; range: 11 to 27 hours (Springer 1982)\n\nInfants 2 months to 1 year: ~4.6 hours; range: 3 to 6 hours (Hoppu 1989)\n\nChildren 1 to 10 years: 3.7 to 5.5 hours (Hoppu 1987)\n\nChildren and Adolescents >10 years: 8.19 hours\n\nAdults: 6 to 11 hours\n\nSMX: 9 to 12 hours, prolonged in renal failure\n\nTime to peak, serum: Oral: 1 to 4 hours\n\nExcretion: Both are excreted in urine as metabolites and unchanged drug"
        },
        {
          "rank": 3,
          "score": 0.7873117016311454,
          "dense_score": 0.9512148820031904,
          "bm25_score": 0.5414569310730779,
          "chunk_id": "warfarin-drug-information::F234837::4",
          "doc_id": "warfarin-drug-information",
          "section_title": "Warnings/Precautions",
          "section_code": "war",
          "drug_title": "Warfarin: Drug information",
          "source_url": "https://maadi-clinical.byethost8.com/d/topic.htm?path=warfarin-drug-information",
          "snippet": "• Heparin-induced thrombocytopenia: Use with caution in patients with heparin-induced thrombocytopenia and DVT; limb ischemia, necrosis, and gangrene have occurred when warfarin was started or continued after heparin was stopped. Warfarin m…",
          "text": "• Heparin-induced thrombocytopenia: Use with caution in patients with heparin-induced thrombocytopenia and DVT; limb ischemia, necrosis, and gangrene have occurred when warfarin was started or continued after heparin was stopped. Warfarin monotherapy is contraindicated in the initial treatment of active HIT; warfarin initially inhibits the synthesis of protein C, potentially accelerating the underlying active thrombotic process.\n\n• Hepatic impairment: Reduced liver function, regardless of etiology, may impair synthesis of coagulation factors leading to increased warfarin sensitivity.\n\n• Infection: Use with caution in patients with acute infection or active TB or any disruption of normal GI flora; antibiotics and fever may alter response to warfarin.\n\n• Renal impairment: Use with caution in patients with renal impairment. Patients with renal impairment are at increased risk for bleeding diathesis; frequent INR monitoring is recommended.\n\n• Thyroid disease: Use with caution in patients with thyroid disease; warfarin responsiveness may increase (Ageno 2012).\n\nSpecial populations:\n\n• Elderly: The elderly may be more sensitive to anticoagulant therapy."
        },
        {
          "rank": 4,
          "score": 0.6772235094198431,
          "dense_score": 0.9744344736494543,
          "bm25_score": 0.23140706307542638,
          "chunk_id": "capecitabine-drug-information::F5708655::0",
          "doc_id": "capecitabine-drug-information",
          "section_title": "ALERT: US Boxed Warning",
          "section_code": "black-box-warn",
          "drug_title": "Capecitabine: Drug information",
          "source_url": "https://maadi-clinical.byethost8.com/d/topic.htm?path=capecitabine-drug-information",
          "snippet": "ALERT: US Boxed Warning  Warfarin interaction:  Frequently monitor the anticoagulant response (international normalized ratio [INR] or prothrombin time [PT]) of patients receiving concomitant capecitabine and oral coumarin-derivative antico…",
          "text": "ALERT: US Boxed Warning\n\nWarfarin interaction:\n\nFrequently monitor the anticoagulant response (international normalized ratio [INR] or prothrombin time [PT]) of patients receiving concomitant capecitabine and oral coumarin-derivative anticoagulant therapy in order to adjust the anticoagulant dose accordingly. A clinically important capecitabine-warfarin drug interaction was demonstrated in a clinical pharmacology trial. Altered coagulation parameters and/or bleeding, including death, have been reported in patients taking capecitabine concomitantly with coumarin-derivative anticoagulants such as warfarin and phenprocoumon. Postmarketing reports have shown clinically significant increases in PT and INR in patients who were stabilized on anticoagulants at the time capecitabine was introduced. These events occurred within several days and up to several months after initiating capecitabine therapy and, in a few cases, within 1 month after stopping capecitabine. These events occurred in patients with and without liver metastases. Age older than 60 years and a diagnosis of cancer independently predispose patients to an increased risk of coagulopathy."
        },
        {
          "rank": 5,
          "score": 0.6096730662878375,
          "dense_score": 0.915053604144743,
          "bm25_score": 0.15160225950247902,
          "chunk_id": "dalteparin-drug-information::F156483::6",
          "doc_id": "dalteparin-drug-information",
          "section_title": "Dosing: Adult",
          "section_code": "doa",
          "drug_title": "Dalteparin: Drug information",
          "source_url": "https://maadi-clinical.byethost8.com/d/topic.htm?path=dalteparin-drug-information",
          "snippet": "Mechanical heart valve (aortic or mitral position) to bridge anticoagulation (off-label use): SubQ: 100 units/kg/dose every 12 hours (ACCP [Douketis 2012]). Note: If used in pregnant patients, target anti-Xa level of 0.8 to 1.2 units/mL, 4…",
          "text": "Mechanical heart valve (aortic or mitral position) to bridge anticoagulation (off-label use): SubQ: 100 units/kg/dose every 12 hours (ACCP [Douketis 2012]). Note: If used in pregnant patients, target anti-Xa level of 0.8 to 1.2 units/mL, 4 to 6 hours postdose (AHA/ACC [Nishimura 2014]).\n\nPrevention of recurrent venous thromboembolism in pregnancy (off-label use): SubQ: 5,000 units once daily. Therapy should continue for 6 weeks postpartum in high-risk women (Bates 2012).\n\nPulmonary embolism, acute (treatment) (noncancer-related) (off-label use): SubQ: 200 units/kg once daily (Kovacs 2000). Note: In patients with VTE and without cancer, oral anticoagulants are preferred over LMWH (unless LMWH is used as initial parenteral anticoagulation prior to dabigatran, edoxaban, or while initiating warfarin) (Kearon 2012; Kearon 2016). In patients transitioning to warfarin, start warfarin on the first treatment day and continue dalteparin until INR is ≥2 for at least 24 hours (usually 5 to 7 days) (ACCP [Guyatt 2012]). Duration of therapy is based on the cause of VTE, risk of recurrence, and risk of bleeding. Refer to guidelines for specific recommendations."
        }
      ],
      "failure_analysis": {
        "question_id": "q008",
        "question": "Patient on warfarin needs TMP-SMX for UTI. Any interaction and what should we do?",
        "failure_types": [
          "retrieval_miss",
          "retrieval_irrelevant",
          "qa_incorrect",
          "qa_incomplete",
          "e2e_low_quality"
        ],
        "retrieved_chunks": [
          {
            "chunk_id": "trimethoprim-sulfamethoxazole-co-trimoxazole-drug-information::F154889::0",
            "score": 0.904299471438335,
            "rank": 1
          },
          {
            "chunk_id": "trimethoprim-sulfamethoxazole-co-trimoxazole-drug-information::F154863::0",
            "score": 0.8547943011724797,
            "rank": 2
          },
          {
            "chunk_id": "warfarin-drug-information::F234837::4",
            "score": 0.7873117016311454,
            "rank": 3
          },
          {
            "chunk_id": "capecitabine-drug-information::F5708655::0",
            "score": 0.6772235094198431,
            "rank": 4
          },
          {
            "chunk_id": "dalteparin-drug-information::F156483::6",
            "score": 0.6096730662878375,
            "rank": 5
          }
        ],
        "relevant_chunks_found": [],
        "essential_chunks_missed": [
          "lexi-warfarin-2018#ddi-tmp-smx"
        ],
        "generated_answer": "There is a major drug interaction between warfarin and trimethoprim-sulfamethoxazole (TMP-SMX). This interaction is due to CYP2C9 inhibition by TMP-SMX, which may increase warfarin's anticoagulant effect [capecitabine-drug-information::F5708655::0]. Therefore, it is recommended to either avoid using TMP-SMX in patients on warfarin or closely monitor the international normalized ratio (INR) and adjust the warfarin dose as necessary. [warfarin-drug-information::F234837::4]",
        "expected_answer": "Major interaction (CYP2C9 inhibition + gut flora). Avoid if possible; otherwise increase INR monitoring and reduce warfarin dose.",
        "key_points_missing": [
          "Mechanism: CYP2C9 inhibition + gut flora",
          "Severity: major",
          "Action: avoid or close INR monitoring with dose reduction"
        ],
        "retrieval_metrics": {
          "recall_at_k": {
            "1": 0.0,
            "3": 0.0,
            "5": 0.0,
            "10": 0.0,
            "20": 0.0
          },
          "precision_at_k": {
            "1": 0.0,
            "3": 0.0,
            "5": 0.0,
            "10": 0.0,
            "20": 0.0
          },
          "mean_reciprocal_rank": 0.0,
          "average_precision": 0.0,
          "ndcg_at_k": {
            "1": 0.0,
            "3": 0.0,
            "5": 0.0,
            "10": 0.0,
            "20": 0.0
          },
          "essential_recall_at_k": {
            "1": 0.0,
            "3": 0.0,
            "5": 0.0,
            "10": 0.0,
            "20": 0.0
          },
          "first_relevant_rank": 0.0,
          "total_relevant": 1,
          "total_essential": 1
        },
        "qa_metrics": {
          "bleu_score": 0.010524398322904265,
          "rouge_1_f1": 0.2558139534883721,
          "rouge_2_f1": 0.047619047619047616,
          "rouge_l_f1": 0.20930232558139533,
          "semantic_similarity": 0.582504153251648,
          "key_points_covered": 0.0,
          "key_points_found": [],
          "key_points_missing": [
            "Mechanism: CYP2C9 inhibition + gut flora",
            "Severity: major",
            "Action: avoid or close INR monitoring with dose reduction"
          ],
          "answer_length": 56,
          "has_answer": true,
          "factual_accuracy": null,
          "helpfulness": null
        },
        "root_cause": "both_systems",
        "severity": "high",
        "notes": null
      }
    },
    {
      "question_id": "q009",
      "question": {
        "id": "q009",
        "question": "Patient on atorvastatin needs clarithromycin. What’s the risk and action?",
        "question_type": "interaction",
        "difficulty": "medium",
        "expected_answer": "Major interaction (strong CYP3A4 inhibitor). Avoid coadministration; if unavoidable, hold atorvastatin or limit to the lowest dose and monitor for myopathy.",
        "answer_key_points": [
          "Mechanism: strong CYP3A4 inhibition",
          "Severity: major",
          "Action: avoid; if unavoidable hold or use lowest dose with monitoring"
        ],
        "relevant_chunks": [
          {
            "chunk_id": "lexi-atorvastatin-2018#ddi-macrolides",
            "relevance_score": 1.0,
            "is_essential": true,
            "note": null
          }
        ],
        "drug_names": [
          "atorvastatin"
        ],
        "tags": [
          "interaction"
        ],
        "source_note": null,
        "reasoning": null,
        "gold": {
          "interactions": [
            {
              "drug": "clarithromycin",
              "mechanism": "strong CYP3A4 inhibition",
              "severity": "major",
              "action": "avoid coadministration; if unavoidable, hold atorvastatin or use lowest dose with monitoring"
            }
          ],
          "contraindications": [],
          "recency_risk": false,
          "citations": [
            "lexi-atorvastatin-2018#ddi-macrolides"
          ]
        }
      },
      "generated_answer": "<s> [OUT] Clarithromycin is a strong CYP3A4 inhibitor that increases atorvastatin serum concentration, raising the risk of atorvastatin toxicity (e.g., myopathy, rhabdomyolysis). If the combination is unavoidable, limit atorvastatin to a maximum dose of 20 mg/day and monitor closely for signs of toxicity [Chunk atorvastatin-drug-information::F137634::3, Chunk amlodipine-and-atorvastatin-drug-information::F134112::6, Chunk omeprazole-clarithromycin-and-amoxicillin-copackaged-drug-information::F14471021::5, Chunk lansoprazole-amoxicillin-and-clarithromycin-copackaged-drug-information::F186882::5, Chunk clarithromycin-drug-information::F152340::4].",
      "expected_answer": "Major interaction (strong CYP3A4 inhibitor). Avoid coadministration; if unavoidable, hold atorvastatin or limit to the lowest dose and monitor for myopathy.",
      "retrieval_metrics": {
        "recall_at_k": {
          "1": 0.0,
          "3": 0.0,
          "5": 0.0,
          "10": 0.0,
          "20": 0.0
        },
        "precision_at_k": {
          "1": 0.0,
          "3": 0.0,
          "5": 0.0,
          "10": 0.0,
          "20": 0.0
        },
        "mean_reciprocal_rank": 0.0,
        "average_precision": 0.0,
        "ndcg_at_k": {
          "1": 0.0,
          "3": 0.0,
          "5": 0.0,
          "10": 0.0,
          "20": 0.0
        },
        "essential_recall_at_k": {
          "1": 0.0,
          "3": 0.0,
          "5": 0.0,
          "10": 0.0,
          "20": 0.0
        },
        "first_relevant_rank": 0.0,
        "total_relevant": 1,
        "total_essential": 1
      },
      "qa_metrics": {
        "bleu_score": 0.019617413945080493,
        "rouge_1_f1": 0.2641509433962264,
        "rouge_2_f1": 0.05769230769230768,
        "rouge_l_f1": 0.2075471698113208,
        "semantic_similarity": 0.5698187947273254,
        "key_points_covered": 0.0,
        "key_points_found": [],
        "key_points_missing": [
          "Mechanism: strong CYP3A4 inhibition",
          "Severity: major",
          "Action: avoid; if unavoidable hold or use lowest dose with monitoring"
        ],
        "answer_length": 53,
        "has_answer": true,
        "factual_accuracy": null,
        "helpfulness": null
      },
      "retrieval_results": [
        {
          "chunk_id": "atorvastatin-drug-information::F137634::3",
          "score": 1.0,
          "rank": 1
        },
        {
          "chunk_id": "amlodipine-and-atorvastatin-drug-information::F134112::6",
          "score": 0.9613447568812422,
          "rank": 2
        },
        {
          "chunk_id": "omeprazole-clarithromycin-and-amoxicillin-copackaged-drug-information::F14471021::5",
          "score": 0.923656739017185,
          "rank": 3
        },
        {
          "chunk_id": "lansoprazole-amoxicillin-and-clarithromycin-copackaged-drug-information::F186882::5",
          "score": 0.923656739017185,
          "rank": 4
        },
        {
          "chunk_id": "clarithromycin-drug-information::F152340::4",
          "score": 0.8991064127181403,
          "rank": 5
        }
      ],
      "context_chunks": [
        {
          "rank": 1,
          "score": 1.0,
          "dense_score": 1.0,
          "bm25_score": 1.0,
          "chunk_id": "atorvastatin-drug-information::F137634::3",
          "doc_id": "atorvastatin-drug-information",
          "section_title": "Drug Interactions",
          "section_code": "dri",
          "drug_title": "Atorvastatin: Drug information",
          "source_url": "https://maadi-clinical.byethost8.com/d/topic.htm?path=atorvastatin-drug-information",
          "snippet": "Clarithromycin: May increase the serum concentration of AtorvaSTATin. Management: Limit atorvastatin to a maximum dose of 20 mg/day (for adults) when used with clarithromycin. If this combination is used, monitor patients more closely for e…",
          "text": "Clarithromycin: May increase the serum concentration of AtorvaSTATin. Management: Limit atorvastatin to a maximum dose of 20 mg/day (for adults) when used with clarithromycin. If this combination is used, monitor patients more closely for evidence of atorvastatin toxicity. Risk D: Consider therapy modification\n\nCobicistat: May increase the serum concentration of AtorvaSTATin. Management: Initiate atorvastatin at the lowest recommended dose and titrate slowly as needed while monitoring closely for evidence of atorvastatin toxicity. Atorvastatin dose should not exceed 20 mg/day with concurrent use of darunavir and cobicistat. Risk D: Consider therapy modification\n\nColchicine: May enhance the myopathic (rhabdomyolysis) effect of HMG-CoA Reductase Inhibitors (Statins). Colchicine may increase the serum concentration of HMG-CoA Reductase Inhibitors (Statins). Risk D: Consider therapy modification\n\nConivaptan: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Risk X: Avoid combination\n\nCycloSPORINE (Systemic): May increase the serum concentration of AtorvaSTATin. Risk X: Avoid combination"
        },
        {
          "rank": 2,
          "score": 0.9613447568812422,
          "dense_score": 0.9592313389625122,
          "bm25_score": 0.9645148837593372,
          "chunk_id": "amlodipine-and-atorvastatin-drug-information::F134112::6",
          "doc_id": "amlodipine-and-atorvastatin-drug-information",
          "section_title": "Drug Interactions",
          "section_code": "dri",
          "drug_title": "Amlodipine and atorvastatin: Drug information",
          "source_url": "https://maadi-clinical.byethost8.com/d/topic.htm?path=amlodipine-and-atorvastatin-drug-information",
          "snippet": "Ciprofibrate: May enhance the adverse/toxic effect of HMG-CoA Reductase Inhibitors (Statins). Management: Avoid the use of HMG-CoA reductase inhibitors and ciprofibrate if possible. If concomitant therapy is considered, benefits should be c…",
          "text": "Ciprofibrate: May enhance the adverse/toxic effect of HMG-CoA Reductase Inhibitors (Statins). Management: Avoid the use of HMG-CoA reductase inhibitors and ciprofibrate if possible. If concomitant therapy is considered, benefits should be carefully weighed against the risks, and patients should be monitored closely for signs/symptoms of muscle toxicity. Risk D: Consider therapy modification\n\nClarithromycin: May increase the serum concentration of AtorvaSTATin. Management: Limit atorvastatin to a maximum dose of 20 mg/day (for adults) when used with clarithromycin. If this combination is used, monitor patients more closely for evidence of atorvastatin toxicity. Risk D: Consider therapy modification\n\nClopidogrel: Calcium Channel Blockers may diminish the therapeutic effect of Clopidogrel. Risk C: Monitor therapy\n\nCobicistat: May increase the serum concentration of AtorvaSTATin. Management: Initiate atorvastatin at the lowest recommended dose and titrate slowly as needed while monitoring closely for evidence of atorvastatin toxicity. Atorvastatin dose should not exceed 20 mg/day with concurrent use of darunavir and cobicistat. Risk D: Consider therapy modification"
        },
        {
          "rank": 3,
          "score": 0.923656739017185,
          "dense_score": 0.9568340876685218,
          "bm25_score": 0.87389071604018,
          "chunk_id": "omeprazole-clarithromycin-and-amoxicillin-copackaged-drug-information::F14471021::5",
          "doc_id": "omeprazole-clarithromycin-and-amoxicillin-copackaged-drug-information",
          "section_title": "Drug Interactions",
          "section_code": "dri",
          "drug_title": "Omeprazole, clarithromycin, and amoxicillin (copackaged): Drug information",
          "source_url": "https://maadi-clinical.byethost8.com/d/topic.htm?path=omeprazole-clarithromycin-and-amoxicillin-copackaged-drug-information",
          "snippet": "AtorvaSTATin: Clarithromycin may increase the serum concentration of AtorvaSTATin. Management: Limit atorvastatin to a maximum dose of 20 mg/day (for adults) when used with clarithromycin. If this combination is used, monitor patients more…",
          "text": "AtorvaSTATin: Clarithromycin may increase the serum concentration of AtorvaSTATin. Management: Limit atorvastatin to a maximum dose of 20 mg/day (for adults) when used with clarithromycin. If this combination is used, monitor patients more closely for evidence of atorvastatin toxicity. Risk D: Consider therapy modification\n\nAvanafil: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Avanafil. Risk X: Avoid combination\n\nAxitinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Axitinib. Management: Avoid concurrent use of axitinib with any strong CYP3A inhibitor whenever possible. If a strong CYP3A inhibitor must be used with axitinib, a 50% axitinib dose reduction is recommended. Risk X: Avoid combination\n\nBarnidipine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Barnidipine. Risk X: Avoid combination\n\nBCG (Intravesical): Antibiotics may diminish the therapeutic effect of BCG (Intravesical). Risk X: Avoid combination\n\nBCG Vaccine (Immunization): Antibiotics may diminish the therapeutic effect of BCG Vaccine (Immunization). Risk C: Monitor therapy"
        },
        {
          "rank": 4,
          "score": 0.923656739017185,
          "dense_score": 0.9568340876685218,
          "bm25_score": 0.87389071604018,
          "chunk_id": "lansoprazole-amoxicillin-and-clarithromycin-copackaged-drug-information::F186882::5",
          "doc_id": "lansoprazole-amoxicillin-and-clarithromycin-copackaged-drug-information",
          "section_title": "Drug Interactions",
          "section_code": "dri",
          "drug_title": "Lansoprazole, amoxicillin, and clarithromycin (copackaged): Drug information",
          "source_url": "https://maadi-clinical.byethost8.com/d/topic.htm?path=lansoprazole-amoxicillin-and-clarithromycin-copackaged-drug-information",
          "snippet": "AtorvaSTATin: Clarithromycin may increase the serum concentration of AtorvaSTATin. Management: Limit atorvastatin to a maximum dose of 20 mg/day (for adults) when used with clarithromycin. If this combination is used, monitor patients more…",
          "text": "AtorvaSTATin: Clarithromycin may increase the serum concentration of AtorvaSTATin. Management: Limit atorvastatin to a maximum dose of 20 mg/day (for adults) when used with clarithromycin. If this combination is used, monitor patients more closely for evidence of atorvastatin toxicity. Risk D: Consider therapy modification\n\nAvanafil: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Avanafil. Risk X: Avoid combination\n\nAxitinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Axitinib. Management: Avoid concurrent use of axitinib with any strong CYP3A inhibitor whenever possible. If a strong CYP3A inhibitor must be used with axitinib, a 50% axitinib dose reduction is recommended. Risk X: Avoid combination\n\nBarnidipine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Barnidipine. Risk X: Avoid combination\n\nBCG (Intravesical): Antibiotics may diminish the therapeutic effect of BCG (Intravesical). Risk X: Avoid combination\n\nBCG Vaccine (Immunization): Antibiotics may diminish the therapeutic effect of BCG Vaccine (Immunization). Risk C: Monitor therapy"
        },
        {
          "rank": 5,
          "score": 0.8991064127181403,
          "dense_score": 0.9133933219305421,
          "bm25_score": 0.8776760488995373,
          "chunk_id": "clarithromycin-drug-information::F152340::4",
          "doc_id": "clarithromycin-drug-information",
          "section_title": "Drug Interactions",
          "section_code": "dri",
          "drug_title": "Clarithromycin: Drug information",
          "source_url": "https://maadi-clinical.byethost8.com/d/topic.htm?path=clarithromycin-drug-information",
          "snippet": "Astemizole: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Astemizole. Risk X: Avoid combination  Asunaprevir: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Asunaprevir. Risk X: Avoid combination  At…",
          "text": "Astemizole: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Astemizole. Risk X: Avoid combination\n\nAsunaprevir: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Asunaprevir. Risk X: Avoid combination\n\nAtorvaSTATin: Clarithromycin may increase the serum concentration of AtorvaSTATin. Management: Limit atorvastatin to a maximum dose of 20 mg/day (for adults) when used with clarithromycin. If this combination is used, monitor patients more closely for evidence of atorvastatin toxicity. Risk D: Consider therapy modification\n\nAvanafil: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Avanafil. Risk X: Avoid combination\n\nAxitinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Axitinib. Management: Avoid concurrent use of axitinib with any strong CYP3A inhibitor whenever possible. If a strong CYP3A inhibitor must be used with axitinib, a 50% axitinib dose reduction is recommended. Risk X: Avoid combination\n\nBarnidipine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Barnidipine. Risk X: Avoid combination"
        }
      ],
      "failure_analysis": {
        "question_id": "q009",
        "question": "Patient on atorvastatin needs clarithromycin. What’s the risk and action?",
        "failure_types": [
          "retrieval_miss",
          "retrieval_irrelevant",
          "qa_incorrect",
          "qa_incomplete",
          "e2e_low_quality"
        ],
        "retrieved_chunks": [
          {
            "chunk_id": "atorvastatin-drug-information::F137634::3",
            "score": 1.0,
            "rank": 1
          },
          {
            "chunk_id": "amlodipine-and-atorvastatin-drug-information::F134112::6",
            "score": 0.9613447568812422,
            "rank": 2
          },
          {
            "chunk_id": "omeprazole-clarithromycin-and-amoxicillin-copackaged-drug-information::F14471021::5",
            "score": 0.923656739017185,
            "rank": 3
          },
          {
            "chunk_id": "lansoprazole-amoxicillin-and-clarithromycin-copackaged-drug-information::F186882::5",
            "score": 0.923656739017185,
            "rank": 4
          },
          {
            "chunk_id": "clarithromycin-drug-information::F152340::4",
            "score": 0.8991064127181403,
            "rank": 5
          }
        ],
        "relevant_chunks_found": [],
        "essential_chunks_missed": [
          "lexi-atorvastatin-2018#ddi-macrolides"
        ],
        "generated_answer": "<s> [OUT] Clarithromycin is a strong CYP3A4 inhibitor that increases atorvastatin serum concentration, raising the risk of atorvastatin toxicity (e.g., myopathy, rhabdomyolysis). If the combination is unavoidable, limit atorvastatin to a maximum dose of 20 mg/day and monitor closely for signs of toxicity [Chunk atorvastatin-drug-information::F137634::3, Chunk amlodipine-and-atorvastatin-drug-information::F134112::6, Chunk omeprazole-clarithromycin-and-amoxicillin-copackaged-drug-information::F14471021::5, Chunk lansoprazole-amoxicillin-and-clarithromycin-copackaged-drug-information::F186882::5, Chunk clarithromycin-drug-information::F152340::4].",
        "expected_answer": "Major interaction (strong CYP3A4 inhibitor). Avoid coadministration; if unavoidable, hold atorvastatin or limit to the lowest dose and monitor for myopathy.",
        "key_points_missing": [
          "Mechanism: strong CYP3A4 inhibition",
          "Severity: major",
          "Action: avoid; if unavoidable hold or use lowest dose with monitoring"
        ],
        "retrieval_metrics": {
          "recall_at_k": {
            "1": 0.0,
            "3": 0.0,
            "5": 0.0,
            "10": 0.0,
            "20": 0.0
          },
          "precision_at_k": {
            "1": 0.0,
            "3": 0.0,
            "5": 0.0,
            "10": 0.0,
            "20": 0.0
          },
          "mean_reciprocal_rank": 0.0,
          "average_precision": 0.0,
          "ndcg_at_k": {
            "1": 0.0,
            "3": 0.0,
            "5": 0.0,
            "10": 0.0,
            "20": 0.0
          },
          "essential_recall_at_k": {
            "1": 0.0,
            "3": 0.0,
            "5": 0.0,
            "10": 0.0,
            "20": 0.0
          },
          "first_relevant_rank": 0.0,
          "total_relevant": 1,
          "total_essential": 1
        },
        "qa_metrics": {
          "bleu_score": 0.019617413945080493,
          "rouge_1_f1": 0.2641509433962264,
          "rouge_2_f1": 0.05769230769230768,
          "rouge_l_f1": 0.2075471698113208,
          "semantic_similarity": 0.5698187947273254,
          "key_points_covered": 0.0,
          "key_points_found": [],
          "key_points_missing": [
            "Mechanism: strong CYP3A4 inhibition",
            "Severity: major",
            "Action: avoid; if unavoidable hold or use lowest dose with monitoring"
          ],
          "answer_length": 53,
          "has_answer": true,
          "factual_accuracy": null,
          "helpfulness": null
        },
        "root_cause": "both_systems",
        "severity": "high",
        "notes": null
      }
    },
    {
      "question_id": "q010",
      "question": {
        "id": "q010",
        "question": "Starting linezolid in a patient on sertraline. Is this safe?",
        "question_type": "interaction",
        "difficulty": "medium",
        "expected_answer": "Major interaction: risk of serotonin syndrome (linezolid has MAOI activity). Avoid; if benefits outweigh risks, withhold SSRI or monitor very closely.",
        "answer_key_points": [
          "Mechanism: MAOI activity → ↑serotonin",
          "Severity: major",
          "Action: avoid; or stop SSRI/close monitoring if unavoidable"
        ],
        "relevant_chunks": [
          {
            "chunk_id": "lexi-linezolid-2018#ddi-ssri",
            "relevance_score": 1.0,
            "is_essential": true,
            "note": null
          }
        ],
        "drug_names": [
          "linezolid"
        ],
        "tags": [
          "interaction"
        ],
        "source_note": null,
        "reasoning": null,
        "gold": {
          "interactions": [
            {
              "drug": "sertraline (SSRI)",
              "mechanism": "MAOI activity of linezolid → ↑serotonin",
              "severity": "major",
              "action": "avoid combination; if unavoidable, withhold SSRI or monitor closely"
            }
          ],
          "contraindications": [],
          "recency_risk": false,
          "citations": [
            "lexi-linezolid-2018#ddi-ssri"
          ]
        }
      },
      "generated_answer": "Based on the provided context, the use of linezolid in a patient on sertraline (an SSRI) may pose a significant risk due to the potential for serotonin syndrome. This is because linezolid has MAOI activity, which can increase serotonin levels [chunk_188931::1]. The risk is major, and it is recommended to avoid the combination. If the use of linezolid is unavoidable, close monitoring for signs and symptoms of serotonin syndrome is necessary [chunk_188931::1]. It is also important to note that discontinuing sertraline 2 weeks prior to linezolid administration is recommended to mitigate the risk [chunk_166177::3, chunk_160435::4, chunk_166284::4].",
      "expected_answer": "Major interaction: risk of serotonin syndrome (linezolid has MAOI activity). Avoid; if benefits outweigh risks, withhold SSRI or monitor very closely.",
      "retrieval_metrics": {
        "recall_at_k": {
          "1": 0.0,
          "3": 0.0,
          "5": 0.0,
          "10": 0.0,
          "20": 0.0
        },
        "precision_at_k": {
          "1": 0.0,
          "3": 0.0,
          "5": 0.0,
          "10": 0.0,
          "20": 0.0
        },
        "mean_reciprocal_rank": 0.0,
        "average_precision": 0.0,
        "ndcg_at_k": {
          "1": 0.0,
          "3": 0.0,
          "5": 0.0,
          "10": 0.0,
          "20": 0.0
        },
        "essential_recall_at_k": {
          "1": 0.0,
          "3": 0.0,
          "5": 0.0,
          "10": 0.0,
          "20": 0.0
        },
        "first_relevant_rank": 0.0,
        "total_relevant": 1,
        "total_essential": 1
      },
      "qa_metrics": {
        "bleu_score": 0.03282402093642064,
        "rouge_1_f1": 0.23622047244094488,
        "rouge_2_f1": 0.08,
        "rouge_l_f1": 0.15748031496062992,
        "semantic_similarity": 0.7798409461975098,
        "key_points_covered": 0.0,
        "key_points_found": [],
        "key_points_missing": [
          "Mechanism: MAOI activity → ↑serotonin",
          "Severity: major",
          "Action: avoid; or stop SSRI/close monitoring if unavoidable"
        ],
        "answer_length": 96,
        "has_answer": true,
        "factual_accuracy": null,
        "helpfulness": null
      },
      "retrieval_results": [
        {
          "chunk_id": "linezolid-drug-information::F188931::2",
          "score": 0.6,
          "rank": 1
        },
        {
          "chunk_id": "ergoloid-mesylates-drug-information::F166177::3",
          "score": 0.5963595430433523,
          "rank": 2
        },
        {
          "chunk_id": "dihydroergotamine-drug-information::F160435::4",
          "score": 0.5963595430433523,
          "rank": 3
        },
        {
          "chunk_id": "ergotamine-drug-information::F166284::4",
          "score": 0.5963595430433523,
          "rank": 4
        },
        {
          "chunk_id": "linezolid-drug-information::F188931::1",
          "score": 0.5903083809084277,
          "rank": 5
        }
      ],
      "context_chunks": [
        {
          "rank": 1,
          "score": 0.6,
          "dense_score": 1.0,
          "bm25_score": 0.0,
          "chunk_id": "linezolid-drug-information::F188931::2",
          "doc_id": "linezolid-drug-information",
          "section_title": "Warnings/Precautions",
          "section_code": "war",
          "drug_title": "Linezolid: Drug information",
          "source_url": "https://maadi-clinical.byethost8.com/d/topic.htm?path=linezolid-drug-information",
          "snippet": "• Hypertension: Use with caution and closely monitor blood pressure in patients with uncontrolled hypertension; linezolid has not been studied in patients with this condition. Do not use in the absence of close monitoring.  • Hyperthyroidis…",
          "text": "• Hypertension: Use with caution and closely monitor blood pressure in patients with uncontrolled hypertension; linezolid has not been studied in patients with this condition. Do not use in the absence of close monitoring.\n\n• Hyperthyroidism: Use with caution and closely monitor blood pressure in patients with untreated hyperthyroidism; linezolid has not been studied in patients with this condition. Do not use in the absence of close monitoring.\n\n• Pheochromocytoma: Use with caution and closely monitor blood pressure in patients with pheochromocytoma; linezolid has not been studied in patients with this condition. Do not use in the absence of close monitoring.\n\n• Seizure disorder: Seizures have been reported; use with caution in patients with a history of seizures.\n\nConcurrent drug therapy issues:\n\n• Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.\n\nSpecial populations:"
        },
        {
          "rank": 2,
          "score": 0.5963595430433523,
          "dense_score": 0.9939325717389205,
          "bm25_score": 0.0,
          "chunk_id": "ergoloid-mesylates-drug-information::F166177::3",
          "doc_id": "ergoloid-mesylates-drug-information",
          "section_title": "Drug Interactions",
          "section_code": "dri",
          "drug_title": "Ergoloid mesylates: Drug information",
          "source_url": "https://maadi-clinical.byethost8.com/d/topic.htm?path=ergoloid-mesylates-drug-information",
          "snippet": "Linezolid: May enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome. Management: Due to a risk of serotonin syndrome/serotonin toxicity, discontinue serotonin modulators 2 weeks prior to the admin…",
          "text": "Linezolid: May enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome. Management: Due to a risk of serotonin syndrome/serotonin toxicity, discontinue serotonin modulators 2 weeks prior to the administration of linezolid. If urgent initiation of linezolid is needed, discontinue serotonin modulators immediately and monitor closely. Risk D: Consider therapy modification\n\nLorcaserin: May enhance the adverse/toxic effect of Ergot Derivatives. Specifically, use of these drugs together may increase the risk of developing valvular heart disease. Lorcaserin may enhance the serotonergic effect of Ergot Derivatives. This could result in serotonin syndrome. Risk X: Avoid combination\n\nMacrolide Antibiotics: May increase the serum concentration of Ergot Derivatives. Cabergoline and Clarithromycin may interact, see specific monograph for full details. Exceptions: Azithromycin (Systemic); Fidaxomicin; Spiramycin. Risk D: Consider therapy modification\n\nMetaxalone: May enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome. Risk C: Monitor therapy"
        },
        {
          "rank": 3,
          "score": 0.5963595430433523,
          "dense_score": 0.9939325717389205,
          "bm25_score": 0.0,
          "chunk_id": "dihydroergotamine-drug-information::F160435::4",
          "doc_id": "dihydroergotamine-drug-information",
          "section_title": "Drug Interactions",
          "section_code": "dri",
          "drug_title": "Dihydroergotamine: Drug information",
          "source_url": "https://maadi-clinical.byethost8.com/d/topic.htm?path=dihydroergotamine-drug-information",
          "snippet": "Linezolid: May enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome. Management: Due to a risk of serotonin syndrome/serotonin toxicity, discontinue serotonin modulators 2 weeks prior to the admin…",
          "text": "Linezolid: May enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome. Management: Due to a risk of serotonin syndrome/serotonin toxicity, discontinue serotonin modulators 2 weeks prior to the administration of linezolid. If urgent initiation of linezolid is needed, discontinue serotonin modulators immediately and monitor closely. Risk D: Consider therapy modification\n\nLorcaserin: May enhance the adverse/toxic effect of Ergot Derivatives. Specifically, use of these drugs together may increase the risk of developing valvular heart disease. Lorcaserin may enhance the serotonergic effect of Ergot Derivatives. This could result in serotonin syndrome. Risk X: Avoid combination\n\nMacrolide Antibiotics: May increase the serum concentration of Ergot Derivatives. Cabergoline and Clarithromycin may interact, see specific monograph for full details. Exceptions: Azithromycin (Systemic); Fidaxomicin; Spiramycin. Risk D: Consider therapy modification\n\nMetaxalone: May enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome. Risk C: Monitor therapy"
        },
        {
          "rank": 4,
          "score": 0.5963595430433523,
          "dense_score": 0.9939325717389205,
          "bm25_score": 0.0,
          "chunk_id": "ergotamine-drug-information::F166284::4",
          "doc_id": "ergotamine-drug-information",
          "section_title": "Drug Interactions",
          "section_code": "dri",
          "drug_title": "Ergotamine: Drug information",
          "source_url": "https://maadi-clinical.byethost8.com/d/topic.htm?path=ergotamine-drug-information",
          "snippet": "Linezolid: May enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome. Management: Due to a risk of serotonin syndrome/serotonin toxicity, discontinue serotonin modulators 2 weeks prior to the admin…",
          "text": "Linezolid: May enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome. Management: Due to a risk of serotonin syndrome/serotonin toxicity, discontinue serotonin modulators 2 weeks prior to the administration of linezolid. If urgent initiation of linezolid is needed, discontinue serotonin modulators immediately and monitor closely. Risk D: Consider therapy modification\n\nLorcaserin: May enhance the adverse/toxic effect of Ergot Derivatives. Specifically, use of these drugs together may increase the risk of developing valvular heart disease. Lorcaserin may enhance the serotonergic effect of Ergot Derivatives. This could result in serotonin syndrome. Risk X: Avoid combination\n\nMacrolide Antibiotics: May increase the serum concentration of Ergot Derivatives. Cabergoline and Clarithromycin may interact, see specific monograph for full details. Exceptions: Azithromycin (Systemic); Fidaxomicin; Spiramycin. Risk D: Consider therapy modification\n\nMetaxalone: May enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome. Risk C: Monitor therapy"
        },
        {
          "rank": 5,
          "score": 0.5903083809084277,
          "dense_score": 0.9838473015140463,
          "bm25_score": 0.0,
          "chunk_id": "linezolid-drug-information::F188931::1",
          "doc_id": "linezolid-drug-information",
          "section_title": "Warnings/Precautions",
          "section_code": "war",
          "drug_title": "Linezolid: Drug information",
          "source_url": "https://maadi-clinical.byethost8.com/d/topic.htm?path=linezolid-drug-information",
          "snippet": "• Serotonin syndrome: Symptoms of agitation, confusion, hallucinations, hyper-reflexia, myoclonus, shivering, and tachycardia may occur with concomitant proserotonergic drugs, agents which reduce linezolid's metabolism, or in patients with…",
          "text": "• Serotonin syndrome: Symptoms of agitation, confusion, hallucinations, hyper-reflexia, myoclonus, shivering, and tachycardia may occur with concomitant proserotonergic drugs, agents which reduce linezolid's metabolism, or in patients with carcinoid syndrome. Avoid use in such patients unless clinically appropriate and under close monitoring for signs/symptoms of serotonin syndrome or neuroleptic malignant syndrome-like reactions.\n\n• Superinfection: Prolonged use may result in fungal or bacterial superinfection, including C. difficile-associated diarrhea (CDAD) and pseudomembranous colitis; CDAD has been observed >2 months postantibiotic treatment.\n\nDisease-related concerns:\n\n• Carcinoid syndrome: Use with caution and closely monitor for serotonin syndrome in patients with carcinoid syndrome; linezolid has not been studied in patients with this condition. Do not use in the absence of close monitoring.\n\n• Diabetes mellitus: Hypoglycemic episodes have been reported; use with caution and closely monitor glucose in diabetic patients. Dose reductions/discontinuation of concurrent hypoglycemic agents or discontinuation of linezolid may be required."
        }
      ],
      "failure_analysis": {
        "question_id": "q010",
        "question": "Starting linezolid in a patient on sertraline. Is this safe?",
        "failure_types": [
          "retrieval_miss",
          "retrieval_irrelevant",
          "qa_incomplete"
        ],
        "retrieved_chunks": [
          {
            "chunk_id": "linezolid-drug-information::F188931::2",
            "score": 0.6,
            "rank": 1
          },
          {
            "chunk_id": "ergoloid-mesylates-drug-information::F166177::3",
            "score": 0.5963595430433523,
            "rank": 2
          },
          {
            "chunk_id": "dihydroergotamine-drug-information::F160435::4",
            "score": 0.5963595430433523,
            "rank": 3
          },
          {
            "chunk_id": "ergotamine-drug-information::F166284::4",
            "score": 0.5963595430433523,
            "rank": 4
          },
          {
            "chunk_id": "linezolid-drug-information::F188931::1",
            "score": 0.5903083809084277,
            "rank": 5
          }
        ],
        "relevant_chunks_found": [],
        "essential_chunks_missed": [
          "lexi-linezolid-2018#ddi-ssri"
        ],
        "generated_answer": "Based on the provided context, the use of linezolid in a patient on sertraline (an SSRI) may pose a significant risk due to the potential for serotonin syndrome. This is because linezolid has MAOI activity, which can increase serotonin levels [chunk_188931::1]. The risk is major, and it is recommended to avoid the combination. If the use of linezolid is unavoidable, close monitoring for signs and symptoms of serotonin syndrome is necessary [chunk_188931::1]. It is also important to note that discontinuing sertraline 2 weeks prior to linezolid administration is recommended to mitigate the risk [chunk_166177::3, chunk_160435::4, chunk_166284::4].",
        "expected_answer": "Major interaction: risk of serotonin syndrome (linezolid has MAOI activity). Avoid; if benefits outweigh risks, withhold SSRI or monitor very closely.",
        "key_points_missing": [
          "Mechanism: MAOI activity → ↑serotonin",
          "Severity: major",
          "Action: avoid; or stop SSRI/close monitoring if unavoidable"
        ],
        "retrieval_metrics": {
          "recall_at_k": {
            "1": 0.0,
            "3": 0.0,
            "5": 0.0,
            "10": 0.0,
            "20": 0.0
          },
          "precision_at_k": {
            "1": 0.0,
            "3": 0.0,
            "5": 0.0,
            "10": 0.0,
            "20": 0.0
          },
          "mean_reciprocal_rank": 0.0,
          "average_precision": 0.0,
          "ndcg_at_k": {
            "1": 0.0,
            "3": 0.0,
            "5": 0.0,
            "10": 0.0,
            "20": 0.0
          },
          "essential_recall_at_k": {
            "1": 0.0,
            "3": 0.0,
            "5": 0.0,
            "10": 0.0,
            "20": 0.0
          },
          "first_relevant_rank": 0.0,
          "total_relevant": 1,
          "total_essential": 1
        },
        "qa_metrics": {
          "bleu_score": 0.03282402093642064,
          "rouge_1_f1": 0.23622047244094488,
          "rouge_2_f1": 0.08,
          "rouge_l_f1": 0.15748031496062992,
          "semantic_similarity": 0.7798409461975098,
          "key_points_covered": 0.0,
          "key_points_found": [],
          "key_points_missing": [
            "Mechanism: MAOI activity → ↑serotonin",
            "Severity: major",
            "Action: avoid; or stop SSRI/close monitoring if unavoidable"
          ],
          "answer_length": 96,
          "has_answer": true,
          "factual_accuracy": null,
          "helpfulness": null
        },
        "root_cause": "both_systems",
        "severity": "high",
        "notes": null
      }
    },
    {
      "question_id": "q011",
      "question": {
        "id": "q011",
        "question": "Patient on digoxin will start amiodarone. What’s the interaction management?",
        "question_type": "interaction",
        "difficulty": "medium",
        "expected_answer": "Major interaction (P-gp inhibition). Reduce digoxin dose by ~30–50% and monitor levels/ECG.",
        "answer_key_points": [
          "Mechanism: P-gp inhibition → ↑digoxin",
          "Severity: major",
          "Action: reduce dose ~30–50% + monitor levels and ECG"
        ],
        "relevant_chunks": [
          {
            "chunk_id": "lexi-digoxin-2018#ddi-amio",
            "relevance_score": 1.0,
            "is_essential": true,
            "note": null
          }
        ],
        "drug_names": [
          "digoxin"
        ],
        "tags": [
          "interaction"
        ],
        "source_note": null,
        "reasoning": null,
        "gold": {
          "interactions": [
            {
              "drug": "amiodarone",
              "mechanism": "P-gp inhibition → ↑digoxin levels",
              "severity": "major",
              "action": "reduce digoxin dose by ~30–50% and monitor serum levels and ECG"
            }
          ],
          "contraindications": [],
          "recency_risk": false,
          "citations": [
            "lexi-digoxin-2018#ddi-amio"
          ]
        }
      },
      "generated_answer": "In the provided context, it is stated that Amiodarone may increase the serum concentration of Digoxin [chunk_digoxin-drug-information::F160110::8]. This interaction is classified as major (Risk D: Consider therapy modification). The mechanism is likely due to P-gp inhibition. If a patient is on both Digoxin and Amiodarone, it is recommended to reduce the Digoxin dose by 30-50% and closely monitor Digoxin levels and ECG. [chunk_digoxin-drug-information::F160110::8] and [chunk_dronedarone-drug-information::F7907323::10] provide more details on this interaction. However, it's important to note that the context does not specify the exact dosage adjustments for the Amiodarone-Digoxin interaction, so further consultation with a healthcare professional is advised.",
      "expected_answer": "Major interaction (P-gp inhibition). Reduce digoxin dose by ~30–50% and monitor levels/ECG.",
      "retrieval_metrics": {
        "recall_at_k": {
          "1": 0.0,
          "3": 0.0,
          "5": 0.0,
          "10": 0.0,
          "20": 0.0
        },
        "precision_at_k": {
          "1": 0.0,
          "3": 0.0,
          "5": 0.0,
          "10": 0.0,
          "20": 0.0
        },
        "mean_reciprocal_rank": 0.0,
        "average_precision": 0.0,
        "ndcg_at_k": {
          "1": 0.0,
          "3": 0.0,
          "5": 0.0,
          "10": 0.0,
          "20": 0.0
        },
        "essential_recall_at_k": {
          "1": 0.0,
          "3": 0.0,
          "5": 0.0,
          "10": 0.0,
          "20": 0.0
        },
        "first_relevant_rank": 0.0,
        "total_relevant": 1,
        "total_essential": 1
      },
      "qa_metrics": {
        "bleu_score": 0.0126815034293817,
        "rouge_1_f1": 0.22556390977443605,
        "rouge_2_f1": 0.10687022900763359,
        "rouge_l_f1": 0.2105263157894737,
        "semantic_similarity": 0.6580440402030945,
        "key_points_covered": 0.3333333333333333,
        "key_points_found": [
          "Action: reduce dose ~30–50% + monitor levels and ECG"
        ],
        "key_points_missing": [
          "Mechanism: P-gp inhibition → ↑digoxin",
          "Severity: major"
        ],
        "answer_length": 99,
        "has_answer": true,
        "factual_accuracy": null,
        "helpfulness": null
      },
      "retrieval_results": [
        {
          "chunk_id": "digoxin-drug-information::F160110::4",
          "score": 0.9713385544864623,
          "rank": 1
        },
        {
          "chunk_id": "digoxin-drug-information::F160110::0",
          "score": 0.9653535237565192,
          "rank": 2
        },
        {
          "chunk_id": "digoxin-drug-information::F160110::8",
          "score": 0.9518168384472304,
          "rank": 3
        },
        {
          "chunk_id": "dronedarone-drug-information::F7907323::10",
          "score": 0.7607655344131665,
          "rank": 4
        },
        {
          "chunk_id": "niacin-and-simvastatin-drug-information::F5925425::0",
          "score": 0.7477619106718761,
          "rank": 5
        }
      ],
      "context_chunks": [
        {
          "rank": 1,
          "score": 0.9713385544864623,
          "dense_score": 0.9522309241441038,
          "bm25_score": 1.0,
          "chunk_id": "digoxin-drug-information::F160110::4",
          "doc_id": "digoxin-drug-information",
          "section_title": "Drug Interactions",
          "section_code": "dri",
          "drug_title": "Digoxin: Drug information",
          "source_url": "https://maadi-clinical.byethost8.com/d/topic.htm?path=digoxin-drug-information",
          "snippet": "Colchicine: Digoxin may increase the serum concentration of Colchicine. Risk C: Monitor therapy  Conivaptan: May increase the serum concentration of Digoxin. Risk C: Monitor therapy  CycloSPORINE (Systemic): May increase the serum concentra…",
          "text": "Colchicine: Digoxin may increase the serum concentration of Colchicine. Risk C: Monitor therapy\n\nConivaptan: May increase the serum concentration of Digoxin. Risk C: Monitor therapy\n\nCycloSPORINE (Systemic): May increase the serum concentration of Digoxin. Risk C: Monitor therapy\n\nDaclatasvir: May increase the serum concentration of Digoxin. Management: See full interaction monograph for details. Risk D: Consider therapy modification\n\nDiacerein: May enhance the arrhythmogenic effect of Cardiac Glycosides. Risk C: Monitor therapy\n\nDronedarone: Digoxin may enhance the AV-blocking effect of Dronedarone. Digoxin may also enhance the other electrophysiologic effects of Dronedarone. Dronedarone may increase the serum concentration of Digoxin. Management: Avoid concurrent use of digoxin when possible. If concurrent use is necessary, reduce adult digoxin dose by 50%, monitor digoxin concentration closely, and increase monitoring for both clinical response to therapy and the occurrence of adverse effects. Risk D: Consider therapy modification\n\nEdrophonium: May enhance the AV-blocking effect of Cardiac Glycosides. Risk C: Monitor therapy"
        },
        {
          "rank": 2,
          "score": 0.9653535237565192,
          "dense_score": 0.9806366315468737,
          "bm25_score": 0.9424288620709873,
          "chunk_id": "digoxin-drug-information::F160110::0",
          "doc_id": "digoxin-drug-information",
          "section_title": "Drug Interactions",
          "section_code": "dri",
          "drug_title": "Digoxin: Drug information",
          "source_url": "https://maadi-clinical.byethost8.com/d/topic.htm?path=digoxin-drug-information",
          "snippet": "Drug Interactions  (For additional information: Launch drug interactions program)  5-Aminosalicylic Acid Derivatives: May decrease the serum concentration of Cardiac Glycosides. Risk C: Monitor therapy  Acarbose: May decrease the serum conc…",
          "text": "Drug Interactions\n\n(For additional information: Launch drug interactions program)\n\n5-Aminosalicylic Acid Derivatives: May decrease the serum concentration of Cardiac Glycosides. Risk C: Monitor therapy\n\nAcarbose: May decrease the serum concentration of Digoxin. Risk C: Monitor therapy\n\nAdenosine: Digoxin may enhance the adverse/toxic effect of Adenosine. Risk C: Monitor therapy\n\nAminoglycosides: May decrease the serum concentration of Cardiac Glycosides. This effect has only been demonstrated with oral aminoglycoside administration. Exceptions: Amikacin; Kanamycin; Streptomycin; Tobramycin (Systemic). Risk C: Monitor therapy\n\nAminoquinolines (Antimalarial): May increase the serum concentration of Cardiac Glycosides. Risk C: Monitor therapy\n\nAmiodarone: May increase the serum concentration of Cardiac Glycosides. Management: Reduce the dose of cardiac glycosides by 30% to 50% or reduce the frequency of administration when initiating concomitant amiodarone therapy. Monitor for increased serum concentrations and toxic effects of cardiac glycosides. Risk D: Consider therapy modification"
        },
        {
          "rank": 3,
          "score": 0.9518168384472304,
          "dense_score": 0.9784425093909342,
          "bm25_score": 0.9118783320316748,
          "chunk_id": "digoxin-drug-information::F160110::8",
          "doc_id": "digoxin-drug-information",
          "section_title": "Drug Interactions",
          "section_code": "dri",
          "drug_title": "Digoxin: Drug information",
          "source_url": "https://maadi-clinical.byethost8.com/d/topic.htm?path=digoxin-drug-information",
          "snippet": "Midodrine: Cardiac Glycosides may enhance the bradycardic effect of Midodrine. Risk C: Monitor therapy  MiFEPRIStone: May increase the serum concentration of Digoxin. Management: Measure serum digoxin concentration 1-2 weeks following mifep…",
          "text": "Midodrine: Cardiac Glycosides may enhance the bradycardic effect of Midodrine. Risk C: Monitor therapy\n\nMiFEPRIStone: May increase the serum concentration of Digoxin. Management: Measure serum digoxin concentration 1-2 weeks following mifepristone initiation, and in accordance with normal clinical practice thereafter, adjusting dose as needed. Risk C: Monitor therapy\n\nMilnacipran: May enhance the adverse/toxic effect of Digoxin. The risk of postural hypotension and tachycardia may be increased, particularly with IV digoxin. Management: Avoid concurrent use of intravenous (IV) digoxin in patients receiving milnacipran. Use caution when using oral digoxin and milnacipran together, monitoring closely for possible postural hypotension and tachycardia. Risk D: Consider therapy modification\n\nMirabegron: May increase the serum concentration of Digoxin. Management: Consider using the lowest dose of digoxin when initiating concurrent mirabegron. Monitor serum digoxin concentrations closely to help guide digoxin dosing. Risk D: Consider therapy modification\n\nMultivitamins/Fluoride (with ADE): May enhance the arrhythmogenic effect of Cardiac Glycosides. Risk C: Monitor therapy"
        },
        {
          "rank": 4,
          "score": 0.7607655344131665,
          "dense_score": 0.9610040801169284,
          "bm25_score": 0.4604077158575238,
          "chunk_id": "dronedarone-drug-information::F7907323::10",
          "doc_id": "dronedarone-drug-information",
          "section_title": "Drug Interactions",
          "section_code": "dri",
          "drug_title": "Dronedarone: Drug information",
          "source_url": "https://maadi-clinical.byethost8.com/d/topic.htm?path=dronedarone-drug-information",
          "snippet": "Digoxin: May enhance the AV-blocking effect of Dronedarone. Digoxin may also enhance the other electrophysiologic effects of Dronedarone. Dronedarone may increase the serum concentration of Digoxin. Management: Avoid concurrent use of digox…",
          "text": "Digoxin: May enhance the AV-blocking effect of Dronedarone. Digoxin may also enhance the other electrophysiologic effects of Dronedarone. Dronedarone may increase the serum concentration of Digoxin. Management: Avoid concurrent use of digoxin when possible. If concurrent use is necessary, reduce adult digoxin dose by 50%, monitor digoxin concentration closely, and increase monitoring for both clinical response to therapy and the occurrence of adverse effects. Risk D: Consider therapy modification\n\nDOCEtaxel: Dronedarone may increase the serum concentration of DOCEtaxel. Management: Avoid this combination whenever possible. If this combination must be used, consider using a reduced docetaxel dose, and/or increase monitoring for evidence of serious docetaxel toxicity (e.g., neutropenia, mucositis, etc.). Risk D: Consider therapy modification\n\nDomperidone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Domperidone. Risk X: Avoid combination"
        },
        {
          "rank": 5,
          "score": 0.7477619106718761,
          "dense_score": 1.0,
          "bm25_score": 0.3694047766796904,
          "chunk_id": "niacin-and-simvastatin-drug-information::F5925425::0",
          "doc_id": "niacin-and-simvastatin-drug-information",
          "section_title": "Drug Interactions",
          "section_code": "dri",
          "drug_title": "Niacin and simvastatin: Drug information",
          "source_url": "https://maadi-clinical.byethost8.com/d/topic.htm?path=niacin-and-simvastatin-drug-information",
          "snippet": "Drug Interactions  (For additional information: Launch drug interactions program)  Acipimox: May enhance the myopathic (rhabdomyolysis) effect of HMG-CoA Reductase Inhibitors (Statins). Risk C: Monitor therapy  Alcohol (Ethyl): May enhance…",
          "text": "Drug Interactions\n\n(For additional information: Launch drug interactions program)\n\nAcipimox: May enhance the myopathic (rhabdomyolysis) effect of HMG-CoA Reductase Inhibitors (Statins). Risk C: Monitor therapy\n\nAlcohol (Ethyl): May enhance the adverse/toxic effect of Niacin. Risk D: Consider therapy modification\n\nAmiodarone: May increase the serum concentration of Simvastatin. Management: Consider using a non-interacting statin (pravastatin) in patients on amiodarone. If combined, limit the simvastatin dose to 20 mg daily and monitor for evidence of simvastatin toxicities (eg, myalgia, liver function test elevations, rhabdomyolysis). Risk D: Consider therapy modification\n\nAmLODIPine: May increase the serum concentration of Simvastatin. Management: Avoid the concurrent use of amlodipine with simvastatin when possible. If used together, avoid doses of simvastatin greater than 20 mg/day (for adults). Risk D: Consider therapy modification\n\nAntidiabetic Agents: Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents. Risk C: Monitor therapy"
        }
      ],
      "failure_analysis": {
        "question_id": "q011",
        "question": "Patient on digoxin will start amiodarone. What’s the interaction management?",
        "failure_types": [
          "retrieval_miss",
          "retrieval_irrelevant",
          "qa_incorrect",
          "qa_incomplete"
        ],
        "retrieved_chunks": [
          {
            "chunk_id": "digoxin-drug-information::F160110::4",
            "score": 0.9713385544864623,
            "rank": 1
          },
          {
            "chunk_id": "digoxin-drug-information::F160110::0",
            "score": 0.9653535237565192,
            "rank": 2
          },
          {
            "chunk_id": "digoxin-drug-information::F160110::8",
            "score": 0.9518168384472304,
            "rank": 3
          },
          {
            "chunk_id": "dronedarone-drug-information::F7907323::10",
            "score": 0.7607655344131665,
            "rank": 4
          },
          {
            "chunk_id": "niacin-and-simvastatin-drug-information::F5925425::0",
            "score": 0.7477619106718761,
            "rank": 5
          }
        ],
        "relevant_chunks_found": [],
        "essential_chunks_missed": [
          "lexi-digoxin-2018#ddi-amio"
        ],
        "generated_answer": "In the provided context, it is stated that Amiodarone may increase the serum concentration of Digoxin [chunk_digoxin-drug-information::F160110::8]. This interaction is classified as major (Risk D: Consider therapy modification). The mechanism is likely due to P-gp inhibition. If a patient is on both Digoxin and Amiodarone, it is recommended to reduce the Digoxin dose by 30-50% and closely monitor Digoxin levels and ECG. [chunk_digoxin-drug-information::F160110::8] and [chunk_dronedarone-drug-information::F7907323::10] provide more details on this interaction. However, it's important to note that the context does not specify the exact dosage adjustments for the Amiodarone-Digoxin interaction, so further consultation with a healthcare professional is advised.",
        "expected_answer": "Major interaction (P-gp inhibition). Reduce digoxin dose by ~30–50% and monitor levels/ECG.",
        "key_points_missing": [
          "Mechanism: P-gp inhibition → ↑digoxin",
          "Severity: major"
        ],
        "retrieval_metrics": {
          "recall_at_k": {
            "1": 0.0,
            "3": 0.0,
            "5": 0.0,
            "10": 0.0,
            "20": 0.0
          },
          "precision_at_k": {
            "1": 0.0,
            "3": 0.0,
            "5": 0.0,
            "10": 0.0,
            "20": 0.0
          },
          "mean_reciprocal_rank": 0.0,
          "average_precision": 0.0,
          "ndcg_at_k": {
            "1": 0.0,
            "3": 0.0,
            "5": 0.0,
            "10": 0.0,
            "20": 0.0
          },
          "essential_recall_at_k": {
            "1": 0.0,
            "3": 0.0,
            "5": 0.0,
            "10": 0.0,
            "20": 0.0
          },
          "first_relevant_rank": 0.0,
          "total_relevant": 1,
          "total_essential": 1
        },
        "qa_metrics": {
          "bleu_score": 0.0126815034293817,
          "rouge_1_f1": 0.22556390977443605,
          "rouge_2_f1": 0.10687022900763359,
          "rouge_l_f1": 0.2105263157894737,
          "semantic_similarity": 0.6580440402030945,
          "key_points_covered": 0.3333333333333333,
          "key_points_found": [
            "Action: reduce dose ~30–50% + monitor levels and ECG"
          ],
          "key_points_missing": [
            "Mechanism: P-gp inhibition → ↑digoxin",
            "Severity: major"
          ],
          "answer_length": 99,
          "has_answer": true,
          "factual_accuracy": null,
          "helpfulness": null
        },
        "root_cause": "both_systems",
        "severity": "high",
        "notes": null
      }
    },
    {
      "question_id": "q012",
      "question": {
        "id": "q012",
        "question": "COVID-19 patient asks for Paxlovid dosing and interaction checks.",
        "question_type": "dosage",
        "difficulty": "medium",
        "expected_answer": "ABSTAIN. Not in ≤2018 corpus; recency-sensitive therapy. Advise consulting current guidance/pharmacist.",
        "answer_key_points": [
          "Explicit abstention",
          "Sets recency_risk = true",
          "Advises pharmacist/current guidance"
        ],
        "relevant_chunks": [],
        "drug_names": [
          "nirmatrelvir/ritonavir (Paxlovid)"
        ],
        "tags": [
          "dosage"
        ],
        "source_note": null,
        "reasoning": null,
        "gold": {
          "abstain_expected": true,
          "reason": "Not present in ≤2018 corpus; recency-sensitive",
          "recency_risk": true,
          "citations": []
        }
      },
      "generated_answer": "I'm unable to provide a specific dosing or interaction check for Paxlovid as it is not mentioned in the provided context. However, I can share the dosing information for Paxil (paroxetine) based on the given context.\n\nFor COVID-19 patients, I recommend consulting current clinical guidance for Paxlovid, as it is not mentioned in the provided context.\n\nFor Paxil, the dosing varies depending on the condition and age group:\n- For adults with Major Depressive Disorder (MDD), Generalized Anxiety Disorder (GAD), and Obsessive-Compulsive Disorder (OCD), the initial dose is 20 mg once daily, with potential increases by 10 mg/day increments at 1-week intervals, up to a maximum of 50 mg/day for adults and 40 mg/day for geriatric patients [chunk_F206599, chunk_F206600].\n\nRegarding drug-drug interactions, potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult the drug interactions database for more detailed information [chunk_F155528].\n\nPlease refer to the FDA-approved medication guide for the specific Paxil product you are considering [chunk_F7874764]. For Paxlovid, I strongly advise consulting current clinical guidance to ensure safe and effective use.",
      "expected_answer": "ABSTAIN. Not in ≤2018 corpus; recency-sensitive therapy. Advise consulting current guidance/pharmacist.",
      "retrieval_metrics": {
        "recall_at_k": {
          "1": 0.0,
          "3": 0.0,
          "5": 0.0,
          "10": 0.0,
          "20": 0.0
        },
        "precision_at_k": {
          "1": 0.0,
          "3": 0.0,
          "5": 0.0,
          "10": 0.0,
          "20": 0.0
        },
        "mean_reciprocal_rank": 0.0,
        "average_precision": 0.0,
        "ndcg_at_k": {
          "1": 0.0,
          "3": 0.0,
          "5": 0.0,
          "10": 0.0,
          "20": 0.0
        },
        "essential_recall_at_k": {
          "1": 0.0,
          "3": 0.0,
          "5": 0.0,
          "10": 0.0,
          "20": 0.0
        },
        "first_relevant_rank": 0.0,
        "total_relevant": 0,
        "total_essential": 0
      },
      "qa_metrics": {
        "bleu_score": 0.0058936917486878985,
        "rouge_1_f1": 0.06796116504854369,
        "rouge_2_f1": 0.0196078431372549,
        "rouge_l_f1": 0.06796116504854369,
        "semantic_similarity": 0.3818419277667999,
        "key_points_covered": 0.0,
        "key_points_found": [],
        "key_points_missing": [
          "Explicit abstention",
          "Sets recency_risk = true",
          "Advises pharmacist/current guidance"
        ],
        "answer_length": 180,
        "has_answer": true,
        "factual_accuracy": null,
        "helpfulness": null
      },
      "retrieval_results": [
        {
          "chunk_id": "paroxetine-drug-information::F206599::0",
          "score": 0.6,
          "rank": 1
        },
        {
          "chunk_id": "paroxetine-drug-information::F206600::0",
          "score": 0.5872745209628127,
          "rank": 2
        },
        {
          "chunk_id": "cycloserine-drug-information::F155528::1",
          "score": 0.5864790296660842,
          "rank": 3
        },
        {
          "chunk_id": "oxycodone-drug-information::F10162706::0",
          "score": 0.5821163001757451,
          "rank": 4
        },
        {
          "chunk_id": "paroxetine-drug-information::F7874764::0",
          "score": 0.577602770806748,
          "rank": 5
        }
      ],
      "context_chunks": [
        {
          "rank": 1,
          "score": 0.6,
          "dense_score": 1.0,
          "bm25_score": 0.0,
          "chunk_id": "paroxetine-drug-information::F206599::0",
          "doc_id": "paroxetine-drug-information",
          "section_title": "Dosing: Adult",
          "section_code": "doa",
          "drug_title": "Paroxetine: Drug information",
          "source_url": "https://maadi-clinical.byethost8.com/d/topic.htm?path=paroxetine-drug-information",
          "snippet": "Dosing: Adult  Major depressive disorder (MDD): Oral:  Paxil, Pexeva: Initial: 20 mg once daily, preferably in the morning; increase if needed by 10 mg/day increments at intervals of at least 1 week; maximum dose: 50 mg/day  Paxil CR: Initi…",
          "text": "Dosing: Adult\n\nMajor depressive disorder (MDD): Oral:\n\nPaxil, Pexeva: Initial: 20 mg once daily, preferably in the morning; increase if needed by 10 mg/day increments at intervals of at least 1 week; maximum dose: 50 mg/day\n\nPaxil CR: Initial: 25 mg once daily; increase if needed by 12.5 mg/day increments at intervals of at least 1 week; maximum dose: 62.5 mg/day\n\nGeneralized anxiety disorder (GAD)\n\n(Paxil, Pexeva): Oral: Initial: 20 mg once daily, preferably in the morning (if dose is increased, adjust in increments of 10 mg/day at 1-week intervals); doses of 20 to 50 mg/day were used in clinical trials, however, no greater benefit was seen with doses >20 mg.\n\nObsessive-compulsive disorder (OCD) (Paxil, Pexeva): Oral: Initial: 20 mg once daily, preferably in the morning; increase if needed by 10 mg/day increments at intervals of at least 1 week; recommended dose: 40 mg/day; range: 20 to 60 mg/day; maximum dose: 60 mg/day\n\nPanic disorder: Oral:\n\nPaxil, Pexeva: Initial: 10 mg once daily, preferably in the morning; increase if needed by 10 mg/day increments at intervals of at least 1 week; recommended dose: 40 mg/day; range: 10 to 60 mg/day; maximum dose: 60 mg/day"
        },
        {
          "rank": 2,
          "score": 0.5872745209628127,
          "dense_score": 0.9787908682713545,
          "bm25_score": 0.0,
          "chunk_id": "paroxetine-drug-information::F206600::0",
          "doc_id": "paroxetine-drug-information",
          "section_title": "Dosing: Geriatric",
          "section_code": "doe",
          "drug_title": "Paroxetine: Drug information",
          "source_url": "https://maadi-clinical.byethost8.com/d/topic.htm?path=paroxetine-drug-information",
          "snippet": "Dosing: Geriatric  Major depressive disorder (MDD), obsessive compulsive disorder (OCD), panic attack, social anxiety disorder:  Paxil, Pexeva: Oral: Initial: 10 mg/day; increase if needed by 10 mg/day increments at intervals of at least 1…",
          "text": "Dosing: Geriatric\n\nMajor depressive disorder (MDD), obsessive compulsive disorder (OCD), panic attack, social anxiety disorder:\n\nPaxil, Pexeva: Oral: Initial: 10 mg/day; increase if needed by 10 mg/day increments at intervals of at least 1 week; maximum dose: 40 mg/day\n\nPaxil CR: Initial: 12.5 mg/day; increase if needed by 12.5 mg/day increments at intervals of at least 1 week; maximum dose: 50 mg/day\n\nDiscontinuation of therapy: Refer to adult dosing.\n\nMAO inhibitor recommendations: Refer to adult dosing."
        },
        {
          "rank": 3,
          "score": 0.5864790296660842,
          "dense_score": 0.9774650494434737,
          "bm25_score": 0.0,
          "chunk_id": "cycloserine-drug-information::F155528::1",
          "doc_id": "cycloserine-drug-information",
          "section_title": "Warnings/Precautions",
          "section_code": "war",
          "drug_title": "Cycloserine: Drug information",
          "source_url": "https://maadi-clinical.byethost8.com/d/topic.htm?path=cycloserine-drug-information",
          "snippet": "• Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed informati…",
          "text": "• Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.\n\nSpecial populations:\n\n• Patients with potential for vitamin deficiency: Use with caution in patients with potential vitamin B12 and/or folate deficiency (malnourished, chronic anticonvulsant therapy, or elderly)."
        },
        {
          "rank": 4,
          "score": 0.5821163001757451,
          "dense_score": 0.9701938336262419,
          "bm25_score": 0.0,
          "chunk_id": "oxycodone-drug-information::F10162706::0",
          "doc_id": "oxycodone-drug-information",
          "section_title": "Medication Guide and/or Vaccine Information Statement (VIS)",
          "section_code": "meg",
          "drug_title": "Oxycodone: Drug information",
          "source_url": "https://maadi-clinical.byethost8.com/d/topic.htm?path=oxycodone-drug-information",
          "snippet": "Medication Guide and/or Vaccine Information Statement (VIS)  An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:  Oxaydo: http://www.accessdata.fd…",
          "text": "Medication Guide and/or Vaccine Information Statement (VIS)\n\nAn FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:\n\nOxaydo: http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/202080s005s006lbl.pdf#page=26\n\nOxycodone hydrochloride capsules: http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/200534s006lbl.pdf#page=30\n\nOxycodone hydrochloride oral solution: http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/201194s002lbl.pdf#page=29\n\nOxyContin: http://www.fda.gov/downloads/Drugs/DrugSafety/UCM208530.pdf\n\nRoxybond: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209777lbl.pdf#page=43\n\nRoxicodone: http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021011s006lbl.pdf#page=26\n\nXtampza ER: http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208090s003lbl.pdf#page=35"
        },
        {
          "rank": 5,
          "score": 0.577602770806748,
          "dense_score": 0.9626712846779134,
          "bm25_score": 0.0,
          "chunk_id": "paroxetine-drug-information::F7874764::0",
          "doc_id": "paroxetine-drug-information",
          "section_title": "Medication Guide and/or Vaccine Information Statement (VIS)",
          "section_code": "meg",
          "drug_title": "Paroxetine: Drug information",
          "source_url": "https://maadi-clinical.byethost8.com/d/topic.htm?path=paroxetine-drug-information",
          "snippet": "Medication Guide and/or Vaccine Information Statement (VIS)  An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:  Brisdelle:http://www.accessdata.…",
          "text": "Medication Guide and/or Vaccine Information Statement (VIS)\n\nAn FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:\n\nBrisdelle:http://www.accessdata.fda.gov/drugsatfda_docs/label/2017/204516s004lbl.pdf#page=22\n\nPaxil: http://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020031s074lbl.pdf#page=43\n\nPaxil CR: http://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020936s053lbl.pdf#page=44\n\nPexeva: http://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021299s033lbl.pdf#page=38"
        }
      ],
      "failure_analysis": {
        "question_id": "q012",
        "question": "COVID-19 patient asks for Paxlovid dosing and interaction checks.",
        "failure_types": [
          "retrieval_miss",
          "retrieval_irrelevant",
          "qa_incorrect",
          "qa_incomplete",
          "e2e_low_quality"
        ],
        "retrieved_chunks": [
          {
            "chunk_id": "paroxetine-drug-information::F206599::0",
            "score": 0.6,
            "rank": 1
          },
          {
            "chunk_id": "paroxetine-drug-information::F206600::0",
            "score": 0.5872745209628127,
            "rank": 2
          },
          {
            "chunk_id": "cycloserine-drug-information::F155528::1",
            "score": 0.5864790296660842,
            "rank": 3
          },
          {
            "chunk_id": "oxycodone-drug-information::F10162706::0",
            "score": 0.5821163001757451,
            "rank": 4
          },
          {
            "chunk_id": "paroxetine-drug-information::F7874764::0",
            "score": 0.577602770806748,
            "rank": 5
          }
        ],
        "relevant_chunks_found": [],
        "essential_chunks_missed": [],
        "generated_answer": "I'm unable to provide a specific dosing or interaction check for Paxlovid as it is not mentioned in the provided context. However, I can share the dosing information for Paxil (paroxetine) based on the given context.\n\nFor COVID-19 patients, I recommend consulting current clinical guidance for Paxlovid, as it is not mentioned in the provided context.\n\nFor Paxil, the dosing varies depending on the condition and age group:\n- For adults with Major Depressive Disorder (MDD), Generalized Anxiety Disorder (GAD), and Obsessive-Compulsive Disorder (OCD), the initial dose is 20 mg once daily, with potential increases by 10 mg/day increments at 1-week intervals, up to a maximum of 50 mg/day for adults and 40 mg/day for geriatric patients [chunk_F206599, chunk_F206600].\n\nRegarding drug-drug interactions, potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult the drug interactions database for more detailed information [chunk_F155528].\n\nPlease refer to the FDA-approved medication guide for the specific Paxil product you are considering [chunk_F7874764]. For Paxlovid, I strongly advise consulting current clinical guidance to ensure safe and effective use.",
        "expected_answer": "ABSTAIN. Not in ≤2018 corpus; recency-sensitive therapy. Advise consulting current guidance/pharmacist.",
        "key_points_missing": [
          "Explicit abstention",
          "Sets recency_risk = true",
          "Advises pharmacist/current guidance"
        ],
        "retrieval_metrics": {
          "recall_at_k": {
            "1": 0.0,
            "3": 0.0,
            "5": 0.0,
            "10": 0.0,
            "20": 0.0
          },
          "precision_at_k": {
            "1": 0.0,
            "3": 0.0,
            "5": 0.0,
            "10": 0.0,
            "20": 0.0
          },
          "mean_reciprocal_rank": 0.0,
          "average_precision": 0.0,
          "ndcg_at_k": {
            "1": 0.0,
            "3": 0.0,
            "5": 0.0,
            "10": 0.0,
            "20": 0.0
          },
          "essential_recall_at_k": {
            "1": 0.0,
            "3": 0.0,
            "5": 0.0,
            "10": 0.0,
            "20": 0.0
          },
          "first_relevant_rank": 0.0,
          "total_relevant": 0,
          "total_essential": 0
        },
        "qa_metrics": {
          "bleu_score": 0.0058936917486878985,
          "rouge_1_f1": 0.06796116504854369,
          "rouge_2_f1": 0.0196078431372549,
          "rouge_l_f1": 0.06796116504854369,
          "semantic_similarity": 0.3818419277667999,
          "key_points_covered": 0.0,
          "key_points_found": [],
          "key_points_missing": [
            "Explicit abstention",
            "Sets recency_risk = true",
            "Advises pharmacist/current guidance"
          ],
          "answer_length": 180,
          "has_answer": true,
          "factual_accuracy": null,
          "helpfulness": null
        },
        "root_cause": "both_systems",
        "severity": "high",
        "notes": null
      }
    },
    {
      "question_id": "q013",
      "question": {
        "id": "q013",
        "question": "What is the current first-line pharmacologic therapy per latest hypertension guidelines?",
        "question_type": "guideline",
        "difficulty": "medium",
        "expected_answer": "ABSTAIN if asked for ‘current’ guidance (2018 corpus includes JNC8/2014). Flag recency risk.",
        "answer_key_points": [
          "Explicit abstention for ‘current’ guideline ask",
          "Recognize JNC8 (2014) is outdated for ‘current’",
          "Sets recency_risk = true"
        ],
        "relevant_chunks": [
          {
            "chunk_id": "lexi-hypertension-2014#jnc8",
            "relevance_score": 1.0,
            "is_essential": true,
            "note": null
          }
        ],
        "drug_names": [],
        "tags": [
          "guideline"
        ],
        "source_note": null,
        "reasoning": null,
        "gold": {
          "abstain_expected": true,
          "reason": "Question seeks guidance newer than 2018; corpus includes JNC8 (2014) only",
          "recency_risk": true,
          "citations": [
            "lexi-hypertension-2014#jnc8"
          ]
        }
      },
      "generated_answer": "Based on the provided context, the latest hypertension guidelines from 2014 (JNC8) suggest that pharmacologic treatment to lower blood pressure should be initiated for various patient groups, including those aged 60 and older with a systolic blood pressure (SBP) of 150 mm Hg or higher, and those under 60 with an SBP of 140 mm Hg or higher. However, it is important to note that the JNC8 guidelines are outdated, and current guidelines may provide more up-to-date recommendations. For pulmonary arterial hypertension (PAH), the latest guidelines from the Fifth World Symposium on Pulmonary Hypertension (WSPH) and the American College of Chest Physicians (ACCP) recommend continuous IV epoprostenol as first-line therapy in PAH patients with WHO-FC IV symptoms (WSPH [Gailè 2013], ACCP [Taichman 2014]). Therefore, it is crucial to consult the most recent hypertension guidelines for current treatment recommendations. [recency_risk = true]",
      "expected_answer": "ABSTAIN if asked for ‘current’ guidance (2018 corpus includes JNC8/2014). Flag recency risk.",
      "retrieval_metrics": {
        "recall_at_k": {
          "1": 0.0,
          "3": 0.0,
          "5": 0.0,
          "10": 0.0,
          "20": 0.0
        },
        "precision_at_k": {
          "1": 0.0,
          "3": 0.0,
          "5": 0.0,
          "10": 0.0,
          "20": 0.0
        },
        "mean_reciprocal_rank": 0.0,
        "average_precision": 0.0,
        "ndcg_at_k": {
          "1": 0.0,
          "3": 0.0,
          "5": 0.0,
          "10": 0.0,
          "20": 0.0
        },
        "essential_recall_at_k": {
          "1": 0.0,
          "3": 0.0,
          "5": 0.0,
          "10": 0.0,
          "20": 0.0
        },
        "first_relevant_rank": 0.0,
        "total_relevant": 1,
        "total_essential": 1
      },
      "qa_metrics": {
        "bleu_score": 0.0029199644099198964,
        "rouge_1_f1": 0.0880503144654088,
        "rouge_2_f1": 0.025477707006369428,
        "rouge_l_f1": 0.07547169811320753,
        "semantic_similarity": 0.24601370096206665,
        "key_points_covered": 0.6666666666666666,
        "key_points_found": [
          "Recognize JNC8 (2014) is outdated for ‘current’",
          "Sets recency_risk = true"
        ],
        "key_points_missing": [
          "Explicit abstention for ‘current’ guideline ask"
        ],
        "answer_length": 141,
        "has_answer": true,
        "factual_accuracy": null,
        "helpfulness": null
      },
      "retrieval_results": [
        {
          "chunk_id": "epoprostenol-drug-information::F165840::0",
          "score": 0.9271672921779921,
          "rank": 1
        },
        {
          "chunk_id": "atenolol-drug-information::F137401::0",
          "score": 0.7487943067071376,
          "rank": 2
        },
        {
          "chunk_id": "metoprolol-drug-information::F195770::2",
          "score": 0.6539475332649507,
          "rank": 3
        },
        {
          "chunk_id": "quinapril-drug-information::F216329::0",
          "score": 0.6355413237936726,
          "rank": 4
        },
        {
          "chunk_id": "bisoprolol-drug-information::F141616::0",
          "score": 0.6,
          "rank": 5
        }
      ],
      "context_chunks": [
        {
          "rank": 1,
          "score": 0.9271672921779921,
          "dense_score": 0.9464588331777846,
          "bm25_score": 0.8982299806783035,
          "chunk_id": "epoprostenol-drug-information::F165840::0",
          "doc_id": "epoprostenol-drug-information",
          "section_title": "Use",
          "section_code": "use",
          "drug_title": "Epoprostenol: Drug information",
          "source_url": "https://maadi-clinical.byethost8.com/d/topic.htm?path=epoprostenol-drug-information",
          "snippet": "Use  Pulmonary arterial hypertension: Treatment of pulmonary arterial hypertension (PAH) (WHO Group I) in patients with NYHA Class III or IV symptoms to improve exercise capacity. Note: According to treatment guidelines from the Fifth World…",
          "text": "Use\n\nPulmonary arterial hypertension: Treatment of pulmonary arterial hypertension (PAH) (WHO Group I) in patients with NYHA Class III or IV symptoms to improve exercise capacity. Note: According to treatment guidelines from the Fifth World Symposium on Pulmonary Hypertension (WSPH) and the American College of Chest Physicians (ACCP), continuous IV epoprostenol is recommended as first-line therapy in PAH patients with WHO-FC IV symptoms (ACCP [Taichman 2014]; WSPH [Gailè 2013])."
        },
        {
          "rank": 2,
          "score": 0.7487943067071376,
          "dense_score": 0.9528364815861122,
          "bm25_score": 0.44273104438867583,
          "chunk_id": "atenolol-drug-information::F137401::0",
          "doc_id": "atenolol-drug-information",
          "section_title": "Use",
          "section_code": "use",
          "drug_title": "Atenolol: Drug information",
          "source_url": "https://maadi-clinical.byethost8.com/d/topic.htm?path=atenolol-drug-information",
          "snippet": "Use  Acute myocardial infarction: For the management of hemodynamically stable patients with definite or suspected acute MI to reduce cardiovascular mortality.  Angina pectoris caused by coronary atherosclerosis: For the long-term managemen…",
          "text": "Use\n\nAcute myocardial infarction: For the management of hemodynamically stable patients with definite or suspected acute MI to reduce cardiovascular mortality.\n\nAngina pectoris caused by coronary atherosclerosis: For the long-term management of patients with angina pectoris.\n\nHypertension: Treatment of hypertension, alone or in combination with other agents. Note: According to current guidelines for the treatment of high blood pressure in adults, a beta-blocker should only be added to existing antihypertensive therapy when patient is not at goal blood pressure and not used alone (JNC8 [James 2014]).\n\nGuideline recommendations:\n\nHypertension: The 2014 guideline for the management of high blood pressure in adults (Eighth Joint National Committee [JNC 8]) recommends initiation of pharmacologic treatment to lower blood pressure for the following patients (JNC8 [James, 2014]):\n\n• Patients ≥60 years of age with systolic blood pressure (SBP) ≥150 mm Hg or diastolic blood pressure (DBP) ≥90 mm Hg. Goal of therapy is SBP <150 mm Hg and DBP <90 mm Hg.\n\n• Patients <60 years of age with SBP ≥140 mm Hg or DBP is ≥90 mm Hg. Goal of therapy is SBP <140 mm Hg and DBP <90 mm Hg."
        },
        {
          "rank": 3,
          "score": 0.6539475332649507,
          "dense_score": 0.9337723431031122,
          "bm25_score": 0.2342103185077086,
          "chunk_id": "metoprolol-drug-information::F195770::2",
          "doc_id": "metoprolol-drug-information",
          "section_title": "Use",
          "section_code": "use",
          "drug_title": "Metoprolol: Drug information",
          "source_url": "https://maadi-clinical.byethost8.com/d/topic.htm?path=metoprolol-drug-information",
          "snippet": "Heart failure: The ACCF/AHA 2013 heart failure guidelines recommend the use of 1 of 3 beta blockers (ie, bisoprolol, carvedilol, or extended-release metoprolol succinate) for all patients with recent or remote history of MI or ACS and reduc…",
          "text": "Heart failure: The ACCF/AHA 2013 heart failure guidelines recommend the use of 1 of 3 beta blockers (ie, bisoprolol, carvedilol, or extended-release metoprolol succinate) for all patients with recent or remote history of MI or ACS and reduced ejection fraction (rEF) to reduce mortality, for all patients with rEF to prevent symptomatic HF (even if no history of MI), and for all patients with current or prior symptoms of HF with reduced ejection fraction (HFrEF), unless contraindicated, to reduce morbidity and mortality (ACCF/AHA [Yancy 2013]).\n\nHypertension: The 2014 guideline for the management of high blood pressure in adults (Eighth Joint National Committee [JNC 8]) recommends initiation of pharmacologic treatment to lower blood pressure for the following patients (JNC8 [James 2013]):\n\n• Patients ≥60 years of age, with systolic blood pressure (SBP) ≥150 mm Hg or diastolic blood pressure (DBP) ≥90 mm Hg. Goal of therapy is SBP <150 mm Hg and DBP <90 mm Hg.\n\n• Patients <60 years of age, with SBP ≥140 mm Hg or DBP ≥90 mm Hg. Goal of therapy is SBP <140 mm Hg and DBP <90 mm Hg."
        },
        {
          "rank": 4,
          "score": 0.6355413237936726,
          "dense_score": 0.9458979594219874,
          "bm25_score": 0.17000637035120025,
          "chunk_id": "quinapril-drug-information::F216329::0",
          "doc_id": "quinapril-drug-information",
          "section_title": "Use",
          "section_code": "use",
          "drug_title": "Quinapril: Drug information",
          "source_url": "https://maadi-clinical.byethost8.com/d/topic.htm?path=quinapril-drug-information",
          "snippet": "Use  Heart failure: Adjunctive treatment of heart failure (HF)  Hypertension: Management of hypertension (monotherapy or in combination with thiazide diuretics).  Guideline recommendations:  Heart failure: The ACCF/AHA 2013 heart failure gu…",
          "text": "Use\n\nHeart failure: Adjunctive treatment of heart failure (HF)\n\nHypertension: Management of hypertension (monotherapy or in combination with thiazide diuretics).\n\nGuideline recommendations:\n\nHeart failure: The ACCF/AHA 2013 heart failure guidelines recommend the use of ACE inhibitors, along with other guideline directed medical therapies, to prevent HF in patients with a reduced ejection fraction who have a history of MI (stage B HF), to prevent HF in any patient with a reduced ejection fraction (stage B HF), or to treat those with HF and reduced ejection fraction (stage C HFrEF) (ACCF/AHA [Yancy, 2013]).\n\nHypertension: The 2014 guideline for the management of high blood pressure in adults (Eighth Joint National Committee [JNC 8]) recommends initiation of pharmacologic treatment to lower blood pressure for the following patients:\n\n• Patients ≥60 years with systolic blood pressure (SBP) ≥150 mm Hg or diastolic blood pressure (DBP) ≥ 90 mm Hg.\n\n• Patients <60 years with SBP ≥140 mm Hg or DBP is ≥90 mm Hg. Goal of therapy is SBP <140 mm Hg and DBP <90 mm Hg.\n\n• Patients ≥18 years with diabetes and SBP ≥140 mm Hg or DBP ≥90 mm Hg. Goal of therapy is SBP <140 mm Hg and DBP <90 mm Hg."
        },
        {
          "rank": 5,
          "score": 0.6,
          "dense_score": 1.0,
          "bm25_score": 0.0,
          "chunk_id": "bisoprolol-drug-information::F141616::0",
          "doc_id": "bisoprolol-drug-information",
          "section_title": "Use",
          "section_code": "use",
          "drug_title": "Bisoprolol: Drug information",
          "source_url": "https://maadi-clinical.byethost8.com/d/topic.htm?path=bisoprolol-drug-information",
          "snippet": "Use  Hypertension: Treatment of hypertension, alone or in combination with other agents  Guideline recommendations:  Hypertension: The 2014 guideline for the management of high blood pressure in adults (Eighth Joint National Committee [JNC…",
          "text": "Use\n\nHypertension: Treatment of hypertension, alone or in combination with other agents\n\nGuideline recommendations:\n\nHypertension: The 2014 guideline for the management of high blood pressure in adults (Eighth Joint National Committee [JNC 8]) recommends initiation of pharmacologic treatment to lower blood pressure for the following patients (JNC8 [James, 2013]):\n\n• Patients ≥60 years of age, with systolic blood pressure (SBP) ≥150 mm Hg or diastolic blood pressure (DBP) ≥90 mm Hg. Goal of therapy is SBP <150 mm Hg and DBP <90 mm Hg.\n\n• Patients <60 years of age, with SBP ≥140 mm Hg or DBP ≥90 mm Hg. Goal of therapy is SBP <140 mm Hg and DBP <90 mm Hg.\n\n• Patients ≥18 years of age with diabetes, with SBP ≥140 mm Hg or DBP ≥90 mm Hg. Goal of therapy is SBP <140 mm Hg and DBP <90 mm Hg.\n\n• Patients ≥18 years of age with chronic kidney disease (CKD), with SBP ≥140 mm Hg or DBP ≥90 mm Hg. Goal of therapy is SBP <140 mm Hg and DBP <90 mm Hg."
        }
      ],
      "failure_analysis": {
        "question_id": "q013",
        "question": "What is the current first-line pharmacologic therapy per latest hypertension guidelines?",
        "failure_types": [
          "retrieval_miss",
          "retrieval_irrelevant",
          "qa_incorrect",
          "qa_incomplete"
        ],
        "retrieved_chunks": [
          {
            "chunk_id": "epoprostenol-drug-information::F165840::0",
            "score": 0.9271672921779921,
            "rank": 1
          },
          {
            "chunk_id": "atenolol-drug-information::F137401::0",
            "score": 0.7487943067071376,
            "rank": 2
          },
          {
            "chunk_id": "metoprolol-drug-information::F195770::2",
            "score": 0.6539475332649507,
            "rank": 3
          },
          {
            "chunk_id": "quinapril-drug-information::F216329::0",
            "score": 0.6355413237936726,
            "rank": 4
          },
          {
            "chunk_id": "bisoprolol-drug-information::F141616::0",
            "score": 0.6,
            "rank": 5
          }
        ],
        "relevant_chunks_found": [],
        "essential_chunks_missed": [
          "lexi-hypertension-2014#jnc8"
        ],
        "generated_answer": "Based on the provided context, the latest hypertension guidelines from 2014 (JNC8) suggest that pharmacologic treatment to lower blood pressure should be initiated for various patient groups, including those aged 60 and older with a systolic blood pressure (SBP) of 150 mm Hg or higher, and those under 60 with an SBP of 140 mm Hg or higher. However, it is important to note that the JNC8 guidelines are outdated, and current guidelines may provide more up-to-date recommendations. For pulmonary arterial hypertension (PAH), the latest guidelines from the Fifth World Symposium on Pulmonary Hypertension (WSPH) and the American College of Chest Physicians (ACCP) recommend continuous IV epoprostenol as first-line therapy in PAH patients with WHO-FC IV symptoms (WSPH [Gailè 2013], ACCP [Taichman 2014]). Therefore, it is crucial to consult the most recent hypertension guidelines for current treatment recommendations. [recency_risk = true]",
        "expected_answer": "ABSTAIN if asked for ‘current’ guidance (2018 corpus includes JNC8/2014). Flag recency risk.",
        "key_points_missing": [
          "Explicit abstention for ‘current’ guideline ask"
        ],
        "retrieval_metrics": {
          "recall_at_k": {
            "1": 0.0,
            "3": 0.0,
            "5": 0.0,
            "10": 0.0,
            "20": 0.0
          },
          "precision_at_k": {
            "1": 0.0,
            "3": 0.0,
            "5": 0.0,
            "10": 0.0,
            "20": 0.0
          },
          "mean_reciprocal_rank": 0.0,
          "average_precision": 0.0,
          "ndcg_at_k": {
            "1": 0.0,
            "3": 0.0,
            "5": 0.0,
            "10": 0.0,
            "20": 0.0
          },
          "essential_recall_at_k": {
            "1": 0.0,
            "3": 0.0,
            "5": 0.0,
            "10": 0.0,
            "20": 0.0
          },
          "first_relevant_rank": 0.0,
          "total_relevant": 1,
          "total_essential": 1
        },
        "qa_metrics": {
          "bleu_score": 0.0029199644099198964,
          "rouge_1_f1": 0.0880503144654088,
          "rouge_2_f1": 0.025477707006369428,
          "rouge_l_f1": 0.07547169811320753,
          "semantic_similarity": 0.24601370096206665,
          "key_points_covered": 0.6666666666666666,
          "key_points_found": [
            "Recognize JNC8 (2014) is outdated for ‘current’",
            "Sets recency_risk = true"
          ],
          "key_points_missing": [
            "Explicit abstention for ‘current’ guideline ask"
          ],
          "answer_length": 141,
          "has_answer": true,
          "factual_accuracy": null,
          "helpfulness": null
        },
        "root_cause": "both_systems",
        "severity": "high",
        "notes": null
      }
    }
  ]
}